

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046491
Article Type:	Original research
Date Submitted by the Author:	31-Oct-2020
Complete List of Authors:	<p>Jhangiri, Marjan; St George's Hospital, Department of Cardiac Surgery Bilkhu, Rajdeep; St George's Hospital, Department of Cardiac Surgery Embleton-Thirsk, Andrew; University College London Institute of Clinical Trials and Methodology Dehbi, Hakim-Moulay; University College London Institute of Clinical Trials and Methodology Mani, Krishna; St George's Hospital, Department of Cardiac Surgery Anderson, Jon ; Hammersmith Hospital, Department of Cardiac Surgery Avlonitis, Vassilios; St Thomas' Hospital, Department of Cardiac Surgery Baghai, Max; King's College Hospital, Department of Cardiac Surgery Birdi, Inderpaul; Essex Cardiothoracic Centre Booth, Karen; Freeman Hospital Cardiothoracic Centre Bose, Amal; Lancashire Cardiac Centre Briffa, Norman; Sheffield Teaching Hospitals NHS Foundation Trust Cardiothoracic Centre Buchan, Keith; Aberdeen Royal Infirmary, Cardiac Surgery Bhudia, Sunil; Harefield Hospital Heart Surgery Cale, Alex; Castle Hill Hospital, Cardiac Surgery Deglurkar, Indu; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Farid, Shakil; Oxford University Hospitals NHS Trust, Cardiac Surgery Hadjinikolaou, Leonidas; University Hospitals of Leicester NHS Trust, Cardiac Surgery Jarvis, Martin; Hull University Teaching Hospitals NHS Trust, Cardiac Surgery Javadpour, Seyed; Mater Misericordiae University Hospital, Cardiac Surgery Jeganathan, Reubendra; Royal Victoria Hospital, Cardiac Surgery Kuduvalli, Manoj; Liverpool Heart and Chest Hospital NHS Foundation Trust, Cardiac Surgery Lall, Kulvinder; Saint Bartholomew's Hospital Barts Heart Centre Mascaro, Jorge; Queen Elizabeth Medical Centre, Cardiac Surgery Mehta, Dheeraj; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Ohri, Sunil; Southampton University Hospitals NHS Trust, Cardiac Surgery Punjabi, Prakash; Hammersmith Hospital, Cardiac Surgery Venkateswaran, Rajamiyer ; Wythenshawe Hospital North West Heart Centre</p>

	Ridley, Paul; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Satur, Christopher; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Stoica, Serban; Bristol Heart Institute Trivedi, Uday; Royal Sussex County Hospital Sussex Cardiac Centre Zaidi, Afzal; Morrilton Hospital, Cardiac Surgery Yiu, Patrick; New Cross Hospital, Cardiac Surgery Moorjani, Narain; Royal Papworth Hospital NHS Foundation Trust Cardiac Surgery Kendall, Simon; James Cook University Hospital, Cardiac Surgery Freemantle, Nick; University College London Institute of Clinical Trials and Methodology, Comprehensive Clinical Trials Unit
Keywords:	Cardiothoracic surgery < SURGERY, Cardiac surgery < SURGERY, CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Marjan Jahangiri, Rajdeep Bilkhu**, Andrew Embleton-Thirsk**, Hakim-Moulay Dehbi*, Krishna Mani, Jon Anderson, Vassilios Avlonitis, Max Baghai, Inderpaul Birdi, Karen Booth, Amal Bose, Norman Briffa, Keith Buchan, Sunil Bhudia, Alex Cale, Indu Deglurkar, Shakil Farid, Leonidas Hadjinikolaou, Martin Jarvis, Seyed Hossein Javadpour, Reubendra Jeganathan, Manoj Kuduvali, Kulvinder Lall, Jorge Mascaro, Dheeraj Mehta, Sunil Ohri, Prakash Punjabi, Venkateswaran Rajamiyer, Paul Ridley, Christopher Satur, Serban Stoica, Uday Trivedi, Afzal Zaidi, Patrick Yiu, Narain Moorjani, Simon Kendall, Nick Freemantle*

** RB/AE equal contributions

Names of cardiac surgical units are given in the Acknowledgement section
Institute of Clinical Trials and Methodology, University College London*

Word Count: 3906

Key words: aortic valve replacement, aortic valve disease, surgery

Address for correspondence:
Marjan Jahangiri
Professor of Cardiac Surgery
St. George's Hospital
London SW17 0QT

Tel: 44-2087252652

Email: marjan.jahangiri@stgeorges.nhs.uk

ABSTRACT

Objectives - To date the reported outcomes of aortic valve replacement (AVR) are mainly in the settings of trials comparing it with evolving transcatheter aortic valve implantation (TAVI). We set out to examine characteristics and outcomes in people who underwent AVR reflecting a national cohort and therefore 'real world' practice.

Design - Retrospective analysis of prospectively collected data of consecutive people who underwent AVR with or without coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the UK. This included elective, urgent and emergency operations. Participants' demographics, pre-operative risk factors, operative data, in-hospital mortality, post-operative complications and effect of the addition of CABG to AVR were analysed.

Setting - 27 (90%) tertiary cardiac surgical centres in the UK submitted their data for analysis.

Participants - 31,277 people with AVR were identified. 19,670 (62.9%) had only AVR and 11,607 (37.1%) had AVR+CABG.

Results - Mortality for isolated AVR was 1.9% (95% CI: 1.6-2.1%) and was 2.4% for AVR+CABG. Mortality by age category for AVR only were: <60 years=2.0%, 60-75 years=1.5%, >75 years=2.2%. For AVR+CABG these were; 2.2%, 1.8% and 3.1%. For different categories of EuroSCORE, mortality for AVR in low risk people was 1.3%, in intermediate risk 1% and for high risk 3.9%. 74.3% of the operations were elective, 24% urgent and 1.7% emergency/salvage. The incidences of re-sternotomy for bleeding and stroke were 3.9% and 1.1% respectively. Multivariable analyses provided no evidence that concomitant CABG influenced outcome. However, urgency of the operation, poor ventricular function, higher EuroSCORE and longer cross clamp and cardiopulmonary bypass times adversely affected outcomes.

1
2
3 **Conclusions** - Surgical AVR±CABG has low mortality risk and a low level of
4 complications in the UK in people of all ages and risk factors. These results should inform
5 consideration of treatment options in people with aortic valve disease.
6
7
8
9
10

11 **Strengths and limitations of this study**

12

- 13 • This is a large study of consecutive participants who have undergone aortic valve
14 replacement ± coronary artery bypass graft surgery in the UK, reporting
15 contemporary outcomes.
- 16 • This study includes people of all age groups and risks factors, and elective as well
17 as urgent and emergency operations.
- 18 • The results are of in-hospital mortality and complications and longer term follow-
19 up data is not available.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Aortic valve disease, especially aortic stenosis affects 5% of the population and 3.9% of those between the ages of 70 and 79 and nearly 10% of those above the age of 80.¹ Severe aortic stenosis when untreated has a risk of death of 50% at 2 years.² Conventionally the gold standard of treatment has been surgical aortic valve replacement (AVR). However, the role of transcatheter aortic valve implantation (TAVI) has evolved in recent years. TAVI was first introduced in 2002, initially being performed in high risk inoperable patients.³ The original Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated a significant reduction in mortality, repeat hospitalisation and cardiac symptoms compared to inoperable patients who had only medical therapy.⁴ The original PIVOTAL study also demonstrated significantly higher survival at one year in high risk patients who underwent AVR.⁵

The role of TAVI is being extended to lower risk and younger patients based on recent trials comparing AVR with TAVI.^{6,7} Several studies suggest there has been a change in demographics and types of surgical valves used since the advent of TAVI.⁸⁻¹⁰ There has been a trend of increased use of tissue valves and a decrease in the use of mechanical valves in recent years.¹¹ This may be due to the evolution of TAVI practice whereby younger patients can have a TAVI valve with the view that they have another TAVI valve in the future when the tissue valve or TAVI has deteriorated, so called valve-in-valve TAVI.^{12,13}

The series in the literature reporting outcomes of AVR are unit based and with small cohorts.^{9,14} Also, people with aortic valve disease are given information about the outcomes of AVR which may be out of date and incorrectly extrapolated from smaller studies. There is a lack of contemporary national data to assess the outcomes of AVR (mortality and complications), and to demonstrate the trend in use of prosthetic valves which would inform people with aortic valve disease better. There are some perceived complications of surgery that may be understood by referring general practitioners and cardiologists to be prohibitive risks for surgery.

In order to inform practitioners, people with aortic valve disease and the cardiac surgical community, we set out to examine the results of contemporaneous AVR in a

1
2
3 multi-centre study of UK cardiac surgical units, in the era of TAVI. In addition, we
4 summarise and interpret some of the more recent trials on the management of aortic valve
5 disease.
6
7

8 9 **METHODS**

10 11 **Data**

12 This is an analysis of prospectively collected data of people who underwent AVR +/-
13 coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the
14 UK and Republic of Ireland. Anonymised data were submitted to the Society for
15 Cardiothoracic Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then
16 stored in a secure database.
17
18

19 Only participants who had had first time surgery, AVR +/- CABG were included. All
20 participants immaterial of their risk for surgery, people of all age groups and risk factors
21 were included. Those who required other concomitant procedures like replacement of
22 parts of the aorta, aortic root enlargement, other valve procedures and redo surgery were
23 excluded.
24
25

26 27 **Pre-operative risk factors and operative features**

28 Baseline demographic data; significant past medical history such as diabetes, renal
29 dysfunction, hypertension or stroke; predominant aortic valve pathology (stenosis or
30 regurgitation or mixed valve disease) and preoperative left ventricular ejection fraction
31 (LVEF) were collected. Logistic EuroSCORE was collected as well as EuroSCORE II
32 where available. The latter was only used since 2017 and therefore not available for all
33 participants. Logistic EuroSCORE was divided into three categories: <3%, 3-6%, >6%.
34
35

36 LVEF was divided into three categories: good (EF>50%), moderate (EF 30-50%)
37 and poor (EF<30%). Operative data including operative urgency: elective, urgent and
38 emergency/salvage were recorded. Elective was defined as when the person was
39 admitted from home, urgent meaning that the person was admitted with an urgent
40 condition and required surgery during the same hospital admission, emergency and
41 salvage meaning that surgery was required within 24 hours of admission and/or the
42 person was in extremis. Other parameters including cardiopulmonary bypass (CPB) time,
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

1
2
3 cross clamp (CCT) time, type of valve implanted as well as concomitant CABG surgery
4 performed were also collected.
5
6

7 **Postoperative outcomes**

8 Postoperative complication data were collected with the main focus being in-hospital
9 mortality, new stroke, return to theatre for bleeding, deep sternal wound infection and
10 duration of postoperative hospital stay.
11
12
13
14
15

16 **Statistical analysis**

17 Once the records for all participants were collated and the data cleaned, each factor was
18 summarised using descriptive methods. Categorical variables are presented as N (%)
19 and continuous variables are presented as median (IQR). New strokes were recoded to
20 be either no stroke or any cerebrovascular accident (transient or permanent). The natural
21 log of post-operative length of stay (days) was used due to positive skewed distribution
22 of this variable. Univariate models were used, logistic regression for binary outcomes and
23 linear regression for continuous outcomes, to assess the impact of the key explanatory
24 variables. In these models, a two-tailed p-value of <0.05 was considered significant. The
25 population analysed included all the participants with data collected, with results checked
26 in the subset who had AVR only (without CABG). Building on this, a multivariable model
27 with all key variables in the model to assess which had the most impact on each of the
28 outcomes was created. Stata/MP 15.1 (StataCorp LLC, Texas, USA) was used for all
29 analyses.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Patient and public involvement**

44 Patients and public were involved in the original design of the database.
45
46
47

48 **Ethics**

49 This data is ordinarily submitted to National Institute of Cardiovascular Outcome
50 Research (NICOR) for which local and national Caldicott guardian approvals have been
51 obtained. The data are validated by the surgical teams and their database
52
53
54
55
56
57
58
59
60

managers/audit officers. For the current study a further approval from the Caldicott Guardian was obtained.

RESULTS

Descriptive analysis

In total 31,277 patients were included. Of these, 19,670 (62.9%) had only AVR and 11,607 (37.1%) had AVR+CABG. There were 14.4% below the age of 60, 46.9% between 60 to 75 and 36.7% older than 75 years with 7.9% missing age data. There were 1.9 times more males than females (10.3% missing).

Regarding pre-operative risk factors, 75.2% had good LVEF, 17.3% had moderate and 4.3% had poor LVEF. 74.3% of the operations were elective, 24% were urgent and 1.7% were emergency or salvage operations.

Logistic EuroSCORE had a median of 1.83 with an IQR of 0.06-6.0. The median EuroSCORE II was 1.95 (IQR 0.67-4.8) albeit with 56.5% with missing data, as this was introduced into the database in 2017. The median CPB time was 104 minutes (IQR 82-135) and CCT was 79 minutes (IQR 61-101).

For valve implant replacement type, 70% had a tissue valve, 12.2% a mechanical valve and 0.2% had homograft or autograft valves. For 17.3% the entry for valve type was unclear. The ratio of mechanical implant to bioprosthetic implant use has remained stable over time.

Overall mortality was 2.4% (95% CI: 2.2-2.6%) and mortality for isolated AVR for all participants was 1.9% (1.6-2.1%). The mortality figures analysed for different age ranges and for categories of EuroSCORE are shown in Table 1.

Overall, 3.9% (3.6% in AVR only) of participants had re-sternotomy for post-operative bleeding or tamponade, 0.04% (0.06% in AVR only) had re-operation for valvular problems (significant paravalvular leak and early endocarditis), 0.7% (0.6% AVR only) had re-operation for other cardiac problems, 0.2% (0.15% for AVR only) had rewiring of sternum for sterile wounds and 0.14% (0.06% for AVR only) had re-wiring of sternum for infection. Transient ischaemic attack occurred in only 0.6% and 1.1% had a stroke (no missing data).

1
2
3 Median post-operative length of stay was 7 days (IQR: 6-11) in those with AVR
4 only and 8 days (IQR: 6-12) in all patients.

5
6 The number of bypass grafts was not analysed due to concerns about inconsistent
7 reporting of data describing the number of grafts.

8
9
10 When comparing the two subsets of patients, the characteristics of those with AVR
11 alone were broadly similar to those with AVR+CABG. In AVR alone there were more
12 people aged <60 years (19.3% vs 6.2%), but less people were older than 75 (30.1% vs
13 43%). A higher proportion of those with AVR+CABG were male (68% vs. 54%). Bypass
14 time was an average of 37 minutes shorter and CCT 27 minutes in the AVR alone group.
15 Amongst those with only AVR the mechanical valve usage was greater, at 16% vs 7%.
16
17
18
19
20
21

22 **Regression analysis**

23 **Univariate**

24 Taken in isolation, all pre-operative risk factors were associated with an increased odds
25 of death, as was addition of CABG. The same pattern was observed when analysing the
26 need for re-operation or surgery, with all explanatory variables indicative of a worse
27 outcome without taking into account any others. For new stroke only age, EuroSCORE,
28 operative urgency, ejection fraction, and cumulative bypass and cross clamp times
29 affected a negative outcome (but not gender), as did CABG. All factors predicted a longer
30 postoperative length of stay, including CABG.
31
32
33
34
35
36
37

38 As a sensitivity analysis, age categories were also assessed. When included as a
39 continuous variable, age was significant both on its own and in all the multivariable
40 models. All participants were categorised into <60, 60-75 and >75 years of age. Those
41 60-75 were at a lower odds of death in comparison to those <60 (OR 0.71, 95% CI 0.53-
42 0.95, P=0.021) with no difference in those >75 (OR 1.09, 95% CI 0.82-1.45) in the AVR
43 alone group. These findings were different in the AVR+CABG group, with no significant
44 difference in those 60-75 (OR 0.81, 95% CI 0.64-1.03) but an increased risk in those >75
45 (OR 1.09, 95% CI 1.12-1.76, P=0.004).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Multivariable Analyses

Analysis of postoperative outcomes using multivariable models including all pre-operative and operative factors are shown in Table 2. This demonstrated that age (OR 1.03 (95% CI 1.02-1.04), $P<0.001$), moderate ejection fraction (OR 1.48 (95% CI 1.18-1.85), $P<0.001$), poor ejection fraction (OR 1.90 (95% CI 1.36-2.69), $P<0.001$), logistic EuroSCORE (OR 1.02 (95% CI 1.02-1.03), $P<0.001$), urgent operation (OR 1.63 (95% CI 1.30-2.00, $P<0.001$), emergency surgery (OR 6.87 (95% CI 4.70-10.16), $P<0.001$) and longer CPB times affected mortality (OR 1.02 (95% CI 1.01-1.02), $P<0.001$).

When all other variables were taken into account CABG was not significantly associated with an increase in the risk of death (OR 1.15 (95% CI 0.93-1.42), $P=0.20$).

Older age, (OR 1.01 (95% CI 1.00-1.01), $p<0.006$), longer CPB time (OR 1.00 (95% CI 1.00-1.01), $P<0.001$), urgent (OR 1.26 (95% CI 1.08-2.00), $P<0.002$) and emergency surgery (OR 2.22 (95% CI 1.51-3.26), $P<0.001$) were significant factors in identifying people requiring return to theatre for bleeding. Again, CABG did not affect the odds of returning to theatre (OR 1.07 (95% CI 0.93-1.24), $P=0.33$).

Factors affecting stroke were age, (OR 1.02 (95% CI 1.01-1.03), $P<0.001$), emergency (OR 7.65 (95% CI 5.00-11.70, $P<0.001$) or salvage surgery (OR 4.38 (95% CI 1.47-13.1) $P=0.008$), and CPB times (OR 1.00 (95% CI 1.00-1.01), $P<0.001$). As in the other outcomes, addition of CABG did not affect the outcome (OR 1.12 (95% CI 0.88-1.42), $P=0.37$).

Age, male gender, moderate and poor ejection fraction, operative urgency, higher logistic EuroSCORE, and cumulative bypass time significantly all affected post-operative length of stay.

DISCUSSION

This study reports contemporary results of AVR and AVR+CABG in the UK, reflecting real world practice, reporting an overall mortality of 1.9% and 2.4% respectively. We have shown a low mortality and complication rate for all comers following surgery in people requiring AVR or AVR+CABG. The complications were low with 3.9% re-sternotomy for bleeding, 0.04% re-operation for valvular problems and 1.1% stroke. Surprisingly, having accounted for other risk factors, addition of CABG did not adversely affect the outcomes.

1
2
3 The strengths of the study include its large number of participants, no exclusion of
4 urgent and emergency/salvage cases, and inclusion of all risk participants. The limitations
5 are that three centres were unable to take part, possible coding errors in using large
6 databases, lack of detailed echocardiographic data on valve annular size and presence
7 or absence of pre-operative infective endocarditis which can adversely affect outcomes.
8 In addition, the results are in-hospital mortality and complications and the database lack
9 longer follow-up information.
10

11
12 Data from the current study are consistent with other large international studies.
13 Data from the US Society of Thoracic Surgeons (STS) database demonstrated in-
14 hospital mortality for isolated AVR of 2.5% and incidence of stroke of 1.5%.¹⁵ A recent
15 analysis of the Japanese Cardiovascular Surgery database which assessed the
16 outcomes of patients undergoing AVR over a 8 year period has demonstrated a similar
17 in-hospital mortality of 2%.¹⁶ They also demonstrated a reduction in mortality over time,
18 despite increasing surgical risk.
19

20
21 We had set out to analyse the results of AVR in the UK to inform practitioners
22 treating people with aortic valve disease and inform people with this condition in an era
23 where other therapies for management of aortic valve disease are evolving with
24 expanding indications. Although the current study did not examine people who received
25 TAVI, we discuss the various trials of AVR and TAVI reported in the context of the
26 literature and compare them with the results of the current study.
27

28
29 In Tables 3-5, the demographics, procedural details and outcomes of the current
30 study are compared with the respective sub-groups of the published trials. Table 5 shows
31 low mortality and complication rate in the participants of this study following surgery in
32 people who required AVR or AVR+CABG. The trials comparing AVR and TAVI have
33 enrolled and classified patients according to the risk of surgery, in particular the more
34 recent trials.^{6,7} The most commonly used surgical risk stratification score is the Society of
35 Thoracic Surgery risk score (STS), although this scoring system has been validated in
36 the US population. We have used EuroSCORE and shown that mortality is low in all
37 categories of risk.
38

39
40 There are several recent trials comparing AVR with TAVI. A meta-analysis of six
41 of these trials performed by Barili and colleagues reported that mortality was affected by
42
43
44
45
46
47
48
49
50
51
52

1
2
3 the treatment modality with a time-varying effect: TAVI was related to better survival in
4 the first months after implantation whereas, after 40 months, it was a risk factor for all-
5 cause mortality.¹⁷ The NOTION trial, which compared outcomes of patients estimated to
6 have low surgical risk who underwent either TAVI or AVR demonstrated similar early
7 mortality results, with mortality of 2.1% in TAVI group vs 3.7% in the AVR group, $p=0.38$.¹⁸
8 The PIVOTAL trial of low risk patients also reported similar results between those who
9 underwent TAVI compared to AVR, with early mortality of 0.5% in TAVI group and 1.3%
10 in AVR.⁷ In addition, the 5 year results of the PARTNER 2 study, comparing TAVI vs AVR
11 in intermediate surgical risk demonstrated no significant difference in the incidence of
12 death or stroke at 5 years following AVR or TAVI.¹⁹ The mortality in the intermediate
13 EuroSCORE risk category of the current study was 1.0% for AVR only and 0.9% for
14 AVR+CABG. PARTNER 3 however demonstrated significantly lower mortality in the
15 TAVI group compared to AVR (1% vs 3.3%, $P=0.01$) at one year.⁶ An observational study
16 of 7618 patients comparing AVR with TAVI at 5 years showed however that in a real world
17 population with low and intermediate risk, AVR was associated with lower mortality and
18 major adverse cardiac events, although this was with first generation TAVI devices.²⁰
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Role of co-existent coronary artery disease and its management**

33
34 60% of patients with aortic valve disease undergoing AVR and 65% of those undergoing
35 TAVI have coexisting coronary artery disease.²¹ In our series, 37% had co-existent
36 coronary artery disease and underwent concomitant CABG. The addition of CABG did
37 not adversely affect outcomes. In PARTNER 2, although both groups had a similar
38 number with coexistent coronary artery disease, 14.5% of the AVR group had
39 concomitant CABG compared to 3.9% of the TAVI group who had percutaneous
40 intervention (Table 4).²² AVR may therefore be the preferred treatment modality in those
41 with aortic stenosis and multivessel coronary artery disease requiring revascularisation
42 and is the standard of care in those in younger age groups.
43
44
45
46
47
48
49

50 Treatment of coronary artery disease in TAVI patients may require more than one
51 hospital admission and can often result in incomplete revascularisation and its
52 consequent increased morbidity and mortality. A meta-analysis by Sankaramangalam
53 and colleagues, demonstrated that whilst there was no increase in mortality in patients
54
55
56
57
58
59
60

1
2
3 with coronary artery disease who underwent TAVI at 30 days, there was a significant
4 increase in mortality at one year following TAVI in these patients.²³ The economic costs
5 of readmission after TAVI have been demonstrated to be higher than in those who are
6 readmitted after surgery and so untreated coronary disease which later requires
7 readmission will have cost implications.^{24,25} Surgery has the advantage of addressing all
8 the pathology with one operation.
9

15 **Durability and choice of prosthetic valves**

16
17 In choosing the technique of treatment for aortic valve disease, life expectancy of the
18 person and durability of the valve need to be considered. Ideally, the prosthetic valve
19 should be durable for the person's lifetime. Both of these are related to person's age. In
20 the UK a 50 year old female has a life expectancy of 34 years and a 70 year old male a
21 life expectancy of 14 years.²⁶
22

23
24 The durability of bioprosthetic valves is well documented in the surgical literature
25 and is inversely proportional to person's age. Structural valve deterioration (SVD) has
26 been demonstrated to increase exponentially beyond 10 years following surgery.^{27,28}
27 Considering the UK life expectancy ²⁶, a 70 year old male has a 5% risk of re-operation
28 and a 50 year old female has a 30% chance of needing a second operation. Although
29 long term data regarding the durability of TAVI valves is awaited, the 5 year results of the
30 PARTNER 2 trial demonstrated that the incidence of SVD in the TAVI group was
31 significantly higher than in the AVR group.¹⁹ However, a sub-study of the NOTION trial
32 looked at SVD up to 6 years suggested no significant difference between the AVR and
33 TAVI.²⁹
34

35
36 The durability of tissue valves in surgery are well documented.²⁷ Bagur and
37 colleagues have introduced the concept of valve durability: life expectancy ratio.³⁰ At best,
38 the TAVI valve which is a tissue valve will have the longevity of the best surgical
39 bioprosthetic valves, excluding the deleterious effects of crimping with TAVI valves.³¹ A
40 systematic review of observational data by Foroutan and colleagues looking at 8914
41 patients who underwent TAVI with a follow-up of 1.5 - 5 years showed SVD incidence of
42 0-1.34 per 100 patient-years with a pooled incidence of 28.08 per 10,000 patient-years.³²
43 Of those with SVD, 12% underwent re-intervention.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surgery has the advantage of offering the patient a mechanical or a bioprosthetic valve. The option of a mechanical valve which is only available in surgical AVR should not be overlooked especially in younger people. In the current study, we have shown a fairly consistent ratio of tissue to mechanical valve use. However, the reported literature shows that the number of mechanical valve implantations has reduced in comparison to bioprosthetic valves.¹⁰ Mechanical valves are durable, with one group reporting 6.9% reintervention rate at 15 years versus 12.1% in those who underwent surgery with a bioprosthesis.³³ For this reason, it has been the most commonly considered prosthesis in those under the age of 60, as in our study where 60.2% of participants <60 years had a mechanical valve. Mechanical valves have the disadvantage of requiring anticoagulation, although, newer generations require a lower level of anticoagulation.³⁴ Whilst mechanical valves are more durable, this has to be balanced against the greater risk of bleeding.³³ At 15 years follow up, Chiang and colleagues also demonstrated no significant difference in survival and stroke between patients who underwent AVR with mechanical vs bioprosthetic valve.³³ Another group demonstrated in the 50-70 year old cohort that survival at 5 years was higher in patients who had undergone AVR with mechanical valve vs bioprosthesis and also demonstrated similar freedom from major bleeding events.³⁵

Paravalvular regurgitation and pacemaker implantation

There are several complications associated with TAVI and less with AVR which affect short and long term outcomes. These include paravalvular regurgitation and conduction abnormalities requiring new pacemaker implantation. In the current study less than 0.04% required surgery for paravalvular regurgitation.

In the earlier trials, moderate to severe paravalvular regurgitation was reported in more than 10% of TAVI patients.^{4,36} With advances in TAVI technology, this has decreased to approximately 3.5%, however mild paravalvular regurgitation persists in up to 30% of the patients undergoing TAVI compared to 3% in AVR.^{6,7} The progression of mild paravalvular regurgitation in AVR has not been studied extensively. In those with mild paravalvular leak, very few are noted to have progression of paravalvular regurgitation.³⁷ In TAVI patients however, even mild degrees of regurgitation have been shown to have an impact on long term mortality.³⁸ Padang and colleagues demonstrated

1
2
3 that mild paravalvular leak in both AVR and TAVI patients had no influence on survival in
4 those with high (>8) STS score, however, it was associated with poorer survival in those
5 with lower STS score.³⁹
6
7

8 The development of conduction abnormalities and requirement for permanent
9 pacemaker implantation in patients following TAVI and AVR also needs to be considered.
10 New pacemaker was inserted in 1.6% of the participants of the current study. The
11 incidence after AVR is reported between 2 and 7% compared to 6-34% following
12 TAVI.^{6,7,40,41} Pacemaker implantation can have deleterious effects on left ventricular
13 function and cause lead induced tricuspid regurgitation resulting in right heart failure, both
14 of which are associated with poor outcomes.⁴²⁻⁴⁴
15
16
17
18
19
20
21

22 **Bicuspid aortic valve and aneurysm of the aorta**

23 A significant number of patients requiring AVR have bicuspid aortic valve, which has an
24 incidence of 1-2% in the general population and may present with aortic valve stenosis,
25 regurgitation and ascending aortic aneurysm. The type of native aortic valve is not
26 recorded in the database of our study. Bicuspid aortic valve anatomy, larger annular size,
27 bulky and asymmetric leaflet calcification and dilated ascending aorta all pose technical
28 challenges to TAVI which are not prohibitive risk factors for surgery. BAV may be present
29 in up to 30% of patients undergoing surgical AVR.⁴⁵ In fact, associated pathology of
30 aneurysms of the aortic root and ascending aorta can be treated at the time of AVR with
31 little additional risk.⁴⁶ People with bicuspid aortic valve disease often present at a younger
32 age than those with tricuspid valve. In GARY (the German Aortic Valve Registry), there
33 was an increased incidence of residual aortic insufficiency in the bicuspid group after
34 TAVI compared to the tricuspid aortic valve group.^{47,48}
35
36
37
38
39
40
41
42
43
44
45

46 European guidelines recommend discussing people with aortic valve disease in a multi-
47 disciplinary setting referred to as Heart Team, comprising of a surgeon, a non-
48 interventional and an interventional cardiologist.⁴⁹ This will allow the best treatment option
49 to be put forward to the person.
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

Surgical AVR with and without CABG has low mortality risk and a low level of complications in the UK in people of all ages and risk factors. Our study provides real world experience of surgical results to improve understanding of the risks of surgery and decision making in a multi-disciplinary team (MDT) setting with Heart Team. The results of this study can be utilised by people with aortic valve disease, referring general practitioners, physicians, surgeons and policy makers. Future studies need to address long term follow-up including factors like quality of life which are currently not collected by the specialist centres.

Acknowledgement. We would like to thank all the units (listed below) and the consultant surgeons who submitted their data for analysis. We are indebted to all the database managers and audit officers who have collected this data.

Aberdeen Royal Infirmary
Barts Heart Centre
Blackpool Victoria Hospital
Bristol Heart Institute
Cardiff, University Hospital Wales
Castle Hill Hospital, Hull
Essex Cardiothoracic Centre, Basildon
Freeman Hospital, Newcastle
Glenfield Hospital, Leicester
James Cook Cardiothoracic Centre, South Tees
Hammersmith Hospital, London
Kings College Hospital, London
Liverpool Heart and Chest Hospital
Mater Misericordiae Hospital, Dublin
Morrison Hospital, Swansea
New Cross Hospital, Wolverhampton

1
2
3 Northern General Hospital, Sheffield
4
5 Oxford Heart Centre
6
7 Queen Elizabeth Hospital, Birmingham
8
9 Southampton General Hospital
10
11 St George's Hospital, London
12
13 St Thomas Hospital, London
14
15 Sussex Cardiac Centre, Brighton
16
17 Royal Brompton & Harefield Hospitals, London
18
19 Royal Papworth Hospital, Cambridge
20
21 Royal Stoke University Hospital
22
23 Royal Victoria Hospital, Belfast
24
25 Wythenshawe Hospital, Manchester

26 **Competing interests:** All authors declare no competing interests.
27
28

29 **Ethical approval:** Anonymised data were submitted to the Society for Cardiothoracic
30 Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then stored in a
31 secure database. This data is ordinarily submitted to National Institute of Cardiovascular
32 Outcome Research (NICOR) for which local and national Caldicott guardian approvals
33 have been obtained. A further approval from the Caldicott Guardian was obtained in
34 2020.
35
36
37
38
39
40

41 **Data sharing:** Requests on data sharing can be made by contacting the corresponding
42 author. Data will be shared after review and approval by the authors and terms of
43 collaboration will be reached together with a signed data access agreement.
44
45
46
47

48 The corresponding author (MJ) affirms that the manuscript is an honest, accurate, and
49 transparent account of the study being reported; that no important aspects of the study
50 have been omitted; and that any discrepancies from the study as planned (and, if relevant,
51 registered) have been explained. The manuscript is read and approved by all authors.
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Zakkar M, Bryan AJ, Angelini GD. Aortic stenosis: diagnosis and management. *BMJ* 2016;355:1–9.
- 2 Otto CM, Burwash IG, Legget ME, *et al.* Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997;95:2262–70.
- 3 Cribier A, Eltchaninoff H, Tron C, *et al.* Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 2004;43:698–703.
- 4 Leon MB, Smith CR, Mack M, *et al.* Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med* 2010;363:1597–607.
- 5 Adams DH, Popma JJ, Reardon MJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370:1790–8.
- 6 Mack MJ, Leon MB, Thourani VH, *et al.* Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;380:1695–705.
- 7 Popma JJ, Michael Deeb G, Yakubov SJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 2019;380:1706–15.
- 8 De Backer O, Luk NHV, Olsen NT, *et al.* Choice of Treatment for Aortic Valve Stenosis in the Era of Transcatheter Aortic Valve Replacement in Eastern Denmark (2005 to 2015). *JACC Cardiovasc Interv* 2016;9:1152–8.
- 9 Martin E, Dagenais F, Voisine P, *et al.* Surgical aortic valve replacement outcomes in the transcatheter era. *J Thorac Cardiovasc Surg* 2015;150:1582–8.
- 10 Silaschi M, Conradi L, Treede H, *et al.* Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. *Thorac Cardiovasc Surg* 2016;64:382–9.
- 11 Tam DY, Rocha R V., Wijeyesundera HC, *et al.* Surgical valve selection in the era of

- transcatheter aortic valve replacement in the Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg* 2020;159:416–27.
- 12 Simonato M, Dvir D. Transcatheter aortic valve replacement in failed surgical valves. *Heart* 2019;105:S38–43.
- 13 Landes U, Webb JG, De Backer O, *et al.* Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. *J Am Coll Cardiol* 2020;75:1882–93.
- 14 Huygens SA, Mokhles MM, Hanif M, *et al.* Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2016;50:605–16.
- 15 Thourani VH, Suri RM, Gunter RL, *et al.* Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. *Ann Thorac Surg* 2015;99:55–61.
- 16 Tokuda Y, Yamamoto H, Miyata H, *et al.* Contemporary outcomes of surgical aortic valve replacement in Japan. *Circ J* 2020;84:277–82.
- 17 Barili F, Freemantle N, Pillozzi Casado A, *et al.* Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. *Eur J Cardiothorac Surg* 2020;58:221–9.
- 18 Thyregod HGH, Steinbrüchel DA, Ihlemann N, *et al.* Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. *J Am Coll Cardiol* 2015;65:2184–94.
- 19 Makkar RR, Thourani VH, Mack MJ, *et al.* Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med* 2020;382:799–809.
- 20 Barbanti M, Tamburino C, D'Errigo P, *et al.* Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in a Real World Population: Final Results from the OBSERVANT Study. *Circ Cardiovasc Interv* 2019;12:1–9.
- 21 Sabbagh A El, Nishimura RA. Clinical conundrum of coronary artery disease and aortic valve stenosis. *J Am Heart Assoc* 2017;6:1–3.

- 1
2
3 22 Leon MB, Smith CR, Mack MJ, *et al.* Transcatheter or Surgical Aortic-Valve
4 Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016;374:1609–20.
5
6 23 Sankaramangalam K, Banerjee K, Kandregula K, *et al.* Impact of coronary artery
7 disease on 30-day and 1-year mortality in patients undergoing transcatheter Aortic
8 valve replacement: A meta-analysis. *J Am Heart Assoc* 2017;6:1–11.
9
10 24 Goldsweig AM, Tak HJ, Chen LW, *et al.* Relative Costs of Surgical and
11 Transcatheter Aortic Valve Replacement and Medical Therapy. *Circ Cardiovasc*
12 *Interv* 2020;13:1–9.
13
14 25 Tripathi A, Flaherty MP, Abbott JD, *et al.* Comparison of Causes and Associated
15 Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical Aortic
16 Valve Replacement in the United States (A National Readmission Database Study).
17 *Am J Cardiol* 2018;122:431–9.
18
19 26 O'Neill A. Life expectancy (from birth) in the United Kingdom from 1765 to 2020.
20 Statista. 2020. [https://www.statista.com/statistics/1040159/life-expectancy-united-](https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/)
21 [kingdom-all-time/](https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/) (accessed 7 Aug 2020).
22
23 27 Foroutan F, Guyatt GH, O'Brien K, *et al.* Prognosis after surgical replacement with
24 a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis:
25 Systematic review of observational studies. *BMJ* 2016;354:1–9.
26
27 28 McClure RS, Narayanasamy N, Wiegerinck E, *et al.* Late Outcomes for Aortic Valve
28 Replacement With the Carpentier-Edwards Pericardial Bioprosthesis: Up to 17-
29 Year Follow-Up in 1,000 Patients. *Ann Thorac Surg* 2010;89:1410–6.
30
31 29 Søndergaard L, Ihlemann N, Capodanno D, *et al.* Durability of Transcatheter and
32 Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. *J Am Coll*
33 *Cardiol* 2019;73:546–53.
34
35 30 Bagur R, Pibarot P, Otto CM. Importance of the valve durability-life expectancy ratio
36 in selection of a prosthetic aortic valve. *Heart* 2017;103:1756–9.
37
38 31 Dasi L, Hatoum H, Kheradvar A, *et al.* On The Mechanics of Transcatheter Aortic
39 Valve Replacement Lakshmi. *Ann Biomed Eng* 2017;45:310–31.
40
41 32 Foroutan F, Guyatt GH, Otto CM, *et al.* Structural valve deterioration after
42 transcatheter aortic valve implantation. *Heart* 2017;103:1899–905.
43
44 33 Chiang YP, Chikwe J, Moskowitz AJ, *et al.* Survival and long-term outcomes
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 following bioprosthetic vs mechanical aortic valve replacement in patients aged 50
4 to 69 years. *JAMA - J Am Med Assoc* 2014;312:1323–9.
5
6
7 34 Puskas JD, Gerdisch M, Nichols D, *et al.* Anticoagulation and Antiplatelet Strategies
8 After On-X Mechanical Aortic Valve Replacement. *J Am Coll Cardiol*
9 2018;71:2717–26.
10
11 35 Huckaby L V., Sultan I, Gleason TG, *et al.* Outcomes of tissue versus mechanical
12 aortic valve replacement in patients 50 to 70 years of age. *J Card Surg* Published
13 Online First: 2020.
14
15 36 Athappan G, Patvardhan E, Tuzcu EM, *et al.* Incidence, predictors, and outcomes
16 of aortic regurgitation after transcatheter aortic valve replacement: Meta-analysis
17 and systematic review of literature. *J Am Coll Cardiol* 2013;61:1585–95.
18
19 37 O'Rourke DJ, Palac RT, Malenka DJ, *et al.* Outcome of mild periprosthetic
20 regurgitation detected by intraoperative transesophageal echocardiography. *J Am*
21 *Coll Cardiol* 2001;38:163–6.
22
23 38 Jones BM, Tuzcu EM, Krishnaswamy A, *et al.* Prognostic significance of mild aortic
24 regurgitation in predicting mortality after transcatheter aortic valve replacement. *J*
25 *Thorac Cardiovasc Surg* 2016;152:783–90.
26
27 39 Padang R, Ali M, Greason KL, *et al.* Comparative survival and role of STS score in
28 aortic paravalvular leak after SAVR or TAVR: A retrospective study from the USA.
29 *BMJ Open* 2018;8:1–10.
30
31 40 Moskowitz G, Hong KN, Giustino G, *et al.* Incidence and Risk Factors for
32 Permanent Pacemaker Implantation Following Mitral or Aortic Valve Surgery. *J Am*
33 *Coll Cardiol* 2019;74:2607–20.
34
35 41 Mehaffey JH, Haywood NS, Hawkins RB, *et al.* Need for Permanent Pacemaker
36 After Surgical Aortic Valve Replacement Reduces Long-Term Survival. *Ann Thorac*
37 *Surg* 2018;106:460–5.
38
39 42 Auffret V, Puri R, Urena M, *et al.* Conduction disturbances after transcatheter aortic
40 valve replacement: Current status and future perspectives. *Circulation*
41 2017;136:1049–69.
42
43 43 Cremer PC, Zhang Y, Alu M, *et al.* The incidence and prognostic implications of
44 worsening right ventricular function after surgical or transcatheter aortic valve
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 replacement: insights from PARTNER IIA. *Eur Heart J* 2018;39:2659–67.
4
5 44 McCarthy FH, Vemulapalli S, Li Z, *et al.* Association of Tricuspid Regurgitation With
6 Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of
7 Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy
8 Registry. *Ann Thorac Surg* 2018;105:1121–8.
9
10
11 45 Cozijnsen L, van der Zaag-Loonen HJ, Cozijnsen MA, *et al.* Differences at surgery
12 between patients with bicuspid and tricuspid aortic valves. *Netherlands Hear J*
13 2019;27:93–9.
14
15
16 46 Wallen T, Habertheuer A, Bavaria JE, *et al.* Elective Aortic Root Replacement in
17 North America: Analysis of STS Adult Cardiac Surgery Database. *Ann Thorac Surg*
18 2019;107:1307–12.
19
20
21 47 Bauer T, Linke A, Sievert H, *et al.* Comparison of the effectiveness of transcatheter
22 aortic valve implantation in patients with stenotic bicuspid versus tricuspid aortic
23 valves (from the German TAVI Registry). *Am J Cardiol* 2014;113:518–21.
24
25
26 48 Halim SA, Edwards FH, Dai D, *et al.* Outcomes of transcatheter aortic valve
27 replacement in patients with bicuspid aortic valve disease: A report from the Society
28 of Thoracic Surgeons/American College of Cardiology Transcatheter valve Therapy
29 registry. *Circulation* 2020;141:1071–9.
30
31
32 49 Baumgartner H, Falk V, Bax J *et al.* 2017 ESC / EACTS Guidelines for the
33 management of valvular heart disease The Task Force for the Management of
34 Valvular Heart Disease of the European Society of Cardiology (ESC) and the
35 European. *Eur Heart J* 2017;38:2739–86.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1. Mortality (%) for different categories of age and EuroSCORE

Age (years)	AVR	AVR+CABG
<60	2.0	2.2
60-75	1.5	1.8
>75	2.2	3.1
EuroSCORE	AVR	AVR+CABG
<3%	1.3	2.0
3-6%	1.0	0.9
>6%	3.9	4.4

Table 2. Multivariable modelling of post-operative outcomes using pre-operative and operative factors

Predictor	missing	Category	Hospital mortality		Return to theatre for bleeding		New stroke		Post-operative length of stay (days)	
			Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value
Age (years)	7.9%	<i>per unit increase</i>	1.03 (1.02-1.04)	<0.001	1.01 (1.00-1.01)	0.006	1.02 (1.01-1.03)	0.001	1.00 (1.00-1.00)	<0.001
Gender	10.3%	Female Male	- 0.63 (0.51-0.77)	<0.001	- 1.18 (1.02-1.36)	- 0.026	- 1.02 (0.80-1.29)	- 0.89	- 0.94 (0.93-0.96)	- <0.001
LVEF	3.1%	Good (>50%) Moderate (30-50%) Poor (<30%)	- 1.48 (1.18-1.85) 1.90 (1.36-2.69)	- 0.001 <0.001	- 1.08 (0.91-1.27) 1.10 (0.82-1.48)	- 0.38 0.53	- 1.13 (0.86-1.48) 0.78 (0.44-1.38)	- 0.38 0.40	- 1.08 (1.06-1.10) 1.07 (1.03-1.11)	- <0.001 0.001
EuroSCORE Logistic	12.1%	<i>per unit increase</i>	1.02 (1.02-1.03)	<0.001	1.01 (1.00-1.01)	0.16	1.00 (0.99-1.02)	0.30	1.01 (1.01-1.01)	<0.001
Operative Urgency	0.02%	1. Elective 2. Urgent 3. Emergency 4. Salvage	- 1.63 (1.30-2.00) 6.87 (4.70-10.16) 11.79 (5.73-24.27)	- <0.001 <0.001 <0.001	- 1.26 (1.08-2.00) 2.22 (1.51-3.26) 1.51 (0.56-4.02)	- 0.002 <0.001 0.41	- 1.08 (0.83-1.41) 7.65 (5.00-11.70) 4.38 (1.47-13.1)	- 0.55 <0.001 0.008	- 1.18 (1.16-1.20) 1.78 (1.67-1.90) 1.25 (1.07-1.46)	- <0.001 <0.001 0.006
Cumulative Bypass Time (mins)	2.4%	<i>per unit increase</i>	1.02 (1.01-1.02)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.00)	<0.001
Cumulative Cross Clamp Time (mins)	2.5%	<i>per unit increase</i>	0.99 (0.99-0.99)	<0.001	1.00 (1.00-1.00)	0.23	1.00 (0.99-1.00)	0.58	1.00 (1.00-1.00)	0.78
CABG	0%	No Yes	- 1.15 (0.93-1.42)	- 0.20	- 1.07 (0.93-1.24)	- 0.33	- 1.12 (0.88-1.42)	- 0.37	- 1.03 (1.00-1.05)	- <0.001

LVEF; left ventricular ejection fraction, CABG; coronary artery bypass graft surgery

Table 3. Baseline characteristics in the current study (UK AVR) versus those in recent trials comparing AVR with TAVI

Characteristic	UK AVR		PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	AVR N=31,277	AVR N=1021	TAVR N=1011	AVR N=454	TAVI N=496	AVR N=678	TAVI N=725	AVR N=357	TAVI N=390	AVR N=135	TAVI N=145	
Age (mean±SD)	70.1±11.5	81.7±6.7	81.5±6.7	73.6±6.1	73.3±5.8	73.6±5.9	74.1±5.8	83.2±6.4	83.1±7.1	79 ± 4.7	79.2 ± 4.9	
% Male	59	54.8	54.2	71.1	67.5	66.2	64	52.4	53.1	53.8	52.8	
BMI (kg/m ²)	28.9±5.5	28.3±6.2	28.6±6.2	30.3±5.1	30.7±5.5	NR	NR	NR	NR	NR	NR	
NYHA class III/IV (%)	44.4	76.3	77.3	23.8	31.2	28.4	25.1	86.9	85.7	45.5	48.6	
Logistic EuroSCORE (%)	4.3±7.3	NR	NR	1.5±0.9*	1.5±1.2*	NR	NR	18.6±13.0	17.7±13.1	8.9 ± 5.5	8.4 ± 4.0	
Diabetes Mellitus (%)	22.2	34.2	37.7	30.2	31.2	30.5	31.4	45.4	34.9	20.7	17.9	
Chronic Kidney Disease (%)	3.1	5.2	5.0	0.2	0.2	0.1	0.4	12.8	12.2	0.7	1.4	
Hypertension (%)	64.9	NR	NR	NR	NR	82.6	84.8	96.1	95.1	76.3	71.0	
Peripheral vascular disease (%)	8.7	32.9	27.9	7.3	6.9	7.5	8.3	41.7	41.1	6.7	4.1	
Previous stroke (%)	8.2	31	32.1	5.1	3.4	10.2	11.8	14.0	12.6	16.3	16.6	
COPD (%)	13.4	30.0	31.8	6.2	5.1	15.0	18.0	9.0	13.3	11.9	11.7	
LV ejection fraction (%)	53.2	55.3±11.9	56.2±10.8	66.2±8.6	65.7±9.0	61.9 ± 7.7	61.7 ± 7.9	NR	NR	NR	NR	
Coronary artery disease (%)	37.1	66.5	69.2	28.0	27.7	NR	NR	75.9	75.4	NR	NR	
Atrial fibrillation	10.3	35.2	31.0	18.8	15.7	14.5	15.4	45.9	40.9	25.6	27.8	
Permanent pacemaker	1.9	12.0	11.7	2.9	2.4	3.8	3.2	21.3	23.3	4.4	3.4	

AVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, BMI; body mass index, NYHA; New York Heart Association classification, COPD; chronic obstructive pulmonary disease, NR; not reported

*EuroSCORE II reported only

Table 4. Operative characteristics in the current study (UK AVR) versus those in recent trials comparing AVR with TAVI

Characteristic	UK AVR	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷		AVOTAL ⁵		NOTION ¹⁸	
	AVR N=31,277	AVR N=1021	TAVI N=1011	AVR N=454	TAVI N=496	AVR N=678	TAVI N=725	AVR N=557	TAVI N= 390	AVR N= 135	TAVI N= 145
Operative urgency											
Elective (%)	74.3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Urgent (%)	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Emergency/Salvage (%)	1.7	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Concomitant CABG (%)	37.1	NR	-	12.8	-	13.6	-	4	-	1	-
Staged PCI	-	-	NR	-	6.5	-	6.9	-	0.3%	-	0
Cross clamp time (minutes)	79.0	NR	-	74.3 ± 27.78	-	68.7 ± 29.0	-	74.9 ± 31.4	-	NR	NR
Cardiopulmonary bypass time (minutes)	104	NR	-	97.7 ± 33.75	-	93.4 ± 40.2	-	104.0 ± 45.8	-	NR	NR
Procedure time (minutes)	NR	NR	NR	208.3 ± 62.1	58.6 ± 36.5	276.6 ± 79.5	148.2 ± 55.1	222 ± 84.8	60.4 ± 35.3	177.2 ± 39.8	90.3 ± 38.6

AVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

Table 5. Outcomes following surgical AVR in the current study (UK AVR) versus those in recent trials comparing AVR with TAVI

Outcome	UK AVR	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	AVR N=31,277	AVR N=1021	TAVI N=1011	AVR N=454	TAVI N=496	AVR N=678	TAVI N=725	AVR N= 357	TAVI N= 390	AVR N= 135	TAVI N= 145
In-hospital death/30-day mortality (%)	1.9	8.0	6.1	3.3	1.0	1.3	0.5	4.5	3.3	3.7	2.1
Stroke (%)	1.1	6.1	5.5	2.4	0.6	3.4	3.4	6.2	4.9	3.0	1.4
Reoperation for bleeding (%)	3.6	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Post procedure bleeding (%)	-	43.4	10.4	11.9	1.2	7.5	2.4	69.5	41.7	11.3	20.9
Deep sternal wound infection (%)	0.14	NR	-	NR	-	NR	-	NR	-	NR	-
Length of hospital stay (days)	7	NR	-	7.0	3.0	NR	NR	NR	NR	8.9 ± 6.2	12.9 ± 11.6
New pacemaker implantation (%)	1.6	6.9	8.	4.0	6.5	6.1	17.4	7.1	19.8	1.6	34.1

AVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2020-046491 on 28 October 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	4-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	6

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9

Discussion

Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA
---------	----	---	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046491.R1
Article Type:	Original research
Date Submitted by the Author:	04-May-2021
Complete List of Authors:	<p>Jhangiri, Marjan; St George's Hospital, Department of Cardiac Surgery Bilkhu, Rajdeep; St George's Hospital, Department of Cardiac Surgery Embleton-Thirsk, Andrew; University College London Institute of Clinical Trials and Methodology Dehbi, Hakim-Moulay; University College London Institute of Clinical Trials and Methodology Mani, Krishna; St George's Hospital, Department of Cardiac Surgery Anderson, Jon ; Hammersmith Hospital, Department of Cardiac Surgery Avlonitis, Vassilios; St Thomas' Hospital, Department of Cardiac Surgery Baghai, Max; King's College Hospital, Department of Cardiac Surgery Birdi, Inderpaul; Essex Cardiothoracic Centre Booth, Karen; Freeman Hospital Cardiothoracic Centre Bose, Amal; Lancashire Cardiac Centre Briffa, Norman; Sheffield Teaching Hospitals NHS Foundation Trust Cardiothoracic Centre Buchan, Keith; Aberdeen Royal Infirmary, Cardiac Surgery Bhudia, Sunil; Harefield Hospital Heart Surgery Cale, Alex; Castle Hill Hospital, Cardiac Surgery Deglurkar, Indu; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Farid, Shakil; Oxford University Hospitals NHS Trust, Cardiac Surgery Hadjinikolaou, Leonidas; University Hospitals of Leicester NHS Trust, Cardiac Surgery Jarvis, Martin; Hull University Teaching Hospitals NHS Trust, Cardiac Surgery Javadpour, Seyed; Mater Misericordiae University Hospital, Cardiac Surgery Jeganathan, Reubendra; Royal Victoria Hospital, Cardiac Surgery Kuduvalli, Manoj; Liverpool Heart and Chest Hospital NHS Foundation Trust, Cardiac Surgery Lall, Kulvinder; Saint Bartholomew's Hospital Barts Heart Centre Mascaro, Jorge; Queen Elizabeth Medical Centre, Cardiac Surgery Mehta, Dheeraj; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Ohri, Sunil; Southampton University Hospitals NHS Trust, Cardiac Surgery Punjabi, Prakash; Hammersmith Hospital, Cardiac Surgery Venkateswaran, Rajamiyer ; Wythenshawe Hospital North West Heart Centre</p>

	Ridley, Paul; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Satur, Christopher; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Stoica, Serban; Bristol Heart Institute Trivedi, Uday; Royal Sussex County Hospital Sussex Cardiac Centre Zaidi, Afzal; Morrison Hospital, Cardiac Surgery Yiu, Patrick; New Cross Hospital, Cardiac Surgery Moorjani, Narain; Royal Papworth Hospital NHS Foundation Trust Cardiac Surgery Kendall, Simon; James Cook University Hospital, Cardiac Surgery Freemantle, Nick; University College London Institute of Clinical Trials and Methodology, Comprehensive Clinical Trials Unit
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiothoracic surgery < SURGERY, Cardiac surgery < SURGERY, CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 **Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK**
6 **national database**
7

8
9
10 Marjan Jahangiri, Rajdeep Bilkhu**, Andrew Embleton-Thirsk**,
11 Hakim-Moulay Dehbi*, Krishna Mani, Jon Anderson, Vassilios Avlonitis, Max Baghai, Inderpaul Birdi, Karen Booth, Amal Bose,
12 Norman Briffa, Keith Buchan, Sunil Bhudia, Alex Cale, Indu Deglurkar, Shakil Farid, Leonidas Hadjinikolaou, Martin Jarvis, Seyed
13 Hossein Javadpour, Reubendra Jeganathan, Manoj Kuduvalli, Kulvinder Lall, Jorge Mascaro, Dheeraj Mehta, Sunil Ohri, Prakash
14 Punjabi, Venkateswaran Rajamiyer, Paul Ridley, Christopher Satur, Serban Stoica, Uday Trivedi, Afzal Zaidi, Patrick Yiu, Narain
15 Moorjani, Simon Kendall, Nick Freemantle*

16
17
18 ** RB/AE equal contributions

19 Names of cardiac surgical units and affiliations are given below
20 Institute of Clinical Trials and Methodology, University College London*
21
22
23
24
25

26 **Word Count:** 3906
27
28
29
30

31 **Key words:** aortic valve replacement, aortic valve disease, surgery
32
33
34

35 Address for correspondence:
36 Marjan Jahangiri
37 Professor of Cardiac Surgery
38 St. George's Hospital
39 London SW17 0QT
40
41
42
43
44

Tel: 44-2087252652

Email: marjan.jahangiri@stgeorges.nhs.uk

1. Marjan Jahangiri
Affiliation: St George's Hospital, London
2. Rajdeep Bilkhu
Affiliation: St Thomas Hospital, London
3. Andrew Embleton-Thirsk
Affiliation: Institute of Clinical Trials and Methodology, University College London
4. Hakim-Moulay Dehbi
Affiliation: Institute of Clinical Trials and Methodology, University College London
5. Krishna Mani
Affiliation: St George's Hospital, London
6. Jon Anderson
Affiliation: Hammersmith Hospital, London
7. Vassilios Avlonitis
Affiliation: St Thomas Hospital, London
8. Max Baghai
Affiliation: Kings College Hospital, London
9. Inderpaul Birdi
Affiliation: Essex Cardiothoracic Centre, Basildon
10. Karen Booth
Affiliation: Freeman Hospital, Newcastle
11. Norman Briffa

- 1
2
3 Affiliation: Northern General Hospital, Sheffield
4
5 12. Keith Buchan
6 Affiliation: Aberdeen Royal Infirmary
7
8 13. Sunil Bhudia
9 Affiliation: Royal Brompton & Harefield Hospitals, London
10
11 14. Alex Cale
12 Affiliation: Castle Hill Hospital, Hull
13
14 15. Indu Deglurkar
15 Affiliation: Cardiff, University Hospital Wales
16
17 16. Shakil Farid
18 Affiliation: Oxford Heart Centre
19
20 17. Leonidas Hadjinikolaou
21 Affiliation: Glenfield Hospital, Leicester
22
23 18. Martin Jarvis
24 Affiliation: Castle Hill Hospital, Hull
25
26 19. Seyed Hossein Javadpour
27 Affiliation: Mater Misericordiae Hospital, Dublin
28
29 20. Reubendra Jeganathan
30 Affiliation: Royal Victoria Hospital, Belfast
31
32 21. Manoj Kuduvalli
33 Affiliation: Liverpool Heart and Chest Hospital
34
35 22. Kulvinder Lall
36 Affiliation: Barts Heart Centre
37
38
39
40
41
42
43
44
45
46
47

- 1
2
3 23. Jorge Mascaro
4 Affiliation: Queen Elizabeth Hospital, Birmingham
5
- 6 24. Dheeraj Mehta
7 Affiliation: Cardiff, University Hospital Wales
8
- 9 25. Sunil Ohri
10 Affiliation: Southampton General Hospital
11
- 12 26. Prakash Punjabi
13 Affiliation: Hammersmith Hospital, London
14
- 15 27. Venkateswaran Rajamiyer
16 Affiliation: Wythenshawe Hospital, Manchester
17
- 18 28. Paul Ridley
19 Affiliation: Royal Stoke University Hospital
20
- 21 29. Christopher Satur
22 Affiliation: Royal Stoke University Hospital
23
- 24 30. Serban Stoica
25 Affiliation: Bristol Heart Institute
26
- 27 31. Uday Trivedi
28 Affiliation: Sussex Cardiac Centre, Brighton
29
- 30 32. Afzal Zaidi
31 Affiliation: Morriston Hospital, Swansea
32
- 33 33. Patrick Yiu
34 Affiliation: New Cross Hospital, Wolverhampton
35
- 36 34. Narain Moorjani
37
38
39
40
41
42
43
44
45
46
47

1
2
3 Affiliation: Royal Papworth Hospital, Cambridge

4
5 35. Simon Kendall

6 Affiliation: James Cook Cardiothoracic Centre, South Tees

7
8 36. Nick Freemantle

9 Affiliation: Institute of Clinical Trials and Methodology, University College London

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

ABSTRACT

Objectives - To date the reported outcomes of surgical aortic valve replacement (SAVR) are mainly in the settings of trials comparing it with evolving transcatheter aortic valve implantation (TAVI). We set out to examine the characteristics and outcomes in people who underwent AVR reflecting a national cohort and therefore 'real world' practice.

Design - Retrospective analysis of prospectively collected data of consecutive people who underwent SAVR with or without coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the UK. This included elective, urgent and emergency operations. Participants' demographics, pre-operative risk factors, operative data, in-hospital mortality, post-operative complications and effect of the addition of CABG to SAVR were analysed.

Setting - 27 (90%) tertiary cardiac surgical centres in the UK submitted their data for analysis.

Participants - 31,277 people with AVR were identified. 19,670 (62.9%) had only SAVR and 11,607 (37.1%) had AVR+CABG.

Results - Mortality for isolated SAVR was 1.9% (95% CI: 1.6-2.1%) and was 2.4% for AVR+CABG. Mortality by age category for SAVR only were: <60 years=2.0%, 60-75 years=1.5%, >75 years=2.2%. For SAVR+CABG these were; 2.2%, 1.8% and 3.1%. For different categories of EuroSCORE, mortality for SAVR in low risk people was 1.3%, in intermediate risk 1% and for high risk 3.9%. 74.3% of the operations were elective, 24% urgent and 1.7% emergency/salvage. The incidences of re-sternotomy for bleeding and stroke were 3.9% and 1.1% respectively. Multivariable analyses provided no evidence that concomitant CABG influenced outcome. However, urgency of the operation, poor ventricular function, higher EuroSCORE and longer cross clamp and cardiopulmonary bypass times adversely affected outcomes.

Conclusions - Surgical SAVR±CABG has low mortality risk and a low level of complications in the UK in people of all ages and risk factors. These results should inform consideration of treatment options in people with aortic valve disease.

Strengths and limitations of this study

- This is a large study of consecutive participants who have undergone surgical aortic valve replacement ± coronary artery bypass graft surgery in the UK, reporting contemporary outcomes.
- This study includes people of all age groups and risks factors, and elective as well as urgent and emergency operations.
- The results are of in-hospital mortality and complications and longer term follow-up data is not available.

BACKGROUND

Aortic valve disease, especially aortic stenosis affects 5% of the population and 3.9% of those between the ages of 70 and 79 and nearly 10% of those above the age of 80.¹ Severe aortic stenosis when untreated has a risk of death of 50% at 2 years.² Conventionally the gold standard of treatment has been surgical aortic valve replacement (SAVR). However, the role of transcatheter aortic valve implantation (TAVI) has evolved in recent years. TAVI was first introduced in 2002, initially being performed in high risk inoperable patients.³ The original Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated a significant reduction in mortality, repeat hospitalisation and cardiac symptoms compared to inoperable patients who had only medical therapy.⁴ The original PIVOTAL study also demonstrated significantly higher survival at one year in high risk patients who underwent SAVR.⁵

The role of TAVI is being extended to lower risk and younger patients based on recent trials comparing SAVR with TAVI.^{6,7} Several studies suggest there has been a change in demographics and types of surgical valves used since the advent of TAVI.⁸⁻¹⁰ There has been a trend of increased use of tissue valves and a decrease in the use of mechanical valves in recent years.¹¹ This may be due to the evolution of TAVI practice whereby younger patients can have a tissue valve with the view that they have a TAVI valve in the future when the tissue valve has deteriorated, so called valve-in-valve.^{12,13}

The series in the literature reporting outcomes of SAVR are generally unit based.^{9,14} Also, people with aortic valve disease are given information about the outcomes of SAVR which may be out of date and incorrectly extrapolated from smaller studies. There is a lack of contemporary national data to assess the outcomes of SAVR (mortality and complications), and to demonstrate the trend in use of prosthetic valves which would inform people with aortic valve disease better. There are some perceived complications of surgery that may be understood by referring general practitioners and cardiologists to be prohibitive risks for surgery.

In order to inform practitioners, people with aortic valve disease and the cardiac surgical community, we set out to examine the results of contemporaneous SAVR in a multi-centre study of UK cardiac surgical units in the era of TAVI. In addition, we summarise and interpret some of the more recent trials on the management of aortic valve disease.

METHODS

Data

This is an analysis of prospectively collected data of people who underwent SAVR +/- coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the UK and Republic of Ireland. Anonymised data were submitted to the Society for Cardiothoracic Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then stored in a secure database. This period was chosen to reflect fairly contemporary practice and also the data is submitted in March every year. The data is collected by each unit, validated and then submitted to the National Institute of Cardiovascular Outcome Research (NICOR). It took approximately nine months to collect, validate and clean all the data. The outcome measures recorded are based on strict definitions provided by NICOR to provide uniformity.

Only participants who had had first time surgery, SAVR +/- CABG were included. All participants immaterial of their risk for surgery, people of all age groups and risk factors were included. Those who required other concomitant procedures like replacement of parts of the aorta, aortic root enlargement, other valve procedures and redo surgery were excluded.

Pre-operative risk factors and operative features

Baseline demographic data; significant past medical history such as diabetes, renal dysfunction, hypertension or stroke; predominant aortic valve pathology (stenosis or regurgitation or mixed valve disease) and preoperative left ventricular ejection fraction (LVEF) were collected. EuroSCORE is the risk stratification model used in the UK. Logistic EuroSCORE

was collected as well as EuroSCORE II where available. The latter was only used since 2017 and therefore not available for all participants. Logistic EuroSCORE was divided into three categories: <3%, 3-6%, >6%.

LVEF was divided into three categories: good (EF>50%), moderate (EF 30-50%) and poor (EF<30%). Transient ischaemic attack was defined as any neurological symptoms lasting <24 hours. Stroke was defined as new neurological dysfunction persisting >24 hours. Operative data including operative urgency: elective, urgent and emergency/salvage were recorded. Elective was defined as when the person was admitted from home, urgent meaning that the person was admitted with an urgent condition and required surgery during the same hospital admission, emergency and salvage meaning that surgery was required within 24 hours of admission and/or the person was in extremis. Other parameters including cardiopulmonary bypass (CPB) time, cross clamp (CCT) time, type of valve implanted as well as concomitant CABG surgery performed were also collected.

Postoperative outcomes

Postoperative complication data were collected with the main focus being in-hospital mortality, new stroke, return to theatre for bleeding, deep sternal wound infection and duration of postoperative hospital stay.

Statistical analysis

Once the records for all participants were collated and the data cleaned, each factor was summarised using descriptive methods. Categorical variables are presented as N (%) and continuous variables are presented as median (IQR). New strokes were recoded to be either no stroke or any cerebrovascular accident (transient or permanent). The natural log of post-operative length of stay (days) was used due to positive skewed distribution of this variable. Univariate models were used, logistic regression for binary outcomes and linear regression for continuous outcomes, to assess the impact of the key explanatory variables. In these models, a two-tailed p-value of <0.05 was considered significant. The population analysed included all the participants with data collected, with results checked in the subset who had SAVR only (without

CABG). Building on this, a multivariable model with all key variables in the model to assess which had the most impact on each of the outcomes was created. Stata/MP 15.1 (StataCorp LLC, Texas, USA) was used for all analyses. Multiple imputation of missing data was not performed. The missingness was mostly negligible. There was no missing mortality and the data is shown in Table 1.

Patient and public involvement

Patients and public were involved in the original design of the database.

Ethics

This data is ordinarily submitted to National Institute of Cardiovascular Outcome Research (NICOR) for which local and national Caldicott guardian approvals have been obtained. The data are validated by the surgical teams and their database managers/audit officers. For the current study a further approval from the Caldicott Guardian was obtained.

RESULTS

Descriptive analysis

In total 31,277 patients were included. Of these, 19,670 (62.9%) had only SAVR and 11,607 (37.1%) had SAVR+CABG. There were 14.4% below the age of 60, 46.9% between 60 to 75 and 36.7% older than 75 years with 7.9% missing age data. There were 1.9 times more males than females (10.3% missing).

Regarding pre-operative risk factors, 75.2% had good LVEF, 17.3% had moderate and 4.3% had poor LVEF. 74.3% of the operations were elective, 24% were urgent and 1.7% were emergency or salvage operations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Logistic EuroSCORE had a median of 1.83 with an IQR of 0.06-6.0. In total, 50% of patients were classified as low risk (<3%), 16% as medium risk (3—6%) and 22% high risk (>6%). 3,792 patients (12.1%) were missing data. The median EuroSCORE II was 1.95 (IQR 0.67-4.8) albeit with 56.5% with missing data, as this was introduced into the database in 2017. The median CPB time was 104 minutes (IQR 82-135) and CCT was 79 minutes (IQR 61-101).

For valve implant replacement type, 70% had a tissue valve, 12.2% a mechanical valve and 0.2% had homograft or autograft valves. For 17.3% the entry for valve type was unclear. The ratio of mechanical implant to bioprosthetic implant use has remained stable over time.

Overall mortality was 2.4% (95% CI: 2.2-2.6%) and mortality for isolated SAVR for all participants was 1.9% (1.6-2.1%). The mortality figures analysed for different age ranges and for categories of EuroSCORE are shown in Table 2.

Overall, 3.9% (3.6% in SAVR only) of participants had re-sternotomy for post-operative bleeding or tamponade, 0.04% (0.06% in SAVR only) had re-operation for valvular problems (significant paravalvular leak and early endocarditis), 0.7% (0.6% SAVR only) had re-operation for other cardiac problems, 0.2% (0.15% for SAVR only) had rewiring of sternum for sterile wounds and 0.14% (0.06% for SAVR only) had re-wiring of sternum for infection. Transient ischaemic attack occurred in only 0.6% and 1.1% had a stroke (no missing data).

Median post-operative length of stay was 7 days (IQR: 6-11) in those with SAVR only and 8 days (IQR: 6-12) in all patients.

The number of bypass grafts was not analysed due to concerns about inconsistent reporting of data describing the number of grafts.

When comparing the two subsets of patients, the characteristics of those with SAVR alone were broadly similar to those with SAVR+CABG. In SAVR alone there were more people aged <60 years (19.3% vs 6.2%), but less people were older than 75 (30.1% vs 43%). A higher proportion of those with SAVR+CABG were male (68% vs. 64%). Bypass time was

an average of 37 minutes shorter and CCT 27 minutes in the SAVR alone group. Amongst those with only SAVR the mechanical valve usage was greater, at 16% vs 7%.

Regression analysis

Univariable

Taken in isolation, all pre-operative risk factors were associated with an increased odds of death, as was addition of CABG. The same pattern was observed when analysing the need for re-operation or surgery, with all explanatory variables indicative of a worse outcome without taking into account any others. For new stroke only age, EuroSCORE, operative urgency, ejection fraction, and cumulative bypass and cross clamp times affected a negative outcome (but not gender), as did CABG. All factors predicted a longer postoperative length of stay, including CABG.

As a sensitivity analysis, age categories were also assessed. When included as a continuous variable, age was significant both on its own and in all the multivariable models. All participants were categorised into <60, 60-75 and >75 years of age. Those 60-75 were at a lower odds of death in comparison to those <60 (OR 0.71, 95% CI 0.53-0.95, P=0.021) with no difference in those >75 (OR 1.09, 95% CI 0.82-1.45) in the AVR alone group. These findings were different in the SAVR+CABG group, with no significant difference in those 60-75 (OR 0.81, 95% CI 0.64-1.03) but an increased risk in those >75 (OR 1.09, 95% CI 1.12-1.76, P=0.004).

Multivariable Analyses

Analysis of postoperative outcomes using multivariable models including all pre-operative and operative factors are shown in Table 1. This demonstrated that age (OR 1.03 (95% CI 1.02-1.04), P<0.001), moderate ejection fraction (OR 1.48 (95% CI 1.18-1.85), P<0.001), poor ejection fraction (OR 1.90 (95% CI 1.36-2.69), P<0.001), logistic EuroSCORE (OR 1.02 (95%

CI 1.02-1.03), $P < 0.001$), urgent operation (OR 1.63 (95% CI 1.30-2.00, $P < 0.001$), emergency surgery (OR 6.87 (95% CI 4.70-10.16), $P < 0.001$) and longer CPB times affected mortality (OR 1.02 (95% CI 1.01-1.02), $P < 0.001$).

When all other variables were taken into account CABG was not significantly associated with an increase in the risk of death (OR 1.15 (95% CI 0.93-1.42), $P = 0.20$).

Older age, (OR 1.01 (95% CI 1.00-1.01), $p < 0.006$), longer CPB time (OR 1.00 (95% CI 1.00-1.01), $P < 0.001$), urgent (OR 1.26 (95% CI 1.08-2.00), $P < 0.002$) and emergency surgery (OR 2.22 (95% CI 1.51-3.26), $P < 0.001$) were significant factors in identifying people requiring return to theatre for bleeding. Again, CABG did not affect the odds of returning to theatre (OR 1.07 (95% CI 0.93-1.24), $P = 0.33$).

Factors affecting stroke were age, (OR 1.02 (95% CI 1.01-1.03), $P < 0.001$), emergency (OR 7.65 (95% CI 5.00-11.70, $P < 0.001$) or salvage surgery (OR 4.38 (95% CI 1.47-13.1) $P = 0.008$), and CPB times (OR 1.00 (95% CI 1.00-1.01), $P < 0.001$). As in the other outcomes, addition of CABG did not affect the outcome (OR 1.12 (95% CI 0.88-1.42), $P = 0.37$).

Age, male gender, moderate and poor ejection fraction, operative urgency, higher logistic EuroSCORE, and cumulative bypass time significantly all affected post-operative length of stay.

DISCUSSION

This study reports contemporary results of SAVR and SAVR+CABG in the UK, reflecting real world practice, reporting an overall mortality of 1.9% and 2.4% respectively. We have shown a low mortality and complication rate for all comers following surgery in people requiring SAVR or SAVR+CABG. The complications were low with 3.9% re-sternotomy for bleeding, 0.04% re-operation for valvular problems and 1.1% stroke. Surprisingly, having accounted for other risk factors, addition of CABG did not adversely affect the outcomes.

The strengths of the study include its large number of participants, no exclusion of urgent and emergency/salvage cases, and inclusion of all risk participants. The limitations are that three centres were unable to take part, possible coding

1
2
3 errors in using large databases, lack of detailed echocardiographic data on valve annular size and presence or absence of
4 pre-operative infective endocarditis which can adversely affect outcomes. In addition, the results are in-hospital mortality
5 and complications and the database lack longer follow-up information.
6
7

8 Data from the current study are consistent with other large international studies. Data from the US Society of Thoracic
9 Surgeons (STS) database demonstrated in-hospital mortality for isolated SAVR of 2.5% and incidence of stroke of 1.5%.¹⁵
10 A recent analysis of the Japanese Cardiovascular Surgery database which assessed the outcomes of patients undergoing
11 SAVR over a 8 year period has demonstrated a similar in-hospital mortality of 2%.¹⁶ They also demonstrated a reduction in
12 mortality over time, despite increasing surgical risk. The age of the patients in our study is lower than some of the trials of
13 SAVR and TAVI. This is probably due to the selection criteria in these trials where older patients were selected.
14
15

16 We had set out to analyse the results of SAVR in the UK to inform practitioners treating people with aortic valve
17 disease and inform people with this condition in an era where other therapies for management of aortic valve disease are
18 evolving with expanding indications. Although the current study did not examine people who received TAVI, we discuss the
19 various trials of SAVR and TAVI reported in the context of the literature and compare them with the results of the current
20 study.
21
22

23 In Tables 3-5, the demographics, procedural details and outcomes of the current study are compared with the
24 respective sub-groups of the published trials. Table 5 shows low mortality and complication rate in the participants of this
25 study following surgery in people who required SAVR or SAVR+CABG. The trials comparing AVR and TAVI have enrolled
26 and classified patients according to the risk of surgery, in particular the more recent trials.^{6,7} The most commonly used
27 surgical risk stratification score is the Society of Thoracic Surgery risk score (STS), although this scoring system has been
28 validated in the US population. We have used EuroSCORE and shown that mortality is low in all categories of risk.
29
30

31 There are several recent trials comparing SAVR with TAVI. A meta-analysis of six of these trials performed by Barili
32 and colleagues reported that mortality was affected by the treatment modality with a time-varying effect: TAVI was related
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

to better survival in the first months after implantation whereas, after 40 months, it was a risk factor for all-cause mortality.¹⁷ The NOTION trial, which compared outcomes of patients estimated to have low surgical risk who underwent either TAVI or SAVR demonstrated similar early mortality results, with mortality of 2.1% in TAVI group vs 3.7% in the SAVR group, $p=0.38$.¹⁸ The PIVOTAL trial of low risk patients also reported similar results between those who underwent TAVI compared to SAVR, with early mortality of 0.5% in TAVI group and 1.3% in SAVR.⁷ In addition, the 5 year results of the PARTNER 2 study, comparing TAVI vs SAVR in intermediate surgical risk demonstrated no significant difference in the incidence of death or stroke at 5 years following SAVR or TAVI.¹⁹ The mortality in the intermediate EuroSCORE II risk category of the current study was 1.0% for SAVR only and 0.9% for SAVR+CABG. PARTNER 3 however demonstrated significantly lower mortality in the TAVI group compared to SAVR (1% vs 3.3%, $P=0.01$) at one year.⁶ An observational study of 7618 patients comparing SAVR with TAVI at 5 years showed however that in a real world population with low and intermediate risk, SAVR was associated with lower mortality and major adverse cardiac events, although this was with first generation TAVI devices.²⁰

Role of co-existent coronary artery disease and its management

60% of patients with aortic valve disease undergoing SAVR and 65% of those undergoing TAVI have coexisting coronary artery disease.²¹ In our series, 37% had co-existent coronary artery disease and underwent concomitant CABG. The addition of CABG did not adversely affect outcomes. The US¹⁵ and Japanese¹⁶ series did not look into concomitant CABG. The percentage of concomitant CABG in our series is higher than the trials of SAVR/TAVI. This probably reflects the selection criteria in the latter. In PARTNER 2, although both groups had a similar number with coexistent coronary artery disease, 14.5% of the SAVR group had concomitant CABG compared to 3.9% of the TAVI group who had percutaneous intervention (Table 4).²² SAVR may therefore be the preferred treatment modality in those with aortic stenosis and multivessel coronary artery disease requiring revascularisation and is the standard of care in those in younger age groups.

1
2
3 Treatment of coronary artery disease in TAVI patients may require more than one hospital admission and can often
4 result in incomplete revascularisation and its consequent increased morbidity and mortality. A meta-analysis by
5 Sankaramangalam and colleagues, demonstrated that whilst there was no increase in mortality in patients with coronary
6 artery disease who underwent TAVI at 30 days, there was a significant increase in mortality at one year following TAVI in
7 these patients.²³ The economic costs of readmission after TAVI have been demonstrated to be higher than in those who
8 are readmitted after surgery and so untreated coronary disease which later requires readmission will have cost
9 implications.^{24,25} Surgery has the advantage of addressing all the pathology with one operation.

17 **Durability and choice of prosthetic valves**

18 In choosing the technique of treatment for aortic valve disease, life expectancy of the person and durability of the valve
19 need to be considered. Ideally, the prosthetic valve should be durable for the person's lifetime. Both of these are related to
20 person's age. In the UK a 50 year old female has a life expectancy of 34 years and a 70 year old male a life expectancy of
21 14 years.²⁶

22 The durability of bioprosthetic valves is well documented in the surgical literature and is inversely proportional to
23 person's age. Structural valve deterioration (SVD) has been demonstrated to increase exponentially beyond 10 years
24 following surgery.^{27,28} Considering the UK life expectancy ²⁶, a 70 year old male has a 5% risk of re-operation and a 50 year
25 old female has a 30% chance of needing a second operation. Although long term data regarding the durability of TAVI
26 valves is awaited, the 5 year results of the PARTNER 2 trial demonstrated that the incidence of SVD in the TAVI group was
27 significantly higher than in the SAVR group.¹⁹ However, a sub-study of the NOTION trial looked at SVD up to 6 years
28 suggested no significant difference between the SAVR and TAVI.²⁹

29 The durability of tissue valves in surgery are well documented.²⁷ Bagur and colleagues have introduced the concept
30 of valve durability: life expectancy ratio.³⁰ More information on durability of TAVI valves is pending, however, there are some
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3 deleterious effects of crimping with TAVI valves.³¹ A systematic review of observational data by Froutan and colleagues
4 looking at 8914 patients who underwent TAVI with a follow-up of 1.5 - 5 years showed SVD incidence of 0-1.34 per 100
5 patient-years with a pooled incidence of 28.08 per 10,000 patient-years.³² Of those with SVD, 12% underwent re-
6 intervention.
7
8
9

10 Surgery has the advantage of offering the patient a mechanical or a bioprosthetic valve. The option of a mechanical
11 valve which is only available in surgical SAVR should not be overlooked especially in younger people. In the current study,
12 we have shown a fairly consistent ratio of tissue to mechanical valve use. However, the reported literature shows that the
13 number of mechanical valve implantations has reduced in comparison to bioprosthetic valves.¹⁰ Mechanical valves are
14 durable, with one group reporting 6.9% reintervention rate at 15 years versus 12.1% in those who underwent surgery with
15 a bioprosthesis.³³ For this reason, it has been the most commonly considered prosthesis in those under the age of 60, as
16 in our study where 60.2% of participants <60 years had a mechanical valve. Mechanical valves have the disadvantage of
17 requiring anticoagulation, although, newer generations require a lower level of anticoagulation.³⁴ Whilst mechanical valves
18 are more durable, this has to be balanced against the greater risk of bleeding.³³ At 15 years follow up Chiang and colleagues
19 also demonstrated no significant difference in survival and stroke between patients who underwent SAVR with mechanical
20 vs bioprosthetic valve.³³ Another group demonstrated in the 50-70 year old cohort that survival at 5 years was higher in
21 patients who had undergone SAVR with mechanical valve vs bioprosthesis and also demonstrated similar freedom from
22 major bleeding events.³⁵
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Bicuspid aortic valve and aneurysm of the aorta**

39
40
41
42
43
44
45
46
47

1
2
3 A significant number of patients requiring SAVR have bicuspid aortic valve, which has an incidence of 1-2% in the general
4 population and may present with aortic valve stenosis, regurgitation and ascending aortic aneurysm. The type of native
5 aortic valve is not recorded in the database of our study. BAV may be present in up to 30% of patients undergoing SAVR.³⁶
6 Bicuspid aortic valve anatomy, larger annular size, bulky and asymmetric leaflet calcification and dilated ascending aorta
7 all pose technical challenges to TAVI which are not prohibitive risk factors for surgery. In fact, associated pathology of
8 aneurysms of the aortic root and ascending aorta can be treated at the time of SAVR with little additional risk.³⁷
9
10
11
12
13
14

15 European guidelines recommend discussing people with aortic valve disease in a multi-disciplinary setting referred to as
16 Heart Team, comprising of a surgeon, a non-interventional and an interventional cardiologist.³⁸ This will allow the best
17 treatment option to be put forward to the person.
18
19
20
21

22 CONCLUSIONS

23 SAVR with and without CABG has low mortality risk and a low level of complications in the UK in people of all ages and risk
24 factors. Our study provides real world experience of surgical results to improve understanding of the risks of surgery and
25 decision making in a multi-disciplinary team (MDT) setting with Heart Team. The results of this study can be utilised by
26 people with aortic valve disease, referring general practitioners, physicians, surgeons and policy makers. Future studies
27 need to address long term follow-up including factors like quality of life which are currently not collected by the specialist
28 centres.
29
30
31
32
33
34
35

36 **Acknowledgement.** We would like to thank all the units (listed below) and the consultant surgeons who submitted their
37 data for analysis. We are indebted to all the database managers and audit officers who have collected this data.
38
39
40
41
42
43
44

Contributorship: The first five authors and the senior author have designed this project, compiled the data set, collected, analysed the data and reviewed the various versions of the manuscript. Other authors have collated, validated and submitted their data on behalf of their unit. They have assisted in the design and analysis of the manuscript. In addition, each author has contributed to the various versions of the manuscript with constructive comments. Every author has contributed to the interpretation of data. More specifically:

1. Marjan Jahangiri - Thought of the concept, designed the project, plan data collection, identified units, approached each unit, collected and analysed the data. Wrote the first draft and author for subsequent versions.
2. Rajdeep Bilkhu - thought of the concept, designed the project, planned data collection, collected the data and cleaned it, contributed significantly to writing major sections of the paper
3. Andrew Embleton-Thirsk – Involved in the design of the study at the outset, of the two main statisticians who carried out the statistical work. Attended several meetings to discuss the project, involved in writing all the versions.
4. Hakim-Moulay Dehbi - Involved in the design of the study at the outset, of the two main statisticians who carried out the statistical work. Attended several meetings to discuss the project, involved in writing all the versions.
5. Krishna Mani - thought of the concept, designed the project, planned data collection, collected the data and cleaned it, contributed significantly to writing major sections of the paper, checked the literature contents and references.
6. Jon Anderson – Planned the project with the first two authors, acquired the data and contributed to several versions during the writing up phase
7. Vassilios Avlonitis - Planned the project with the first two authors, acquired the data and contributed to several versions during the writing up phase
8. Max Baghai - Planned the project with the first two authors, acquired the data and contributed to several versions during the writing up phase

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
9. Inderpaul Birdi – Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
10. Karen Booth - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
11. Norman Briffa - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
12. Keith Buchan - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
13. Sunil Bhudia - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase
14. Alex Cale - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
15. Indu Deglurkar - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
16. Shakil Farid - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
17. Leonidas Hadjinikolaou - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
18. Martin Jarvis - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase
19. Seyed Hossein Javadpour - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
20. Reubendra Jeganathan - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase

- 1
2
3 21. Manoj Kuduvali - Planned the project with the first two authors, acquired the data and contributed to several verisons during
4 the writing up phase
- 5
6 22. Kulvinder Lall - Planned the project with the first two authors, acquired the data
- 7
8 23. Jorge Mascaro - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
9 writing up phase
- 10
11 24. Dheeraj Mehta - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
12 writing up phase
- 13
14 25. Sunil Ohri - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
15 writing up phase
- 16
17 26. Prakash Punjabi - Planned the project with the first two authors, acquired the data and contributed to several verisons during
18 the writing up phase
- 19
20 27. Venkateswaran Rajamiyer - Planned the project with the first two authors, acquired the data and contributed to several verisons
21 during the wirting up phase
- 22
23 28. Paul Ridley - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
24 writing up phase
- 25
26 29. Christopher Satur - Planned the project with the first two authors, acquired the data and contributed to several verisons during
27 the writing up phase
- 28
29 30. Serban Stoica - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
30 writing up phase
- 31
32 31. Uday Trivedi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
33 writing up phase
- 34
35 32. Afzal Zaidi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the
36 writing up phase
- 37
38
39
40
41
42
43
44

- 1
2
3 33. Patrick Yiu - Planned the project with the first two authors, acquired the data and contributed to several versions during the
4 writing up phase
5
6 34. Narain Moorjani - Planned the project with the first two authors, acquired the data and contributed to several versions during
7 the writing up phase. Facilitated the acquisition of the data through the Society for Cardiothoracic Surgery of GB & Ireland.
8
9 35. Simon Kendall - Planned the project with the first two authors, acquired the data and contributed to several versions during the
10 writing up phase. Facilitated the acquisition of the data through the Society for Cardiothoracic Surgery of GB & Ireland.
11
12 36. Nick Freemantle – Senior statistician who designed the project, defend the original plan for the study, assisted the
13 other two statistician to analyse the data, took part in several meetings interpreting the data with further analysis,
14 assisted in writing the paper and final analysis.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Competing interests:** All authors declare no competing interests.
39
40
41
42
43
44
45
46
47

1
2
3 **Ethical approval:** Anonymised data were submitted to the Society for Cardiothoracic Surgery of Great Britain & Ireland
4 (SCTS) for 27 of the 30 units and then stored in a secure database. This data is ordinarily submitted to National Institute of
5 Cardiovascular Outcome Research (NICOR) for which local and national Caldicott guardian approvals have been obtained.
6
7 A further approval from the Caldicott Guardian was obtained in 2020.
8
9

10
11 **Funding:** We would like to express our gratitude to Edwards Lifesciences for their support for a part time research person
12 and administrator for this study.
13
14

15
16 **Data sharing:** Requests on data sharing can be made by contacting the corresponding author. Data will be shared after
17 review and approval by the authors and terms of collaboration will be reached together with a signed data access agreement.
18
19

20
21 The corresponding author (MJ) affirms that the manuscript is an honest, accurate, and transparent account of the study
22 being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as
23 planned (and, if relevant, registered) have been explained. The manuscript is read and approved by all authors.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

REFERENCES

- 1 Zakkar M, Bryan AJ, Angelini GD. Aortic stenosis: diagnosis and management. *BMJ* 2016;352:1–9.
- 2 Otto CM, Burwash IG, Legget ME, *et al.* Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997;95:2262–70.
- 3 Cribier A, Eltchaninoff H, Tron C, *et al.* Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 2004;43:698–703.
- 4 Leon MB, Smith CR, Mack M, *et al.* Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med* 2010;363:1597–607.
- 5 Adams DH, Popma JJ, Reardon MJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370:1790–8.
- 6 Mack MJ, Leon MB, Thourani VH, *et al.* Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;380:1695–705.
- 7 Popma JJ, Michael Deeb G, Yakubov SJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 2019;380:1706–15.
- 8 De Backer O, Luk NHV, Olsen NT, *et al.* Choice of Treatment for Aortic Valve Stenosis in the Era of Transcatheter Aortic Valve Replacement in Eastern Denmark (2005 to 2015). *JACC Cardiovasc Interv* 2016;9:1152–8.
- 9 Martin E, Dagenais F, Voisine P, *et al.* Surgical aortic valve replacement outcomes in the transcatheter era. *J Thorac Cardiovasc Surg* 2015;150:1582–8.
- 10 Silaschi M, Conradi L, Treede H, *et al.* Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. *Thorac Cardiovasc Surg* 2016;64:382–9.

- 1
2
3 11 Tam DY, Rocha R V., Wijeyesundera HC, *et al.* Surgical valve selection in the era of transcatheter aortic valve
4 replacement in the Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg* 2020;59:416–27.
5
6 12 Simonato M, Dvir D. Transcatheter aortic valve replacement in failed surgical valves. *Heart* 2019;105:S38–43.
7
8 13 Landes U, Webb JG, De Backer O, *et al.* Repeat Transcatheter Aortic Valve Replacement for Transcatheter
9 Prosthesis Dysfunction. *J Am Coll Cardiol* 2020;75:1882–93.
10
11 14 Huygens SA, Mokhles MM, Hanif M, *et al.* Contemporary outcomes after surgical aortic valve replacement with
12 bioprostheses and allografts: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2016;50:605–16.
13
14 15 Thourani VH, Suri RM, Gunter RL, *et al.* Contemporary real-world outcomes of surgical aortic valve replacement in
15 141,905 low-risk, intermediate-risk, and high-risk patients. *Ann Thorac Surg* 2015;99:55–61.
16
17 16 Tokuda Y, Yamamoto H, Miyata H, *et al.* Contemporary outcomes of surgical aortic valve replacement in Japan. *Circ*
18 *J* 2020;84:277–82.
19
20 17 Barili F, Freemantle N, Pillozzi Casado A, *et al.* Mortality in trials on transcatheter aortic valve implantation versus
21 surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. *Eur J*
22 *Cardiothorac Surg* 2020;58:221–9.
23
24 18 Thyregod HGH, Steinbrüchel DA, Ihlemann N, *et al.* Transcatheter versus surgical aortic valve replacement in patients
25 with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. *J Am Coll*
26 *Cardiol* 2015;65:2184–94.
27
28 19 Makkar RR, Thourani VH, Mack MJ, *et al.* Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve
29 Replacement. *N Engl J Med* 2020;382:799–809.
30
31 20 Barbanti M, Tamburino C, D’Errigo P, *et al.* Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve
32 Replacement or Surgical Aortic Valve Replacement in a Real World Population: Final Results from the OBSERVANT
33 Study. *Circ Cardiovasc Interv* 2019;12:1–9.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

- 1
2
3 21 Sabbagh A El, Nishimura RA. Clinical conundrum of coronary artery disease and aortic valve stenosis. *J Am Heart*
4 *Assoc* 2017;6:1–3.
5
6 22 Leon MB, Smith CR, Mack MJ, *et al.* Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk
7 Patients. *N Engl J Med* 2016;374:1609–20.
8
9 23 Sankaramangalam K, Banerjee K, Kandregula K, *et al.* Impact of coronary artery disease on 30-day and 1-year
10 mortality in patients undergoing transcatheter Aortic valve replacement: A meta-analysis. *J Am Heart Assoc* 2017;6:1–
11 11.
12
13 24 Goldsweig AM, Tak HJ, Chen LW, *et al.* Relative Costs of Surgical and Transcatheter Aortic Valve Replacement and
14 Medical Therapy. *Circ Cardiovasc Interv* 2020;13:1–9.
15
16 25 Tripathi A, Flaherty MP, Abbott JD, *et al.* Comparison of Causes and Associated Costs of 30-Day Readmission of
17 Transcatheter Implantation Versus Surgical Aortic Valve Replacement in the United States (A National Readmission
18 Database Study). *Am J Cardiol* 2018;122:431–9.
19
20 26 O'Neill A. Life expectancy (from birth) in the United Kingdom from 1765 to 2020. Statista.
21 2020. <https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/> (accessed 7 Aug 2020).
22
23 27 Foroutan F, Guyatt GH, O'Brien K, *et al.* Prognosis after surgical replacement with a bioprosthetic aortic valve in
24 patients with severe symptomatic aortic stenosis: Systematic review of observational studies. *BMJ* 2016;354:1–9.
25
26 28 McClure RS, Narayanasamy N, Wiegerinck E, *et al.* Late Outcomes for Aortic Valve Replacement With the Carpentier-
27 Edwards Pericardial Bioprosthesis: Up to 17-Year Follow-Up in 1,000 Patients. *Ann Thorac Surg* 2010;89:1410–6.
28
29 29 Søndergaard L, Ihlemann N, Capodanno D, *et al.* Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves
30 in Patients at Lower Surgical Risk. *J Am Coll Cardiol* 2019;73:546–53.
31
32 30 Bagur R, Pibarot P, Otto CM. Importance of the valve durability-life expectancy ratio in selection of a prosthetic
33 aortic valve. *Heart* 2017;103:1756–9.
34
35
36
37
38
39
40
41
42
43
44
45
46
47

- 1
2
3 31 Dasi L, Hatoum H, Kheradvar A, *et al.* On The Mechanics of Transcatheter Aortic Valve Replacement Lakshmi. *Ann*
4 *Biomed Eng* 2017;45:310–31.
5
6 32 Foroutan F, Guyatt GH, Otto CM, *et al.* Structural valve deterioration after transcatheter aortic valve implantation.
7 *Heart* 2017;103:1899–905.
8
9 33 Chiang YP, Chikwe J, Moskowitz AJ, *et al.* Survival and long-term outcomes following bioprosthetic vs mechanical
10 aortic valve replacement in patients aged 50 to 69 years. *JAMA - J Am Med Assoc* 2014;312:1323–9.
11
12 34 Puskas JD, Gerdisch M, Nichols D, *et al.* Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic
13 Valve Replacement. *J Am Coll Cardiol* 2018;71:2717–26.
14
15 35 Huckaby L V., Sultan I, Gleason TG, *et al.* Outcomes of tissue versus mechanical
16 aortic Valve Replacement Reduces Long-Term Survival. *Ann Thorac*
17
18 36 Cozijnsen L, van der Zaag-Loonen HJ, Cozijnsen MA, *et al.* Differences at surgery between patients with bicuspid
19 and tricuspid aortic valves. *Netherlands Hear J* 2019;27:93–9.
20
21 37 Wallen T, Habertheuer A, Bavaria JE, *et al.* Elective Aortic Root Replacement in North America: Analysis of STS Adult
22 Cardiac Surgery Database. *Ann Thorac Surg* 2019;107:1307–12.
23
24 38 Baumgartner H, Falk V, Bax J *et al.* 2017 ESC / EACTS Guidelines for the management of valvular heart disease
25 The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and
26 the European. *Eur Heart J* 2017;38:2739–86.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 1. Multivariable modelling of post-operative outcomes using pre-operative and operative factors

Predictor	missing	Category	Hospital mortality		Return to theatre for bleeding		New stroke		Post-operative length of stay (days)	
			Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value
Age (years)	7.9%	<i>per unit increase</i>	1.03 (1.02-1.04)	<0.001	1.01 (1.00-1.01)	0.006	1.02 (1.01-1.03)	0.001	1.00 (1.00-1.00)	<0.001
Gender	10.3%	Female Male	- 0.63 (0.51-0.77)	<0.001	- 1.18 (1.02-1.36)	- 0.026	- 1.02 (0.80-1.29)	- 0.89	- 0.94 (0.93-0.96)	- <0.001
LVEF	3.1%	Good (>50%) Moderate (30-50%) Poor (<30%)	- 1.48 (1.18-1.85) 1.90 (1.36-2.69)	- 0.001 <0.001	- 1.08 (0.91-1.27) 1.10 (0.82-1.48)	- 0.38 0.53	- 1.13 (0.86-1.48) 0.78 (0.44-1.38)	- 0.38 0.40	- 1.08 (1.06-1.10) 1.07 (1.03-1.11)	- <0.001 0.001
EuroSCORE Logistic	12.1%	<i>per unit increase</i>	1.02 (1.02-1.03)	<0.001	1.01 (1.00-1.01)	0.16	1.00 (0.99-1.02)	0.30	1.01 (1.01-1.01)	<0.001
Operative Urgency	0.02%	1. Elective 2. Urgent 3. Emergency 4. Salvage	- 1.63 (1.30-2.00) 6.87 (4.70-10.16) 11.79 (5.73-24.27)	- <0.001 <0.001 <0.001	- 1.26 (1.08-2.00) 2.22 (1.51-3.26) 1.51 (0.56-4.02)	- 0.002 <0.001 0.41	- 1.08 (0.83-1.41) 7.65 (5.00-11.70) 4.38 (1.47-13.1)	- 0.55 <0.001 0.008	- 1.18 (1.16-1.20) 1.78 (1.67-1.90) 1.25 (1.07-1.46)	- <0.001 <0.001 0.006
Cumulative Bypass Time (mins)	2.4%	<i>per unit increase</i>	1.02 (1.01-1.02)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.00)	<0.001
Cumulative Cross Clamp Time (mins)	2.5%	<i>per unit increase</i>	0.99 (0.99-0.99)	<0.001	1.00 (1.00-1.00)	0.23	1.00 (0.99-1.00)	0.58	1.00 (1.00-1.00)	0.78
CABG	0%	No Yes	- 1.15 (0.93-1.42)	- 0.20	- 1.07 (0.93-1.24)	- 0.33	- 1.12 (0.88-1.42)	- 0.37	- 1.03 (1.00-1.05)	- <0.001

LVEF; left ventricular ejection fraction, CABG; coronary artery bypass graft surgery

Tables 2. Mortality (%) for different categories of age and EuroSCORE

Euroscore	N (%)	SAVR+CABG (Mortality %)	SAVR (Mortality %)
<3%	15619 (50.0)	2.0	1.3
3-6%	5020 (16.1)	0.9	1.0
>6%	6846 (21.9)	4.4	3.9
Age (years)		SAVR+CABG	SAVR
<60		2.2	2.0
60-75		1.8	1.5
>75		3.1	2.2

Table 3. Baseline characteristics in the current study (UK SAVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁴	NOTIO	PIVOTAL ⁵		NOTIO
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVR N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N=357	TAVI N=390	SAVR N=135
Age (mean±SD)	70.1±11.5	67.6 ± 13.4	NR	81.7±6.7	81.5±6.7	73.6±6.1	73.3±5.8	73.6±5.9	77.1±5.8	83.2±6.4	83.1±7.1	79 ± 4.7
% Male	59	58	51.1	54.8	54.2	71.1	67.5	66.2	64	52.4	53.1	53.8
BMI (kg/m ²)	28.9±5.5	29.3 ± 6.6	NR	28.3±6.2	28.6±6.2	30.3±5.1	30.7±5.5	NR	NR	NR	NR	NR
NYHA class III/IV (%)	44.4	38.4	15.9	76.3	77.3	23.8	31.2	28.4	25.1	86.9	85.7	45.5
Logistic EuroSCORE (%)	4.3±7.3	NR	NR	NR	NR	1.5±0.9*	1.5±1.2*	NR	NR	18.6±13.0	17.7±13.1	8.9 ± 5.5
Diabetes Mellitus (%)	22.2	25.5	NR	34.2	37.7	30.2	31.2	30.5	31.4	45.4	34.9	20.7
Chronic Kidney Disease (%)	3.1	NR	NR	5.2	5.0	0.2	0.2	0.1	0.4	12.8	12.2	0.7
Hypertension (%)	64.9	NR	NR	NR	NR	NR	NR	82.6	84.8	96.1	95.1	76.3
Peripheral vascular disease (%)	8.7	9.2	NR	32.9	27.9	7.3	6.9	7.5	8.3	41.7	41.1	6.7
Previous stroke (%)	8.2	12.6	0.13	31	32.1	5.1	3.4	10.2	11.8	14.0	12.6	16.3
COPD (%)	13.4	NR	13.6	30.0	31.8	6.2	5.1	15.0	18.0	9.0	13.3	11.9
LV ejection fraction (%)	53.2	54.9 ± 12.9	NR	55.3±11.9	56.2±10.8	66.2±8.6	65.7±9.0	61.9 ± 7.7	61.7 ± 7.9	NR	NR	NR
Coronary artery disease (%)	37.1	NR	NR	66.5	69.2	28.0	27.7	NR	NR	75.9	75.4	NR
Atrial fibrillation	10.3	NR	5.6	35.2	31.0	18.8	15.7	14.5	15.4	45.9	40.9	25.6
Permanent pacemaker	1.9			12.0	11.7	2.9	2.4	3.8	3.2	21.3	23.3	4.4

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, BMI; body mass index, NYHA; New York Heart Association classification,

COPD; chronic obstructive pulmonary disease, NR; not reported

*EuroSCORE II reported only

Table 4. Operative characteristics in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ¹⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=25	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 145
Operative urgency													
Elective (%)	74.3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Urgent (%)	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Emergency/Salvage (%)	1.7	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Concomitant CABG (%)	37.1	NR	NR	NR	-	12.8	-	13.6	6	4.8	-	1	-
Staged PCI	-	NR	NR	-	NR	-	6.5	-	6	-	0.3%	-	0
Cross clamp time (minutes)	79.0	77.0 ± 28.5	NR	NR	-	74.3 ± 27.78	-	68.7 ± 29.0	6	74.0 ± 31.4	-	NR	NR
Cardiopulmonary bypass time (minutes)	104	104.9 ± 39.1	NR	NR	-	97.7 ± 33.75	-	93.4 ± 40.2	6	104.0± 45.8	-	NR	NR
Procedure time (minutes)	NR	NR	NR	NR	NR	208.3 ± 62.1	58.6 ± 36.5	276.6 ± 79.5	148.2 ± 55.1	221 ± 84.8	60.4 ± 35.3	177.2 ± 39.8	90.3 ± 38.6

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

136/bmjopen-2020-01491 on 28 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

136/bmjopen-2020-046491 on 28 October 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Table 5. Outcomes following SAVR in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Outcome	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUS ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 144
In-hospital death/30-day mortality (%)	1.9	2.5	NR	8.0	6.1	3.3	1.0	1.3	0.5	4.5	3.3	3.7	2.1
Stroke (%)	1.1	NR	1.6	6.1	5.5	2.4	0.6	3.4	3.4	6.2	4.9	3.0	1.4
Reoperation for bleeding (%)	3.6	3.9	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Post procedure bleeding (%)	-	NR		43.4	10.4	11.9	1.2	7.5	2.4	69.5	41.7	11.3	20.9
Deep sternal wound infection (%)	0.14	0.3	1.1	NR	-	NR	-	NR	-	NR	-	NR	-
Length of hospital stay (days)	7	7.9 ± 7.2	NR	NR	-	7.0	3.0	NR	NR	NR	NR	8.9 ± 6.2	12.9 ± 11.6
New pacemaker implantation (%)	1.6	NR	NR	6.9	8.	4.0	6.5	6.1	7.4	7.1	19.8	1.6	34.1

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	4-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	6

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9

Discussion

Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA
---------	----	---	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046491.R2
Article Type:	Original research
Date Submitted by the Author:	02-Aug-2021
Complete List of Authors:	<p>Jhangiri, Marjan; St George's Hospital, Department of Cardiac Surgery Bilkhu, Rajdeep; St George's Hospital, Department of Cardiac Surgery Embleton-Thirsk, Andrew; University College London Institute of Clinical Trials and Methodology Dehbi, Hakim-Moulay; University College London Institute of Clinical Trials and Methodology Mani, Krishna; St George's Hospital, Department of Cardiac Surgery Anderson, Jon ; Hammersmith Hospital, Department of Cardiac Surgery Avlonitis, Vassilios; St Thomas' Hospital, Department of Cardiac Surgery Baghai, Max; King's College Hospital, Department of Cardiac Surgery Birdi, Inderpaul; Essex Cardiothoracic Centre Booth, Karen; Freeman Hospital Cardiothoracic Centre Bose, Amal; Lancashire Cardiac Centre Briffa, Norman; Sheffield Teaching Hospitals NHS Foundation Trust Cardiothoracic Centre Buchan, Keith; Aberdeen Royal Infirmary, Cardiac Surgery Bhudia, Sunil; Harefield Hospital Heart Surgery Cale, Alex; Castle Hill Hospital, Cardiac Surgery Deglurkar, Indu; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Farid, Shakil; Oxford University Hospitals NHS Trust, Cardiac Surgery Hadjinikolaou, Leonidas; University Hospitals of Leicester NHS Trust, Cardiac Surgery Jarvis, Martin; Hull University Teaching Hospitals NHS Trust, Cardiac Surgery Javadpour, Seyed; Mater Misericordiae University Hospital, Cardiac Surgery Jeganathan, Reubendra; Royal Victoria Hospital, Cardiac Surgery Kuduvalli, Manoj; Liverpool Heart and Chest Hospital NHS Foundation Trust, Cardiac Surgery Lall, Kulvinder; Saint Bartholomew's Hospital Barts Heart Centre Mascaro, Jorge; Queen Elizabeth Medical Centre, Cardiac Surgery Mehta, Dheeraj; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Ohri, Sunil; Southampton University Hospitals NHS Trust, Cardiac Surgery Punjabi, Prakash; Hammersmith Hospital, Cardiac Surgery Venkateswaran, Rajamiyer ; Wythenshawe Hospital North West Heart Centre</p>

	Ridley, Paul; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Satur, Christopher; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Stoica, Serban; Bristol Heart Institute Trivedi, Uday; Royal Sussex County Hospital Sussex Cardiac Centre Zaidi, Afzal; Morrilton Hospital, Cardiac Surgery Yiu, Patrick; New Cross Hospital, Cardiac Surgery Moorjani, Narain; Royal Papworth Hospital NHS Foundation Trust Cardiac Surgery Kendall, Simon; James Cook University Hospital, Cardiac Surgery Freemantle, Nick; University College London Institute of Clinical Trials and Methodology, Comprehensive Clinical Trials Unit
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiothoracic surgery < SURGERY, Cardiac surgery < SURGERY, CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Marjan Jahangiri, Rajdeep Bilkhu**, Andrew Embleton-Thirsk**,
Hakim-Moulay Dehbi*, Krishna Mani, Jon Anderson, Vassilios Avlonitis, Max Baghai, Inderpaul
Birdi, Karen Booth, Amal Bose, Norman Briffa, Keith Buchan, Sunil Bhudia, Alex Cale, Indu
Deglurkar, Shakil Farid, Leonidas Hadjinikolaou, Martin Jarvis, Seyed Hossein Javadpour,
Reubendra Jeganathan, Manoj Kuduvali, Kulvinder Lall, Jorge Mascaro, Dheeraj Mehta, Sunil
Ohri, Prakash Punjabi, Venkateswaran Rajamiyer, Paul Ridley, Christopher Satur, Serban
Stoica, Uday Trivedi, Afzal Zaidi, Patrick Yiu, Narain Moorjani, Simon Kendall, Nick Freemantle*

** RB/AE equal contributions

Names of cardiac surgical units are given in the Acknowledgement section
Institute of Clinical Trials and Methodology, University College London*

Word Count: 3972

Key words: aortic valve replacement, aortic valve disease, surgery

Address for correspondence:

Marjan Jahangiri
Professor of Cardiac Surgery
St. George's Hospital
London SW17 0QT

Tel: 44-2087252652

Email: marjan.jahangiri@stgeorges.nhs.uk

1. Marjan Jahangiri
Affiliation: St George's Hospital, London
2. Rajdeep Bilkhu
Affiliation: St Thomas Hospital, London
3. Andrew Embleton-Thirsk
Affiliation: Institute of Clinical Trials and Methodology, University College London
4. Hakim-Moulay Dehbi
Affiliation: Institute of Clinical Trials and Methodology, University College London
5. Krishna Mani
Affiliation: St George's Hospital, London
6. Jon Anderson
Affiliation: Hammersmith Hospital, London
7. Vassilios Avlonitis
Affiliation: St Thomas Hospital, London
8. Max Baghai
Affiliation: Kings College Hospital, London
9. Inderpaul Birdi
Affiliation: Essex Cardiothoracic Centre, Basildon
10. Karen Booth
Affiliation: Freeman Hospital, Newcastle
11. Norman Briffa
Affiliation: Northern General Hospital, Sheffield
12. Keith Buchan
Affiliation: Aberdeen Royal Infirmary
13. Sunil Bhudia
Affiliation: Royal Brompton & Harefield Hospitals, London
14. Alex Cale
Affiliation: Castle Hill Hospital, Hull
15. Indu Deglurkar
Affiliation: Cardiff, University Hospital Wales
16. Shakil Farid
Affiliation: Oxford Heart Centre
17. Leonidas Hadjinikolaou
Affiliation: Glenfield Hospital, Leicester
18. Martin Jarvis
Affiliation: Castle Hill Hospital, Hull
19. Seyed Hossein Javadpour
Affiliation: Mater Misericordiae Hospital, Dublin
20. Reubendra Jeganathan
Affiliation: Royal Victoria Hospital, Belfast
21. Manoj Kuduvali
Affiliation: Liverpool Heart and Chest Hospital
22. Kulvinder Lall
Affiliation: Barts Heart Centre
23. Jorge Mascaro

1
2
3 Affiliation: Queen Elizabeth Hospital, Birmingham

4 24. Dheeraj Mehta

5 Affiliation: Cardiff, University Hospital Wales

6 25. Sunil Ohri

7 Affiliation: Southampton General Hospital

8 26. Prakash Punjabi

9 Affiliation: Hammersmith Hospital, London

10 27. Venkateswaran Rajamiyer

11 Affiliation: Wythenshawe Hospital, Manchester

12 28. Paul Ridley

13 Affiliation: Royal Stoke University Hospital

14 29. Christopher Satur

15 Affiliation: Royal Stoke University Hospital

16 30. Serban Stoica

17 Affiliation: Bristol Heart Institute

18 31. Uday Trivedi

19 Affiliation: Sussex Cardiac Centre, Brighton

20 32. Afzal Zaidi

21 Affiliation: Morrison Hospital, Swansea

22 33. Patrick Yiu

23 Affiliation: New Cross Hospital, Wolverhampton

24 34. Narain Moorjani

25 Affiliation: Royal Papworth Hospital, Cambridge

26 35. Simon Kendall

27 Affiliation: James Cook Cardiothoracic Centre, South Tees

28 36. Nick Freemantle

29 Affiliation: Institute of Clinical Trials and Methodology, University College London

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives - To date the reported outcomes of surgical aortic valve replacement (SAVR) are mainly in the settings of trials comparing it with evolving transcatheter aortic valve implantation (TAVI). We set out to examine characteristics and outcomes in people who underwent SAVR reflecting a national cohort and therefore 'real world' practice.

Design - Retrospective analysis of prospectively collected data of consecutive people who underwent SAVR with or without coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the UK. This included elective, urgent and emergency operations. Participants' demographics, pre-operative risk factors, operative data, in-hospital mortality, post-operative complications and effect of the addition of CABG to SAVR were analysed.

Setting - 27 (90%) tertiary cardiac surgical centres in the UK submitted their data for analysis.

Participants - 31,277 people with AVR were identified. 19,670 (62.9%) had only SAVR and 11,607 (37.1%) had AVR+CABG.

Results – In-hospital mortality for isolated SAVR was 1.9% (95% CI: 1.6-2.1%) and was 2.4% for AVR+CABG. Mortality by age category for SAVR only were: <60 years=2.0%, 60-75 years=1.5%, >75 years=2.2%. For SAVR+CABG these were; 2.2%, 1.8% and 3.1%. For different categories of EuroSCORE, mortality for SAVR in low risk people was 1.3%, in intermediate risk 1% and for high risk 3.9%. 74.3% of the operations were elective, 24% urgent and 1.7% emergency/salvage. The incidences of re-sternotomy for bleeding and stroke were 3.9% and 1.1% respectively. Multivariable analyses provided no evidence that concomitant CABG influenced outcome. However, urgency of the operation, poor ventricular function, higher EuroSCORE and longer cross clamp and cardiopulmonary bypass times adversely affected outcomes.

1
2
3 **Conclusions** - Surgical SAVR±CABG has low mortality risk and a low level of
4 complications in the UK in people of all ages and risk factors. These results should
5 inform consideration of treatment options in people with aortic valve disease.
6
7
8
9
10

11 **Strengths and limitations of this study**

- 12 • This is a large study of consecutive participants who have undergone surgical
13 aortic valve replacement ± coronary artery bypass graft surgery in the UK,
14 reporting contemporary outcomes.
- 15 • This study includes people of all age groups and risks factors, and elective as
16 well as urgent and emergency operations.
- 17 • The results are of in-hospital mortality and complications and longer term follow-
18 up data is not available.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Aortic valve disease, especially aortic stenosis affects 5% of the population and 3.9% of those between the ages of 70 and 79 and nearly 10% of those above the age of 80.¹ Severe aortic stenosis when untreated has a risk of death of 50% at 2 years.² Conventionally the gold standard of treatment has been surgical aortic valve replacement (SAVR). However, the role of transcatheter aortic valve implantation (TAVI) has evolved in recent years. TAVI was first introduced in 2002, initially being performed in high risk inoperable patients.³ The original Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated a significant reduction in mortality, repeat hospitalisation and cardiac symptoms compared to inoperable patients who had only medical therapy.⁴ The original PIVOTAL study also demonstrated significantly higher survival at one year in high risk patients who underwent SAVR.⁵

The role of TAVI is being extended to lower risk and younger patients based on recent trials comparing SAVR with TAVI.^{6,7} Several studies suggest there has been a change in demographics and types of surgical valves used since the advent of TAVI.⁸⁻¹⁰ There has been a trend of increased use of tissue valves and a decrease in the use of mechanical valves in recent years.¹¹ This may be due to the evolution of TAVI practice whereby younger patients can have a tissue valve with the view that they have a TAVI valve in the future when the tissue valve has deteriorated, so called valve-in-valve.^{12,13}

The series in the literature reporting outcomes of SAVR are generally unit based.^{9,14} Also, people with aortic valve disease are given information about the outcomes of SAVR which may be out of date and incorrectly extrapolated from smaller studies. There is a lack of contemporary national data to assess the outcomes of SAVR (mortality and complications), and to demonstrate the trend in use of prosthetic valves which would inform people with aortic valve disease better. There are some perceived complications of surgery that may be understood by referring general practitioners and cardiologists to be prohibitive risks for surgery.

In order to inform practitioners, people with aortic valve disease and the cardiac surgical community, we set out to examine the results of contemporaneous SAVR in a multi-centre study of UK cardiac surgical units, in the era of TAVI. In addition, we

1
2
3 summarise and interpret some of the more recent trials on the management of aortic
4 valve disease.
5
6

7 8 **METHODS**

9 10 **Data**

11 This is an analysis of prospectively collected data of people who underwent SAVR +/-
12 coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the
13 UK and Republic of Ireland. Anonymised data were submitted to the Society for
14 Cardiothoracic Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then
15 stored in a secure database. This period was chosen to reflect fairly contemporary
16 practice and also the data is submitted in March every year. The data is collected by
17 each unit, validated and then submitted to the National Institute of Cardiovascular
18 Outcome Research (NICOR). It took approximately nine months to collect, validate and
19 clean all the data. The outcome measures recorded are based on strict definitions
20 provided by NICOR to provide uniformity.
21
22
23
24
25
26
27
28

29 Only participants who had had first time surgery, SAVR +/- CABG were included.
30 All participants immaterial of their risk for surgery, people of all age groups and risk
31 factors were included. Those who required other concomitant procedures like
32 replacement of parts of the aorta, aortic root enlargement, other valve procedures and
33 redo surgery were excluded.
34
35
36
37
38

39 **Pre-operative risk factors and operative features**

40 Baseline demographic data; significant past medical history such as diabetes, renal
41 dysfunction, hypertension or stroke; predominant aortic valve pathology (stenosis or
42 regurgitation or mixed valve disease) and preoperative left ventricular ejection fraction
43 (LVEF) were collected. EuroSCORE is the risk stratification model used in the UK.
44 Logistic EuroSCORE was collected as well as EuroSCORE II where available. The
45 latter was only used since 2017 and therefore not available for all participants. Logistic
46 EuroSCORE was divided into three categories: <3%, 3-6%, >6%.
47
48
49
50
51
52

53 LVEF was divided into three categories: good (EF>50%), moderate (EF 30-50%)
54 and poor (EF<30%). Transient ischaemic attack was defined as any neurological
55
56
57
58
59
60

1
2
3 symptoms lasting <24 hours. Stroke was defined as new neurological dysfunction
4 persisting >24 hours. Operative data including operative urgency: elective, urgent and
5 emergency/salvage were recorded. Elective was defined as when the person was
6 admitted from home, urgent meaning that the person was admitted with an urgent
7 condition and required surgery during the same hospital admission, emergency and
8 salvage meaning that surgery was required within 24 hours of admission and/or the
9 person was in extremis. Other parameters including cardiopulmonary bypass (CPB)
10 time, cross clamp (CCT) time, type of valve implanted as well as concomitant CABG
11 surgery performed were also collected.
12
13
14
15
16
17
18
19

20 **Postoperative outcomes**

21 Postoperative complication data were collected with the main focus being in-hospital
22 mortality, new stroke, return to theatre for bleeding, deep sternal wound infection and
23 duration of postoperative hospital stay.
24
25
26
27

28 **Statistical analysis**

29
30 Once the records for all participants were collated and the data cleaned, each factor
31 was summarised using descriptive methods. Categorical variables are presented as N
32 (%) and continuous variables are presented as median (IQR). New strokes were
33 recoded to be either no stroke or any cerebrovascular accident (transient or
34 permanent). The natural log of post-operative length of stay (days) was used due to
35 positive skewed distribution of this variable. Univariate models were used, logistic
36 regression for binary outcomes and linear regression for continuous outcomes, to
37 assess the impact of the key explanatory variables. In these models, a two-tailed p-
38 value of <0.05 was considered significant. The population analysed included all the
39 participants with data collected, with results checked in the subset who had SAVR only
40 (without CABG). Building on this, a multivariable model with all key variables in the
41 model to assess which had the most impact on each of the outcomes was created.
42 Stata/MP 15.1 (StataCorp LLC, Texas, USA) was used for all analyses. Multiple
43 imputation of missing data was not performed. The missingness was mostly negligible.
44 There was no missing mortality and the data is shown in table 2.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient and public involvement

Patients and public were involved in the original design of the database.

Ethics

This data is ordinarily submitted to National Institute of Cardiovascular Outcome Research (NICOR) for which local and national Caldicott guardian approvals have been obtained. The data are validated by the surgical teams and their database managers/audit officers. For the current study a further approval from the Caldicott Guardian was obtained.

RESULTS

Descriptive analysis

In total 31,277 patients were included. Of these, 19,670 (62.9%) had only SAVR and 11,607 (37.1%) had SAVR+CABG. There were 14.4% below the age of 60, 46.9% between 60 to 75 and 36.7% older than 75 years with 7.9% missing age data. There were 1.9 times more males than females (10.3% missing).

Regarding pre-operative risk factors, 75.2% had good LVEF, 17.3% had moderate and 4.3% had poor LVEF. 74.3% of the operations were elective, 24% were urgent and 1.7% were emergency or salvage operations.

Logistic EuroSCORE had a median of 1.83 with an IQR of 0.06-6.0. In total, 50% of patients were classified as low risk (<3%), 16% as medium risk (3—6%) and 22% high risk (>6%). 3,792 patients (12.1%) were missing data. The median EuroSCORE II was 1.95 (IQR 0.67-4.8) albeit with 56.5% with missing data, as this was introduced into the database in 2017. The median CPB time was 104 minutes (IQR 82-135) and CCT was 79 minutes (IQR 61-101).

For valve implant replacement type, 70% had a tissue valve, 12.2% a mechanical valve and 0.2% had homograft or autograft valves. For 17.3% the entry for valve type was unclear. The ratio of mechanical implant to bioprosthetic implant use has remained stable over time.

Overall mortality was 2.4% (95% CI: 2.2-2.6%) and mortality for isolated SAVR for all participants was 1.9% (1.6-2.1%). The mortality figures analysed for different age ranges and for categories of EuroSCORE are shown in Table 1.

Overall, 3.9% (3.6% in SAVR only) of participants had re-sternotomy for post-operative bleeding or tamponade, 0.04% (0.06% in SAVR only) had re-operation for valvular problems (significant paravalvular leak and early endocarditis), 0.7% (0.6% SAVR only) had re-operation for other cardiac problems, 0.2% (0.15% for SAVR only) had rewiring of sternum for sterile wounds and 0.14% (0.06% for SAVR only) had rewiring of sternum for infection. Transient ischaemic attack occurred in only 0.6% and 1.1% had a stroke (no missing data).

Median post-operative length of stay was 7 days (IQR: 6-11) in those with SAVR only and 8 days (IQR: 6-12) in all patients.

The number of bypass grafts was not analysed due to concerns about inconsistent reporting of data describing the number of grafts.

When comparing the two subsets of patients, the characteristics of those with SAVR alone were broadly similar to those with SAVR+CABG. In SAVR alone there were more people aged <60 years (19.3% vs 6.2%), but less people were older than 75 (30.1% vs 43%). A higher proportion of those with SAVR+CABG were male (68% vs. 54%). Bypass time was an average of 37 minutes shorter and CCT 27 minutes in the SAVR alone group. Amongst those with only SAVR the mechanical valve usage was greater, at 16% vs 7%.

Regression analysis

Univariable

Taken in isolation, all pre-operative risk factors were associated with an increased odds of death, as was addition of CABG. The same pattern was observed when analysing the need for re-operation or surgery, with all explanatory variables indicative of a worse outcome without taking into account any others. For new stroke only age, EuroSCORE, operative urgency, ejection fraction, and cumulative bypass and cross clamp times affected a negative outcome (but not gender), as did CABG. All factors predicted a longer postoperative length of stay, including CABG.

1
2
3 As a sensitivity analysis, age categories were also assessed. When included as
4 a continuous variable, age was significant both on its own and in all the multivariable
5 models. All participants were categorised into <60, 60-75 and >75 years of age. Those
6 60-75 were at a lower odds of death in comparison to those <60 (OR 0.71, 95% CI 0.53-
7 0.95, P=0.021) with no difference in those >75 (OR 1.09, 95% CI 0.82-1.45) in the AVR
8 alone group. These findings were different in the SAVR+CABG group, with no
9 significant difference in those 60-75 (OR 0.81, 95% CI 0.64-1.03) but an increased risk
10 in those >75 (OR 1.09, 95% CI 1.12-1.76, P=0.004).
11
12
13
14
15
16
17
18

19 **Multivariable Analyses**

20 Analysis of postoperative outcomes using multivariable models including all pre-
21 operative and operative factors are shown in Table 2. This demonstrated that age (OR
22 1.03 (95% CI 1.02-1.04), P<0.001), moderate ejection fraction (OR 1.48 (95% CI 1.18-
23 1.85), P<0.001), poor ejection fraction (OR 1.90 (95% CI 1.36-2.69), P<0.001), logistic
24 EuroSCORE (OR 1.02 (95% CI 1.02-1.03), P<0.001), urgent operation (OR 1.63 (95%
25 CI 1.30-2.00, P<0.001), emergency surgery (OR 6.87 (95% CI 4.70-10.16), P<0.001)
26 and longer CPB times affected mortality (OR 1.02 (95% CI 1.01-1.02), P<0.001).
27
28
29
30
31
32

33 When all other variables were taken into account CABG was not significantly
34 associated with an increase in the risk of death (OR 1.15 (95% CI 0.93-1.42), P=0.20).
35

36 Older age, (OR 1.01 (95% CI 1.00-1.01), p<0.006), longer CPB time (OR 1.00
37 (95% CI 1.00-1.01), P<0.001), urgent (OR 1.26 (95% CI 1.08-2.00), P<0.002) and
38 emergency surgery (OR 2.22 (95% CI 1.51-3.26), P<0.001) were significant factors in
39 identifying people requiring return to theatre for bleeding. Again, CABG did not affect
40 the odds of returning to theatre (OR 1.07 (95% CI 0.93-1.24), P=0.33).
41
42
43
44

45 Factors affecting stroke were age, (OR 1.02 (95% CI 1.01-1.03), P<0.001),
46 emergency (OR 7.65 (95% CI 5.00-11.70, P<0.001) or salvage surgery (OR 4.38 (95%
47 CI 1.47-13.1) P=0.008), and CPB times (OR 1.00 (95% CI 1.00-1.01), P<0.001). As in
48 the other outcomes, addition of CABG did not affect the outcome (OR 1.12 (95% CI
49 0.88-1.42), P=0.37).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Age, male gender, moderate and poor ejection fraction, operative urgency,
4 higher logistic EuroSCORE, and cumulative bypass time significantly all affected post-
5 operative length of stay.
6
7
8
9

10 **DISCUSSION**

11 This study reports contemporary results of SAVR and SAVR+CABG in the UK,
12 reflecting real world practice, reporting an overall mortality of 1.9% and 2.4%
13 respectively. We have shown a low mortality and complication rate for all comers
14 following surgery in people requiring SAVR or SAVR+CABG. The complications were
15 low with 3.9% re-sternotomy for bleeding, 0.04% re-operation for valvular problems and
16 1.1% stroke. Surprisingly, having accounted for other risk factors, addition of CABG did
17 not adversely affect the outcomes.
18
19
20
21
22
23

24 The strengths of the study include its large number of participants, no exclusion
25 of urgent and emergency/salvage cases, and inclusion of all risk participants. The
26 limitations are that three centres were unable to take part, possible coding errors in
27 using large databases, lack of detailed echocardiographic data on valve annular size
28 and presence or absence of pre-operative infective endocarditis which can adversely
29 affect outcomes. In addition, the results are in-hospital mortality and complications and
30 the database lack longer follow-up information.
31
32
33
34
35

36 Data from the current study are consistent with other large international studies.
37 Data from the US Society of Thoracic Surgeons (STS) database demonstrated in-
38 hospital mortality for isolated SAVR of 2.5% and incidence of stroke of 1.5%.¹⁵ A recent
39 analysis of the Japanese Cardiovascular Surgery database which assessed the
40 outcomes of patients undergoing SAVR over a 8 year period has demonstrated a similar
41 in-hospital mortality of 2%.¹⁶ They also demonstrated a reduction in mortality over time,
42 despite increasing surgical risk. The age of the patients in our study is lower than some
43 of the trials of SAVR and TAVI. This is probably due to the selection criteria in these
44 trials where older patients were selected.
45
46
47
48
49
50

51 We had set out to analyse the results of SAVR in the UK to inform practitioners
52 treating people with aortic valve disease and inform people with this condition in an era
53 where other therapies for management of aortic valve disease are evolving with
54
55
56
57
58
59
60

1
2
3 expanding indications. Although the current study did not examine people who received
4 TAVI, we discuss the various trials of SAVR and TAVI reported in the context of the
5 literature and compare them with the results of the current study.
6
7

8 In Tables 3-5, the demographics, procedural details and outcomes of the current
9 study are compared with the respective sub-groups of the published trials. Table 5
10 shows low mortality and complication rate in the participants of this study following
11 surgery in people who required SAVR or SAVR+CABG. The trials comparing AVR and
12 TAVI have enrolled and classified patients according to the risk of surgery, in particular
13 the more recent trials.^{6,7} The most commonly used surgical risk stratification score is the
14 Society of Thoracic Surgery risk score (STS), although this scoring system has been
15 validated in the US population. We have used EuroSCORE and shown that mortality is
16 low in all categories of risk.
17
18
19
20
21
22
23

24 There are several recent trials comparing SAVR with TAVI. A meta-analysis of
25 six of these trials performed by Barili and colleagues reported that mortality was
26 affected by the treatment modality with a time-varying effect: TAVI was related to better
27 survival in the first months after implantation whereas, after 40 months, it was a risk
28 factor for all-cause mortality.¹⁷ The NOTION trial, which compared outcomes of patients
29 estimated to have low surgical risk who underwent either TAVI or SAVR demonstrated
30 similar early mortality results, with mortality of 2.1% in TAVI group vs 3.7% in the SAVR
31 group, $p=0.38$.¹⁸ The PIVOTAL trial of low risk patients also reported similar results
32 between those who underwent TAVI compared to SAVR, with early mortality of 0.5% in
33 TAVI group and 1.3% in SAVR.⁷ In addition, the 5 year results of the PARTNER 2
34 study, comparing TAVI vs SAVR in intermediate surgical risk demonstrated no
35 significant difference in the incidence of death or stroke at 5 years following SAVR or
36 TAVI.¹⁹ The mortality in the intermediate EuroSCORE risk category of the current study
37 was 1.0% for SAVR only and 0.9% for SAVR+CABG. PARTNER 3 however
38 demonstrated significantly lower mortality in the TAVI group compared to SAVR (1% vs
39 2.5%, $P=0.01$) at one year.⁶ An observational study of 7618 patients comparing SAVR
40 with TAVI at 5 years showed however that in a real world population with low and
41 intermediate risk, SAVR was associated with lower mortality and major adverse cardiac
42 events, although this was with first generation TAVI devices.²⁰
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Role of co-existent coronary artery disease and its management

60% of patients with aortic valve disease undergoing SAVR and 65% of those undergoing TAVI have coexisting coronary artery disease.²¹ In our series, 37% had co-existent coronary artery disease and underwent concomitant CABG. The addition of CABG did not adversely affect outcomes. The US¹⁵ and Japanese¹⁶ series did not look into concomitant CABG. The percentage of concomitant CABG in our series is higher than the trials of SAVR/TAVI. This probably reflects the selection criteria in the latter. In PARTNER 2, although both groups had a similar number with coexistent coronary artery disease, 14.5% of the SAVR group had concomitant CABG compared to 3.9% of the TAVI group who had percutaneous intervention (Table 4).²² SAVR may therefore be the preferred treatment modality in those with aortic stenosis and multivessel coronary artery disease requiring revascularisation.

Treatment of coronary artery disease in TAVI patients may require more than one hospital admission and can often result in incomplete revascularisation and its consequent increased morbidity and mortality. A meta-analysis by Sankaramangalam and colleagues, demonstrated that whilst there was no increase in mortality in patients with coronary artery disease who underwent TAVI at 30 days, there was a significant increase in mortality at one year following TAVI in these patients.²³ The economic costs of readmission after TAVI have been demonstrated to be higher than in those who are readmitted after surgery and so untreated coronary disease which later requires readmission will have cost implications.^{24,25} Surgery has the advantage of addressing all the pathology with one operation.

Durability and choice of prosthetic valves

In choosing the technique of treatment for aortic valve disease, life expectancy of the person and durability of the valve need to be considered. Ideally, the prosthetic valve should be durable for the person's lifetime. Both of these are related to person's age. In the UK a 50 year old female has a life expectancy of 34 years and a 70 year old male a life expectancy of 14 years.²⁶

The durability of bioprosthetic valves is well documented in the surgical literature and is inversely proportional to person's age. Structural valve deterioration (SVD) has

1
2
3 been demonstrated to increase exponentially beyond 10 years following surgery.^{27,28}
4 Considering the UK life expectancy ²⁶, a 70 year old male has a 5% risk of re-operation
5 and a 50 year old female has a 30% chance of needing a second operation.
6
7

8 Surgery has the advantage of offering the patient a mechanical or a bioprosthetic
9 valve. The option of a mechanical valve which is only available in surgical SAVR should
10 not be overlooked especially in younger people. In the current study, we have shown a
11 fairly consistent ratio of tissue to mechanical valve use. However, the reported literature
12 shows that the number of mechanical valve implantations has reduced in comparison to
13 bioprosthetic valves.¹⁰ Mechanical valves are durable, with one group reporting 6.9%
14 reintervention rate at 15 years versus 12.1% in those who underwent surgery with a
15 bioprosthesis.²⁹ For this reason, it has been the most commonly considered prosthesis
16 in those under the age of 60, as in our study where 60.2% of participants <60 years had
17 a mechanical valve. Mechanical valves have the disadvantage of requiring
18 anticoagulation, although, newer generations require a lower level of anticoagulation.
19 ³⁰Whilst mechanical valves are more durable, this has to be balanced against the
20 greater risk of bleeding. ²⁹ At 15 years follow up, Chiang and colleagues also
21 demonstrated no significant difference in survival and stroke between patients who
22 underwent SAVR with mechanical vs bioprosthetic valve.²⁹ Another group demonstrated
23 in the 50-70 year old cohort that survival at 5 years was higher in patients who had
24 undergone SAVR with mechanical valve vs bioprosthesis and also demonstrated similar
25 freedom from major bleeding events.³¹
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Bicuspid aortic valve and aneurysm of the aorta**

42 A significant number of patients requiring SAVR have bicuspid aortic valve, which has
43 an incidence of 1-2% in the general population and may present with aortic valve
44 stenosis, regurgitation and ascending aortic aneurysm. The type of native aortic valve is
45 not recorded in the database of our study. BAV may be present in up to 30% of patients
46 undergoing SAVR.³² Bicuspid aortic valve anatomy, larger annular size, bulky and
47 asymmetric leaflet calcification and dilated ascending aorta all pose technical
48 challenges to TAVI which are not prohibitive risk factors for surgery. In fact, associated
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 pathology of aneurysms of the aortic root and ascending aorta can be treated at the
4 time of SAVR with little additional risk.³³
5
6
7

8 European guidelines recommend discussing people with aortic valve disease in a multi-
9 disciplinary setting referred to as Heart Team, comprising of a surgeon, a non-
10 interventional and an interventional cardiologist.³⁴ This will allow the best treatment
11 option to be put forward to the person.
12
13
14

15 16 17 **CONCLUSIONS**

18 SAVR with and without CABG has low mortality risk and a low level of complications in
19 the UK in people of all ages and risk factors. Our study provides real world experience
20 of surgical results to improve understanding of the risks of surgery and decision making
21 in a multi-disciplinary team (MDT) setting with Heart Team. The results of this study can
22 be utilised by people with aortic valve disease, referring general practitioners,
23 physicians, surgeons and policy makers. Future studies need to address long term
24 follow-up including factors like quality of life which are currently not collected by the
25 specialist centres.
26
27
28
29
30
31
32
33

34 **Acknowledgement.** We would like to thank all the units (listed below) and the
35 consultant surgeons who submitted their data for analysis. We are indebted to all the
36 database managers and audit officers who have collected this data.
37
38

39 We would like to express our gratitude to Edwards Lifesciences for their support for a
40 part time research fellow and administrator for this study.
41
42
43

44 **Contributorship:** The first five authors and the senior author have designed this
45 project, compile the data set, collected, analysed the data and reviewed the various
46 versions of the manuscript. Other authors have collated, validated and submitted their
47 data on behalf of their unit. They have assisted in the design and analysis of the
48 manuscript. In addition,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 each author has contributed to the various versions of the manuscript with constructive
4 comments. Every author has contributed to the interpretation of data. More specifically:
5
6
7

8 1. Marjan Jahangiri - Thought of the concept, designed the project, plan data collection,
9 identified units, approached each unit, collected and analysed the data. Wrote the first
10 draft and author for subsequent versions.
11

12 2. Rajdeep Bilkhu - thought of the concept, designed the project, planned data
13 collection, collected the data and cleaned it, contributed significantly to writing major
14 sections of the paper
15

16 3. Andrew Embleton-Thirsk – Involved in the design of the study at the outset, of the two
17 main statistician who carried out the statistical work. Attended several meetings to
18 discuss the project, involved in writing all the versions.
19

20 4. Hakim-Moulay Dehbi - Involved in the design of the study at the outset, of the two
21 main statistician who carried out the statistical work. Attended several meetings to
22 discuss the project, involved in writing all the versions.
23

24 5. Krishna Mani - thought of the concept, designed the project, planned data collection,
25 collected the data and cleaned it, contributed significantly to writing major sections of
26 the paper, checked the literature contents and references.
27

28 6. Jon Anderson – Planned the project with the first two authors, acquired the data and
29 contributed to several versions during the writing up phase
30

31 7. Vassilios Avlonitis - Planned the project with the first two authors, acquired the data
32 and contributed to several versions during the writing up phase
33

34 8. Max Baghai - Planned the project with the first two authors, acquired the data and
35 contributed to several versions during the writing up phase
36

37 9. Inderpaul Birdi – Planned the project with the first two authors, acquired the data and
38 contributed to several versions during the writing up phase
39

40 10. Karen Booth - Planned the project with the first two authors, acquired the data and
41 contributed to several versions during the writing up phase
42

43 11. Norman Briffa - Planned the project with the first two authors, acquired the data and
44 contributed to several versions during the writing up phase
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

12. Keith Buchan - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
13. Sunil Bhudia - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase
14. Alex Cale - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
15. Indu Deglurkar - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
16. Shakil Farid - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
17. Leonidas Hadjinikolaou - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
18. Martin Jarvis - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase
19. Seyed Hossein Javadpour - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
20. Reubendra Jeganathan - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
9. Inder21. Manoj Kuduvali - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
22. Kulvinder Lall - Planned the project with the first two authors, acquired the data
23. Jorge Mascaro - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
24. Dheeraj Mehta - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
25. Sunil Ohri - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
26. Prakash Punjabi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
27. Venkateswaran Rajamiyer - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase

1
2
3 28. Paul Ridley - Planned the project with the first two authors, acquired the data and
4 contributed to several verisons during the writing up phase

5
6 29. Christopher Satur - Planned the project with the first two authors, acquired the data
7 and contributed to several verisons during the writing up phase

8
9
10 30. Serban Stoica - Planned the project with the first two authors, acquired the data and
11 contributed to several verisons during the writing up phase

12
13 31. Uday Trivedi - Planned the project with the first two authors, acquired the data and
14 contributed to several verisons during the writing up phase

15
16 32. Afzal Zaidi - Planned the project with the first two authors, acquired the data and
17 contributed to several verisons during the writing up phase

18
19 33. Patrick Yiu - Planned the project with the first two authors, acquired the data and
20 contributed to several verisons during the writing up phase

21
22 34. Narain Moorjani - Planned the project with the first two authors, acquired the data
23 and contributed to several verisons during the writing up phase. Facilitated the
24 acquisition of thedata through the Society for Cardiothoracic Surgery of GB & Ireland.

25
26 35. Simon Kendall - Planned the project with the first two authors, acquired the data and
27 contributed to several verisons during the writing up phase. Facilitated the acquisition of
28 thedata through the Society for Cardiothoracic Surgery of GB & Ireland.

29
30 36. Nick Freemantle – Senior statistician who designed the project, defiend the original
31 plan for the study, assisted the other two statistician to analyse the data, took part in
32 several meetings interpreting the data with further analysis,
33 assisted in writing the paper and final analysis

34
35
36
37
38
39
40
41
42
43 **Competing interests:** All authors declare no competing interests.

44
45
46 **Ethical approval:** Anonymised data were submitted to the Society for Cardiothoracic
47 Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then stored in a
48 secure database. This data is ordinarily submitted to National Institute of Cardiovascular
49 Outcome Research (NICOR) for which local and national Caldicott guardian approvals
50 have been obtained. A further approval from the Caldicott Guardian was obtained in
51 2020.
52
53
54
55
56
57
58
59
60

1
2
3 **Funding:** We would like to express our gratitude to Edwards Lifesciences for their support for a
4 part time research person and administrator for this study
5
6
7

8 **Data sharing:** Requests on data sharing can be made by contacting the corresponding
9 author. Data will be shared after review and approval by the authors and terms of
10 collaboration will be reached together with a signed data access agreement.
11
12
13

14
15 The corresponding author (MJ) affirms that the manuscript is an honest, accurate, and
16 transparent account of the study being reported; that no important aspects of the study
17 have been omitted; and that any discrepancies from the study as planned (and, if
18 relevant, registered) have been explained. The manuscript is read and approved by all
19 authors.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Zakkar M, Bryan AJ, Angelini GD. Aortic stenosis: diagnosis and management. *BMJ* 2016;355:1–9.
- 2 Otto CM, Burwash IG, Legget ME, *et al.* Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997;95:2262–70.
- 3 Cribier A, Eltchaninoff H, Tron C, *et al.* Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 2004;43:698–703.
- 4 Leon MB, Smith CR, Mack M, *et al.* Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med* 2010;363:1597–607.
- 5 Adams DH, Popma JJ, Reardon MJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370:1790–8.
- 6 Mack MJ, Leon MB, Thourani VH, *et al.* Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;380:1695–705.
- 7 Popma JJ, Michael Deeb G, Yakubov SJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 2019;380:1706–15.
- 8 De Backer O, Luk NHV, Olsen NT, *et al.* Choice of Treatment for Aortic Valve Stenosis in the Era of Transcatheter Aortic Valve Replacement in Eastern Denmark (2005 to 2015). *JACC Cardiovasc Interv* 2016;9:1152–8.
- 9 Martin E, Dagenais F, Voisine P, *et al.* Surgical aortic valve replacement outcomes in the transcatheter era. *J Thorac Cardiovasc Surg* 2015;150:1582–8.
- 10 Silaschi M, Conradi L, Treede H, *et al.* Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. *Thorac Cardiovasc Surg* 2016;64:382–9.
- 11 Tam DY, Rocha R V., Wijeyesundera HC, *et al.* Surgical valve selection in the era

- of transcatheter aortic valve replacement in the Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg* 2020;159:416–27.
- 12 Simonato M, Dvir D. Transcatheter aortic valve replacement in failed surgical valves. *Heart* 2019;105:S38–43.
- 13 Landes U, Webb JG, De Backer O, *et al.* Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. *J Am Coll Cardiol* 2020;75:1882–93.
- 14 Huygens SA, Mokhles MM, Hanif M, *et al.* Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2016;50:605–16.
- 15 Thourani VH, Suri RM, Gunter RL, *et al.* Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. *Ann Thorac Surg* 2015;99:55–61.
- 16 Tokuda Y, Yamamoto H, Miyata H, *et al.* Contemporary outcomes of surgical aortic valve replacement in Japan. *Circ J* 2020;84:277–82.
- 17 Barili F, Freemantle N, Pilozzi Casado A, *et al.* Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. *Eur J Cardiothorac Surg* 2020;58:221–9.
- 18 Thyregod HGH, Steinbrüchel DA, Ihlemann N, *et al.* Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. *J Am Coll Cardiol* 2015;65:2184–94.
- 19 Makkar RR, Thourani VH, Mack MJ, *et al.* Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med* 2020;382:799–809.
- 20 Barbanti M, Tamburino C, D'Errigo P, *et al.* Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in a Real World Population: Final Results from the OBSERVANT Study. *Circ Cardiovasc Interv* 2019;12:1–9.
- 21 Sabbagh A El, Nishimura RA. Clinical conundrum of coronary artery disease and aortic valve stenosis. *J Am Heart Assoc* 2017;6:1–3.

- 1
2
3 22 Leon MB, Smith CR, Mack MJ, *et al.* Transcatheter or Surgical Aortic-Valve
4 Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016;374:1609–20.
5
6 23 Sankaramangalam K, Banerjee K, Kandregula K, *et al.* Impact of coronary artery
7 disease on 30-day and 1-year mortality in patients undergoing transcatheter
8 Aortic valve replacement: A meta-analysis. *J Am Heart Assoc* 2017;6:1–11.
9
10 24 Goldsweig AM, Tak HJ, Chen LW, *et al.* Relative Costs of Surgical and
11 Transcatheter Aortic Valve Replacement and Medical Therapy. *Circ Cardiovasc*
12 *Interv* 2020;13:1–9.
13
14 25 Tripathi A, Flaherty MP, Abbott JD, *et al.* Comparison of Causes and Associated
15 Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical
16 Aortic Valve Replacement in the United States (A National Readmission
17 Database Study). *Am J Cardiol* 2018;122:431–9.
18
19 26 O'Neill A. Life expectancy (from birth) in the United Kingdom from 1765 to 2020.
20 Statista. 2020. [https://www.statista.com/statistics/1040159/life-expectancy-united-](https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/)
21 [kingdom-all-time/](https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/) (accessed 7 Aug 2020).
22
23 27 Foroutan F, Guyatt GH, O'Brien K, *et al.* Prognosis after surgical replacement with
24 a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis:
25 Systematic review of observational studies. *BMJ* 2016;354:1–9.
26
27 28 McClure RS, Narayanasamy N, Wiegerinck E, *et al.* Late Outcomes for Aortic
28 Valve Replacement With the Carpentier-Edwards Pericardial Bioprosthesis: Up to
29 17-Year Follow-Up in 1,000 Patients. *Ann Thorac Surg* 2010;89:1410–6.
30
31 29 Chiang YP, Chikwe J, Moskowitz AJ, *et al.* Survival and long-term outcomes
32 following bioprosthetic vs mechanical aortic valve replacement in patients aged 50
33 to 69 years. *JAMA - J Am Med Assoc* 2014;312:1323–9.
34
35 30 Puskas JD, Gerdisch M, Nichols D, *et al.* Anticoagulation and Antiplatelet
36 Strategies After On-X Mechanical Aortic Valve Replacement. *J Am Coll Cardiol*
37 2018;71:2717–26.
38
39 31 Huckaby L V., Sultan I, Gleason TG, *et al.* Outcomes of tissue versus mechanical
40 aortic Valve Replacement Reduces Long-Term Survival. *Ann Thorac*
41
42 32 Cozijnsen L, van der Zaag-Loonen HJ, Cozijnsen MA, *et al.* Differences at
43 surgery between patients with bicuspid and tricuspid aortic valves. *Netherlands*
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Hear J 2019;27:93–9.

33 Wallen T, Habertheuer A, Bavaria JE, *et al.* Elective Aortic Root Replacement in North America: Analysis of STS Adult Cardiac Surgery Database. *Ann Thorac Surg* 2019;107:1307–12.

34 Baumgartner H, Falk V, Bax J *et al.* 2017 ESC / EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European. *Eur Heart J* 2017;38:2739–86.

Tables 1. Mortality (%) for different categories of age and EuroSCORE

Euroscore	N (%)	SAVR+CABG (Mortality %)	SAVR (Mortality %)
<3%	15619 (50.0)	2.0	1.3
3-6%	5020 (16.1)	0.9	1.0
>6%	6846 (21.9)	4.4	3.9
Age (years)		SAVR+CABG	SAVR
<60		2.2	2.0
60-75		1.8	1.5
>75		3.1	2.2

Table 2. Multivariable modelling of post-operative outcomes using pre-operative and operative factors

Predictor	missing	Category	Hospital mortality		Return to theatre for bleeding		New stroke		Post-operative length of stay (days)	
			Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value
Age (years)	7.9%	<i>per unit increase</i>	1.03 (1.02-1.04)	<0.001	1.01 (1.00-1.01)	0.006	1.02 (1.01-1.03)	0.001	1.00 (1.00-1.00)	<0.001
Gender	10.3%	Female Male	- 0.63 (0.51-0.77)	<0.001	- 1.18 (1.02-1.36)	- 0.026	- 1.02 (0.80-1.29)	- 0.89	- 0.94 (0.93-0.96)	- <0.001
LVEF	3.1%	Good (>50%) Moderate (30-50%) Poor (<30%)	- 1.48 (1.18-1.85) 1.90 (1.36-2.69)	- 0.001 <0.001	- 1.08 (0.91-1.27) 1.10 (0.82-1.48)	- 0.38 0.53	- 1.13 (0.86-1.48) 0.78 (0.44-1.38)	- 0.38 0.40	- 1.08 (1.06-1.10) 1.07 (1.03-1.11)	- <0.001 0.001
EuroSCORE Logistic	12.1%	<i>per unit increase</i>	1.02 (1.02-1.03)	<0.001	1.01 (1.00-1.01)	0.16	1.00 (0.99-1.02)	0.30	1.01 (1.01-1.01)	<0.001
Operative Urgency	0.02%	1. Elective 2. Urgent 3. Emergency 4. Salvage	- 1.63 (1.30-2.00) 6.87 (4.70-10.16) 11.79 (5.73-24.27)	- <0.001 <0.001 <0.001	- 1.26 (1.08-2.00) 2.22 (1.51-3.26) 1.51 (0.56-4.02)	- 0.002 <0.001 0.41	- 1.08 (0.83-1.41) 7.65 (5.00-11.70) 4.38 (1.47-13.1)	- 0.55 <0.001 0.008	- 1.18 (1.16-1.20) 1.78 (1.67-1.90) 1.25 (1.07-1.46)	- <0.001 <0.001 0.006
Cumulative Bypass Time (mins)	2.4%	<i>per unit increase</i>	1.02 (1.01-1.02)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.00)	<0.001
Cumulative Cross Clamp Time (mins)	2.5%	<i>per unit increase</i>	0.99 (0.99-0.99)	<0.001	1.00 (1.00-1.00)	0.23	1.00 (0.99-1.00)	0.58	1.00 (1.00-1.00)	0.78
CABG	0%	No Yes	- 1.15 (0.93-1.42)	- 0.20	- 1.07 (0.93-1.24)	- 0.33	- 1.12 (0.88-1.42)	- 0.37	- 1.03 (1.00-1.05)	- <0.001

LVEF; left ventricular ejection fraction, CABG; coronary artery bypass graft surgery

136/bmjopen-2020-046491 on 28 October 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Table 3. Baseline characteristics in the current study (UK SAVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷	PIVOTAL ⁵		NOTION ⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVR N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N=357	TAVI N=390	SAVR N=135
Age (mean±SD)	70.1±11.5	67.6 ± 13.4	NR	81.7±6.7	81.5±6.7	73.6±6.1	73.3±5.8	73.6±5.9	74.4±5.8	83.2±6.4	83.1±7.1	79 ± 4.7
% Male	59	58	51.1	54.8	54.2	71.1	67.5	66.2	64	52.4	53.1	53.8
BMI (kg/m ²)	28.9±5.5	29.3 ± 6.6	NR	28.3±6.2	28.6±6.2	30.3±5.1	30.7±5.5	NR	NR	NR	NR	NR
NYHA class III/IV (%)	44.4	38.4	15.9	76.3	77.3	23.8	31.2	28.4	25.1	86.9	85.7	45.5
Logistic EuroSCORE (%)	4.3±7.3	NR	NR	NR	NR	1.5±0.9*	1.5±1.2*	NR	NR	18.6±13.0	17.7±13.1	8.9 ± 5.5
Diabetes Mellitus (%)	22.2	25.5	NR	34.2	37.7	30.2	31.2	30.5	31.4	45.4	34.9	20.7
Chronic Kidney Disease (%)	3.1	NR	NR	5.2	5.0	0.2	0.2	0.1	0.4	12.8	12.2	0.7
Hypertension (%)	64.9	NR	NR	NR	NR	NR	NR	82.6	84.8	96.1	95.1	76.3
Peripheral vascular disease (%)	8.7	9.2	NR	32.9	27.9	7.3	6.9	7.5	7.3	41.7	41.1	6.7
Previous stroke (%)	8.2	12.6	0.13	31	32.1	5.1	3.4	10.2	7.8	14.0	12.6	16.3
COPD (%)	13.4	NR	13.6	30.0	31.8	6.2	5.1	15.0	13.0	9.0	13.3	11.9
LV ejection fraction (%)	53.2	54.9 ± 12.9	NR	55.3±11.9	56.2±10.8	66.2±8.6	65.7±9.0	61.9 ± 7.7	61.7 ± 7.9	NR	NR	NR
Coronary artery disease (%)	37.1	NR	NR	66.5	69.2	28.0	27.7	NR	NR	75.9	75.4	NR
Atrial fibrillation	10.3	NR	5.6	35.2	31.0	18.8	15.7	14.5	14.4	45.9	40.9	25.6
Permanent pacemaker	1.9			12.0	11.7	2.9	2.4	3.8	2.2	21.3	23.3	4.4

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, BMI; body mass index, NYHA; New York Heart Association classification,

COPD; chronic obstructive pulmonary disease, NR; not reported

*EuroSCORE II reported only

Table 4. Operative characteristics in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 145
Operative urgency													
Elective (%)	74.3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Urgent (%)	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Emergency/Salvage (%)	1.7	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Concomitant CABG (%)	37.1	NR	NR	NR	-	12.8	-	13.6	-	4.8	-	1	-
Staged PCI	-	NR	NR	-	NR	-	6.5	-	6.9	-	0.3%	-	0
Cross clamp time (minutes)	79.0	77.0 ± 28.5	NR	NR	-	74.3 ± 27.78	-	68.7 ± 29.0	-	74.0 ± 31.4	-	NR	NR
Cardiopulmonary bypass time (minutes)	104	104.9 ± 39.1	NR	NR	-	97.7 ± 33.75	-	93.4 ± 40.2	-	104.0 ± 45.8	-	NR	NR
Procedure time (minutes)	NR	NR	NR	NR	NR	208.3 ± 62.1	58.6 ± 36.5	276.6 ± 79.5	148.2 ± 55.1	221 ± 84.8	60.4 ± 35.3	177.2 ± 39.8	90.3 ± 38.6

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

136/bmjopen-2020-024911 on 28 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

Table 5. Outcomes following SAVR in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Outcome	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 145
In-hospital death/30-day mortality (%)	1.9	2.5	NR	8.0	6.1	1.1	0.4	1.3	0.5	4.5	3.3	3.7	2.1
Stroke (%)	1.1	NR	1.6	6.1	5.5	2.4	0.6	3.4	3.4	6.2	4.9	3.0	1.4
Reoperation for bleeding* (%)	3.6	3.9	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Post procedure bleeding* (%)	-	NR		43.4	10.4	11.9	1.2	7.5	2.4	69.5	41.7	11.3	20.9
Deep sternal wound infection (%)	0.14	0.3	1.1	NR	-	NR	-	NR	NR	NR	-	NR	-
Length of hospital stay (days)	7	7.9 ± 7.2	NR	NR	-	7.0	3.0	NR	NR	NR	NR	8.9 ± 6.2	12.9 ± 11.6
New pacemaker implantation (%)	1.6	NR	NR	6.9	8.	4.0	6.5	6.1	1.4	7.1	19.8	1.6	34.1

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery, NR; not reported

*Reoperation for bleeding and post-operative bleeding were major and required intervention

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	4-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	6

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9

Discussion

Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA
---------	----	---	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046491.R3
Article Type:	Original research
Date Submitted by the Author:	19-Sep-2021
Complete List of Authors:	<p>Jahangiri, Marjan; St George's Hospital, Department of Cardiac Surgery Bilkhu, Rajdeep; St George's Hospital, Department of Cardiac Surgery Embleton-Thirsk, Andrew; University College London Institute of Clinical Trials and Methodology Dehbi, Hakim-Moulay; University College London Institute of Clinical Trials and Methodology Mani, Krishna; St George's Hospital, Department of Cardiac Surgery Anderson, Jon ; Hammersmith Hospital, Department of Cardiac Surgery Avlonitis, Vassilios; St Thomas' Hospital, Department of Cardiac Surgery Baghai, Max; King's College Hospital, Department of Cardiac Surgery Birdi, Inderpaul; Essex Cardiothoracic Centre Booth, Karen; Freeman Hospital Cardiothoracic Centre Bose, Amal; Lancashire Cardiac Centre Briffa, Norman; Sheffield Teaching Hospitals NHS Foundation Trust Cardiothoracic Centre Buchan, Keith; Aberdeen Royal Infirmary, Cardiac Surgery Bhudia, Sunil; Harefield Hospital Heart Surgery Cale, Alex; Castle Hill Hospital, Cardiac Surgery Deglurkar, Indu; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Farid, Shakil; Oxford University Hospitals NHS Trust, Cardiac Surgery Hadjinikolaou, Leonidas; University Hospitals of Leicester NHS Trust, Cardiac Surgery Jarvis, Martin; Hull University Teaching Hospitals NHS Trust, Cardiac Surgery Javadpour, Seyed; Mater Misericordiae University Hospital, Cardiac Surgery Jeganathan, Reubendra; Royal Victoria Hospital, Cardiac Surgery Kuduvalli, Manoj; Liverpool Heart and Chest Hospital NHS Foundation Trust, Cardiac Surgery Lall, Kulvinder; Saint Bartholomew's Hospital Barts Heart Centre Mascaro, Jorge; Queen Elizabeth Medical Centre, Cardiac Surgery Mehta, Dheeraj; University Hospital of Wales Healthcare NHS Trust, Cardiac Surgery Ohri, Sunil; Southampton University Hospitals NHS Trust, Cardiac Surgery Punjabi, Prakash; Hammersmith Hospital, Cardiac Surgery Venkateswaran, Rajamiyer ; Wythenshawe Hospital North West Heart Centre</p>

	Ridley, Paul; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Satur, Christopher; University Hospital of North Staffordshire NHS Trust, Cardiac Surgery Stoica, Serban; Bristol Heart Institute Trivedi, Uday; Royal Sussex County Hospital Sussex Cardiac Centre Zaidi, Afzal; Morrison Hospital, Cardiac Surgery Yiu, Patrick; New Cross Hospital, Cardiac Surgery Moorjani, Narain; Royal Papworth Hospital NHS Foundation Trust Cardiac Surgery Kendall, Simon; James Cook University Hospital, Cardiac Surgery Freemantle, Nick; University College London Institute of Clinical Trials and Methodology, Comprehensive Clinical Trials Unit
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiothoracic surgery < SURGERY, Cardiac surgery < SURGERY, CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Surgical aortic valve replacement in the era of transcatheter aortic valve implantation - A review of the UK national database

Marjan Jahangiri, Rajdeep Bilkhu**, Andrew Embleton-Thirsk**, Hakim-Moulay Dehbi*, Krishna Mani, Jon Anderson, Vassilios Avlonitis, Max Baghai, Inderpaul Birdi, Karen Booth, Amal Bose, Norman Briffa, Keith Buchan, Sunil Bhudia, Alex Cale, Indu Deglurkar, Shakil Farid, Leonidas Hadjinikolaou, Martin Jarvis, Seyed Hossein Javadpour, Reubendra Jeganathan, Manoj Kuduvali, Kulvinder Lall, Jorge Mascaro, Dheeraj Mehta, Sunil Ohri, Prakash Punjabi, Venkateswaran Rajamiyer, Paul Ridley, Christopher Satur, Serban Stoica, Uday Trivedi, Afzal Zaidi, Patrick Yiu, Narain Moorjani, Simon Kendall, Nick Freemantle*

** RB/AE equal contributions

Names of cardiac surgical units are given in the Acknowledgement section
Institute of Clinical Trials and Methodology, University College London*

Word Count: 3972

Key words: aortic valve replacement, aortic valve disease, surgery

Address for correspondence:
Marjan Jahangiri
Professor of Cardiac Surgery
St. George's Hospital
London SW17 0QT

Tel: 44-2087252652
Email: marjan.jahangiri@stgeorges.nhs.uk

1. Marjan Jahangiri
Affiliation: St George's Hospital, London
2. Rajdeep Bilkhu
Affiliation: St Thomas Hospital, London
3. Andrew Embleton-Thirsk
Affiliation: Institute of Clinical Trials and Methodology, University College London
4. Hakim-Moulay Dehbi
Affiliation: Institute of Clinical Trials and Methodology, University College London
5. Krishna Mani
Affiliation: St George's Hospital, London
6. Jon Anderson
Affiliation: Hammersmith Hospital, London
7. Vassilios Avlonitis
Affiliation: St Thomas Hospital, London
8. Max Baghai
Affiliation: Kings College Hospital, London
9. Inderpaul Birdi
Affiliation: Essex Cardiothoracic Centre, Basildon
10. Karen Booth
Affiliation: Freeman Hospital, Newcastle
11. Amal Bose
Affiliation: Blackpool Teaching Hospitals NHS Trust
12. Norman Briffa
Affiliation: Northern General Hospital, Sheffield
13. Keith Buchan
Affiliation: Aberdeen Royal Infirmary
14. Sunil Bhudia
Affiliation: Royal Brompton & Harefield Hospitals, London
15. Alex Cale
Affiliation: Castle Hill Hospital, Hull
16. Indu Deglurkar
Affiliation: Cardiff, University Hospital Wales
17. Shakil Farid
Affiliation: Oxford Heart Centre
18. Leonidas Hadjinikolaou
Affiliation: Glenfield Hospital, Leicester
19. Martin Jarvis
Affiliation: Castle Hill Hospital, Hull
20. Seyed Hossein Javadpour
Affiliation: Mater Misericordiae Hospital, Dublin
21. Reubendra Jeganathan
Affiliation: Royal Victoria Hospital, Belfast
22. Manoj Kuduvali
Affiliation: Liverpool Heart and Chest Hospital
23. Kulvinder Lall
Affiliation: Barts Heart Centre

- 1
2
3 24. Jorge Mascaro
4 Affiliation: Queen Elizabeth Hospital, Birmingham
5
6 25. Dheeraj Mehta
7 Affiliation: Cardiff, University Hospital Wales
8
9 26. Sunil Ohri
10 Affiliation: Southampton General Hospital
11
12 27. Prakash Punjabi
13 Affiliation: Hammersmith Hospital, London
14
15 28. Venkateswaran Rajamiyer
16 Affiliation: Wythenshawe Hospital, Manchester
17
18 29. Paul Ridley
19 Affiliation: Royal Stoke University Hospital
20
21 30. Christopher Satur
22 Affiliation: Royal Stoke University Hospital
23
24 31. Serban Stoica
25 Affiliation: Bristol Heart Institute
26
27 32. Uday Trivedi
28 Affiliation: Sussex Cardiac Centre, Brighton
29
30 33. Afzal Zaidi
31 Affiliation: Morrision Hospital, Swansea
32
33 34. Patrick Yiu
34 Affiliation: New Cross Hospital, Wolverhampton
35
36 35. Narain Moorjani
37 Affiliation: Royal Papworth Hospital, Cambridge
38
39 36. Simon Kendall
40 Affiliation: James Cook Cardiothoracic Centre, South Tees
41
42 37. Nick Freemantle
43 Affiliation: Institute of Clinical Trials and Methodology, University College London
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives - To date the reported outcomes of surgical aortic valve replacement (SAVR) are mainly in the settings of trials comparing it with evolving transcatheter aortic valve implantation (TAVI). We set out to examine characteristics and outcomes in people who underwent SAVR reflecting a national cohort and therefore 'real world' practice.

Design - Retrospective analysis of prospectively collected data of consecutive people who underwent SAVR with or without coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the UK. This included elective, urgent and emergency operations. Participants' demographics, pre-operative risk factors, operative data, in-hospital mortality, post-operative complications and effect of the addition of CABG to SAVR were analysed.

Setting - 27 (90%) tertiary cardiac surgical centres in the UK submitted their data for analysis.

Participants - 31,277 people with AVR were identified. 19,670 (62.9%) had only SAVR and 11,607 (37.1%) had AVR+CABG.

Results – In-hospital mortality for isolated SAVR was 1.9% (95% CI: 1.6-2.1%) and was 2.4% for AVR+CABG. Mortality by age category for SAVR only were: <60 years=2.0%, 60-75 years=1.5%, >75 years=2.2%. For SAVR+CABG these were; 2.2%, 1.8% and 3.1%. For different categories of EuroSCORE, mortality for SAVR in low risk people was 1.3%, in intermediate risk 1% and for high risk 3.9%. 74.3% of the operations were elective, 24% urgent and 1.7% emergency/salvage. The incidences of re-sternotomy for bleeding and stroke were 3.9% and 1.1% respectively. Multivariable analyses provided no evidence that concomitant CABG influenced outcome. However, urgency of the operation, poor ventricular function, higher EuroSCORE and longer cross clamp and cardiopulmonary bypass times adversely affected outcomes.

1
2
3 **Conclusions** - Surgical SAVR±CABG has low mortality risk and a low level of
4 complications in the UK in people of all ages and risk factors. These results should inform
5 consideration of treatment options in people with aortic valve disease.
6
7
8
9
10

11 **Strengths and limitations of this study**

- 12 • This is a large study of consecutive participants who have undergone surgical
13 aortic valve replacement ± coronary artery bypass graft surgery in the UK,
14 reporting contemporary outcomes.
- 15 • This study includes people of all age groups and risks factors, and elective as well
16 as urgent and emergency operations.
- 17 • The results are of in-hospital mortality and complications and longer term follow-
18 up data is not available.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Aortic valve disease, especially aortic stenosis affects 5% of the population and 3.9% of those between the ages of 70 and 79 and nearly 10% of those above the age of 80.¹ Severe aortic stenosis when untreated has a risk of death of 50% at 2 years.² Conventionally the gold standard of treatment has been surgical aortic valve replacement (SAVR). However, the role of transcatheter aortic valve implantation (TAVI) has evolved in recent years. TAVI was first introduced in 2002, initially being performed in high risk inoperable patients.³ The original Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated a significant reduction in mortality, repeat hospitalisation and cardiac symptoms compared to inoperable patients who had only medical therapy.⁴ The original PIVOTAL study also demonstrated significantly higher survival at one year in high risk patients who underwent SAVR.⁵

The role of TAVI is being extended to lower risk and younger patients based on recent trials comparing SAVR with TAVI.^{6,7} Several studies suggest there has been a change in demographics and types of surgical valves used since the advent of TAVI.⁸⁻¹⁰ There has been a trend of increased use of tissue valves and a decrease in the use of mechanical valves in recent years.¹¹ This may be due to the evolution of TAVI practice whereby younger patients can have a tissue valve with the view that they have a TAVI valve in the future when the tissue valve has deteriorated, so called valve-in-valve.^{12,13}

The series in the literature reporting outcomes of SAVR are generally unit based.^{9,14} Also, people with aortic valve disease are given information about the outcomes of SAVR which may be out of date and incorrectly extrapolated from smaller studies. There is a lack of contemporary national data to assess the outcomes of SAVR (mortality and complications), and to demonstrate the trend in use of prosthetic valves which would inform people with aortic valve disease better. There are some perceived complications of surgery that may be understood by referring general practitioners and cardiologists to be prohibitive risks for surgery.

In order to inform practitioners, people with aortic valve disease and the cardiac surgical community, we set out to examine the results of contemporaneous SAVR in a multi-centre study of UK cardiac surgical units, in the era of TAVI. In addition, we

1
2
3 summarise and interpret some of the more recent trials on the management of aortic valve
4 disease.
5

6 7 8 **METHODS**

9 10 **Data**

11 This is an analysis of prospectively collected data of people who underwent SAVR +/-
12 coronary artery bypass graft (CABG) surgery between April 2013 and March 2018 in the
13 UK and Republic of Ireland. Anonymised data were submitted to the Society for
14 Cardiothoracic Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then
15 stored in a secure database. This period was chosen to reflect fairly contemporary
16 practice and also the data is submitted in March every year. The data is collected by each
17 unit, validated and then submitted to the National Institute of Cardiovascular Outcome
18 Research (NICOR). It took approximately nine months to collect, validate and clean all
19 the data. The outcome measures recorded are based on strict definitions provided by
20 NICOR to provide uniformity.
21
22

23
24
25
26
27
28
29 Only participants who had had first time surgery, SAVR +/- CABG were included.
30 All participants immaterial of their risk for surgery, people of all age groups and risk factors
31 were included. Those who required other concomitant procedures like replacement of
32 parts of the aorta, aortic root enlargement, other valve procedures and redo surgery were
33 excluded.
34
35
36
37
38

39 40 **Pre-operative risk factors and operative features**

41 Baseline demographic data; significant past medical history such as diabetes, renal
42 dysfunction, hypertension or stroke; predominant aortic valve pathology (stenosis or
43 regurgitation or mixed valve disease) and preoperative left ventricular ejection fraction
44 (LVEF) were collected. EuroSCORE is the risk stratification model used in the UK.
45 Logistic EuroSCORE was collected as well as EuroSCORE II where available. The latter
46 was only used since 2017 and therefore not available for all participants. Logistic
47 EuroSCORE was divided into three categories: <3%, 3-6%, >6%.
48
49

50
51
52
53 LVEF was divided into three categories: good (EF>50%), moderate (EF 30-50%)
54 and poor (EF<30%). Transient ischaemic attack was defined as any neurological
55
56
57
58
59

1
2
3 symptoms lasting <24 hours. Stroke was defined as new neurological dysfunction
4 persisting >24 hours. Operative data including operative urgency: elective, urgent and
5 emergency/salvage were recorded. Elective was defined as when the person was
6 admitted from home, urgent meaning that the person was admitted with an urgent
7 condition and required surgery during the same hospital admission, emergency and
8 salvage meaning that surgery was required within 24 hours of admission and/or the
9 person was in extremis. Other parameters including cardiopulmonary bypass (CPB) time,
10 cross clamp (CCT) time, type of valve implanted as well as concomitant CABG surgery
11 performed were also collected.
12
13
14
15
16
17
18

19 20 **Postoperative outcomes**

21 Postoperative complication data were collected with the main focus being in-hospital
22 mortality, new stroke, return to theatre for bleeding, deep sternal wound infection and
23 duration of postoperative hospital stay.
24
25
26
27

28 29 **Statistical analysis**

30 Once the records for all participants were collated and the data cleaned, each factor was
31 summarised using descriptive methods. Categorical variables are presented as N (%)
32 and continuous variables are presented as median (IQR). New strokes were recoded to
33 be either no stroke or any cerebrovascular accident (transient or permanent). The natural
34 log of post-operative length of stay (days) was used due to positive skewed distribution
35 of this variable. Univariate models were used, logistic regression for binary outcomes and
36 linear regression for continuous outcomes, to assess the impact of the key explanatory
37 variables. In these models, a two-tailed p-value of <0.05 was considered significant. The
38 population analysed included all the participants with data collected, with results checked
39 in the subset who had SAVR only (without CABG). Building on this, a multivariable model
40 with all key variables in the model to assess which had the most impact on each of the
41 outcomes was created. Stata/MP 15.1 (StataCorp LLC, Texas, USA) was used for all
42 analyses. Multiple imputation of missing data was not performed. The missingness was
43 mostly negligible. There was no missing mortality and the data is shown in table 1.
44
45
46
47
48
49
50
51
52
53

54 55 **Patient and public involvement**

56
57
58
59
60

1
2
3 Patients and public were involved in the original design of the database.
4
5
6
7

8 RESULTS

9

10 Descriptive analysis

11
12 In total 31,277 patients were included. Of these, 19,670 (62.9%) had only SAVR and
13 11,607 (37.1%) had SAVR+CABG. There were 14.4% below the age of 60, 46.9%
14 between 60 to 75 and 36.7% older than 75 years with 7.9% missing age data. There were
15 1.9 times more males than females (10.3% missing).
16
17
18

19
20 Regarding pre-operative risk factors, 75.2% had good LVEF, 17.3% had moderate
21 and 4.3% had poor LVEF. 74.3% of the operations were elective, 24% were urgent and
22 1.7% were emergency or salvage operations.
23
24

25
26 Logistic EuroSCORE had a median of 1.83 with an IQR of 0.06-6.0. In total, 50%
27 of patients were classified as low risk (<3%), 16% as medium risk (3—6%) and 22% high
28 risk (>6%). 3,792 patients (12.1%) were missing data. The median EuroSCORE II was
29 1.95 (IQR 0.67-4.8) albeit with 56.5% with missing data, as this was introduced into the
30 database in 2017. The median CPB time was 104 minutes (IQR 82-135) and CCT was
31 79 minutes (IQR 61-101).
32
33

34
35 For valve implant replacement type, 70% had a tissue valve, 12.2% a mechanical
36 valve and 0.2% had homograft or autograft valves. For 17.3% the entry for valve type was
37 unclear. The ratio of mechanical implant to bioprosthetic implant use has remained stable
38 over time.
39
40

41
42 Overall mortality was 2.4% (95% CI: 2.2-2.6%) and mortality for isolated SAVR for
43 all participants was 1.9% (1.6-2.1%). The mortality figures analysed for different age
44 ranges and for categories of EuroSCORE are shown in Table 2.
45
46

47
48 Overall, 3.9% (3.6% in SAVR only) of participants had re-sternotomy for post-
49 operative bleeding or tamponade, 0.04% (0.06% in SAVR only) had re-operation for
50 valvular problems (significant paravalvular leak and early endocarditis), 0.7% (0.6%
51 SAVR only) had re-operation for other cardiac problems, 0.2% (0.15% for SAVR only)
52 had rewiring of sternum for sterile wounds and 0.14% (0.06% for SAVR only) had re-
53
54
55
56
57
58
59
60

wiring of sternum for infection. Transient ischaemic attack occurred in only 0.6% and 1.1% had a stroke (no missing data).

Median post-operative length of stay was 7 days (IQR: 6-11) in those with SAVR only and 8 days (IQR: 6-12) in all patients.

The number of bypass grafts was not analysed due to concerns about inconsistent reporting of data describing the number of grafts.

When comparing the two subsets of patients, the characteristics of those with SAVR alone were broadly similar to those with SAVR+CABG. In SAVR alone there were more people aged <60 years (19.3% vs 6.2%), but less people were older than 75 (30.1% vs 43%). A higher proportion of those with SAVR+CABG were male (68% vs. 54%). Bypass time was an average of 37 minutes shorter and CCT 27 minutes in the SAVR alone group. Amongst those with only SAVR the mechanical valve usage was greater, at 16% vs 7%.

Regression analysis

Univariable

Taken in isolation, all pre-operative risk factors were associated with an increased odds of death, as was addition of CABG. The same pattern was observed when analysing the need for re-operation or surgery, with all explanatory variables indicative of a worse outcome without taking into account any others. For new stroke only age, EuroSCORE, operative urgency, ejection fraction, and cumulative bypass and cross clamp times affected a negative outcome (but not gender), as did CABG. All factors predicted a longer postoperative length of stay, including CABG.

As a sensitivity analysis, age categories were also assessed. When included as a continuous variable, age was significant both on its own and in all the multivariable models. All participants were categorised into <60, 60-75 and >75 years of age. Those 60-75 were at a lower odds of death in comparison to those <60 (OR 0.71, 95% CI 0.53-0.95, P=0.021) with no difference in those >75 (OR 1.09, 95% CI 0.82-1.45) in the AVR alone group. These findings were different in the SAVR+CABG group, with no significant difference in those 60-75 (OR 0.81, 95% CI 0.64-1.03) but an increased risk in those >75 (OR 1.09, 95% CI 1.12-1.76, P=0.004).

Multivariable Analyses

Analysis of postoperative outcomes using multivariable models including all pre-operative and operative factors are shown in Table 1. This demonstrated that age (OR 1.03 (95% CI 1.02-1.04), $P<0.001$), moderate ejection fraction (OR 1.48 (95% CI 1.18-1.85), $P<0.001$), poor ejection fraction (OR 1.90 (95% CI 1.36-2.69), $P<0.001$), logistic EuroSCORE (OR 1.02 (95% CI 1.02-1.03), $P<0.001$), urgent operation (OR 1.63 (95% CI 1.30-2.00, $P<0.001$), emergency surgery (OR 6.87 (95% CI 4.70-10.16), $P<0.001$) and longer CPB times affected mortality (OR 1.02 (95% CI 1.01-1.02), $P<0.001$).

When all other variables were taken into account CABG was not significantly associated with an increase in the risk of death (OR 1.15 (95% CI 0.93-1.42), $P=0.20$).

Older age, (OR 1.01 (95% CI 1.00-1.01), $p<0.006$), longer CPB time (OR 1.00 (95% CI 1.00-1.01), $P<0.001$), urgent (OR 1.26 (95% CI 1.08-2.00), $P<0.002$) and emergency surgery (OR 2.22 (95% CI 1.51-3.26), $P<0.001$) were significant factors in identifying people requiring return to theatre for bleeding. Again, CABG did not affect the odds of returning to theatre (OR 1.07 (95% CI 0.93-1.24), $P=0.33$).

Factors affecting stroke were age, (OR 1.02 (95% CI 1.01-1.03), $P<0.001$), emergency (OR 7.65 (95% CI 5.00-11.70, $P<0.001$) or salvage surgery (OR 4.38 (95% CI 1.47-13.1) $P=0.008$), and CPB times (OR 1.00 (95% CI 1.00-1.01), $P<0.001$). As in the other outcomes, addition of CABG did not affect the outcome (OR 1.12 (95% CI 0.88-1.42), $P=0.37$).

Age, male gender, moderate and poor ejection fraction, operative urgency, higher logistic EuroSCORE, and cumulative bypass time significantly all affected post-operative length of stay.

DISCUSSION

This study reports contemporary results of SAVR and SAVR+CABG in the UK, reflecting real world practice, reporting an overall mortality of 1.9% and 2.4% respectively. We have shown a low mortality and complication rate for all comers following surgery in people requiring SAVR or SAVR+CABG. The complications were low with 3.9% re-sternotomy for bleeding, 0.04% re-operation for valvular problems and 1.1% stroke. Surprisingly,

1
2
3 having accounted for other risk factors, addition of CABG did not adversely affect the
4 outcomes.
5

6 The strengths of the study include its large number of participants, no exclusion of
7 urgent and emergency/salvage cases, and inclusion of all risk participants. The limitations
8 are that three centres were unable to take part, possible coding errors in using large
9 databases, lack of detailed echocardiographic data on valve annular size and presence
10 or absence of pre-operative infective endocarditis which can adversely affect outcomes.
11 In addition, the results are in-hospital mortality and complications and the database lack
12 longer follow-up information.
13
14
15
16
17

18 Data from the current study are consistent with other large international studies.
19 Data from the US Society of Thoracic Surgeons (STS) database demonstrated in-
20 hospital mortality for isolated SAVR of 2.5% and incidence of stroke of 1.5%.¹⁵ A recent
21 analysis of the Japanese Cardiovascular Surgery database which assessed the
22 outcomes of patients undergoing SAVR over a 8 year period has demonstrated a similar
23 in-hospital mortality of 2%.¹⁶ They also demonstrated a reduction in mortality over time,
24 despite increasing surgical risk. The age of the patients in our study is lower than some
25 of the trials of SAVR and TAVI. This is probably due to the selection criteria in these trials
26 where older patients were selected.
27
28
29
30
31
32
33

34 We had set out to analyse the results of SAVR in the UK to inform practitioners
35 treating people with aortic valve disease and inform people with this condition in an era
36 where other therapies for management of aortic valve disease are evolving with
37 expanding indications. Although the current study did not examine people who received
38 TAVI, we discuss the various trials of SAVR and TAVI reported in the context of the
39 literature and compare them with the results of the current study.
40
41
42
43
44

45 In Tables 3-5, the demographics, procedural details and outcomes of the current
46 study are compared with the respective sub-groups of the published trials. Table 5 shows
47 low mortality and complication rate in the participants of this study following surgery in
48 people who required SAVR or SAVR+CABG. The trials comparing AVR and TAVI have
49 enrolled and classified patients according to the risk of surgery, in particular the more
50 recent trials.^{6,7} The most commonly used surgical risk stratification score is the Society of
51 Thoracic Surgery risk score (STS), although this scoring system has been validated in
52
53
54
55
56
57
58
59
60

1
2
3 the US population. We have used EuroSCORE and shown that mortality is low in all
4 categories of risk.
5

6
7 There are several recent trials comparing SAVR with TAVI. A meta-analysis of six
8 of these trials performed by Barili and colleagues reported that mortality was affected by
9 the treatment modality with a time-varying effect: TAVI was related to better survival in
10 the first months after implantation whereas, after 40 months, it was a risk factor for all-
11 cause mortality.¹⁷ The NOTION trial, which compared outcomes of patients estimated to
12 have low surgical risk who underwent either TAVI or SAVR demonstrated similar early
13 mortality results, with mortality of 2.1% in TAVI group vs 3.7% in the SAVR group,
14 $p=0.38$.¹⁸ The PIVOTAL trial of low risk patients also reported similar results between
15 those who underwent TAVI compared to SAVR, with early mortality of 0.5% in TAVI group
16 and 1.3% in SAVR.⁷ In addition, the 5 year results of the PARTNER 2 study, comparing
17 TAVI vs SAVR in intermediate surgical risk demonstrated no significant difference in the
18 incidence of death or stroke at 5 years following SAVR or TAVI.¹⁹ The mortality in the
19 intermediate EuroSCORE risk category of the current study was 1.0% for SAVR only and
20 0.9% for SAVR+CABG. PARTNER 3 however demonstrated significantly lower mortality
21 in the TAVI group compared to SAVR (1% vs 2.5%, $P=0.01$) at one year.⁶ An
22 observational study of 7618 patients comparing SAVR with TAVI at 5 years showed
23 however that in a real world population with low and intermediate risk, SAVR was
24 associated with lower mortality and major adverse cardiac events, although this was with
25 first generation TAVI devices.²⁰
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Role of co-existent coronary artery disease and its management**

40
41 60% of patients with aortic valve disease undergoing SAVR and 65% of those undergoing
42 TAVI have coexisting coronary artery disease.²¹ In our series, 37% had co-existent
43 coronary artery disease and underwent concomitant CABG. The addition of CABG did
44 not adversely affect outcomes. The US¹⁵ and Japanese¹⁶ series did not look into
45 concomitant CABG. The percentage of concomitant CABG in our series is higher than
46 the trials of SAVR/TAVI. This probably reflects the selection criteria in the latter. In
47 PARTNER 2, although both groups had a similar number with coexistent coronary artery
48 disease, 14.5% of the SAVR group had concomitant CABG compared to 3.9% of the TAVI
49 group who had percutaneous intervention (Table 4).²² SAVR may therefore be the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 preferred treatment modality in those with aortic stenosis and multivessel coronary artery
4 disease requiring revascularisation.
5

6
7 Treatment of coronary artery disease in TAVI patients may require more than one
8 hospital admission and can often result in incomplete revascularisation and its
9 consequent increased morbidity and mortality. A meta-analysis by Sankaramangalam
10 and colleagues, demonstrated that whilst there was no increase in mortality in patients
11 with coronary artery disease who underwent TAVI at 30 days, there was a significant
12 increase in mortality at one year following TAVI in these patients.²³ The economic costs
13 of readmission after TAVI have been demonstrated to be higher than in those who are
14 readmitted after surgery and so untreated coronary disease which later requires
15 readmission will have cost implications.^{24,25} Surgery has the advantage of addressing all
16 the pathology with one operation.
17
18
19
20
21
22
23
24
25

26 **Durability and choice of prosthetic valves**

27 In choosing the technique of treatment for aortic valve disease, life expectancy of the
28 person and durability of the valve need to be considered. Ideally, the prosthetic valve
29 should be durable for the person's lifetime. Both of these are related to person's age. In
30 the UK a 50 year old female has a life expectancy of 34 years and a 70 year old male a
31 life expectancy of 14 years.²⁶
32
33
34
35

36 The durability of bioprosthetic valves is well documented in the surgical literature
37 and is inversely proportional to person's age. Structural valve deterioration (SVD) has
38 been demonstrated to increase exponentially beyond 10 years following surgery.^{27,28}
39 Considering the UK life expectancy ²⁶, a 70 year old male has a 5% risk of re-operation
40 and a 50 year old female has a 30% chance of needing a second operation.
41
42
43
44

45 Surgery has the advantage of offering the patient a mechanical or a bioprosthetic
46 valve. The option of a mechanical valve which is only available in surgical SAVR should
47 not be overlooked especially in younger people. In the current study, we have shown a
48 fairly consistent ratio of tissue to mechanical valve use. However, the reported literature
49 shows that the number of mechanical valve implantations has reduced in comparison to
50 bioprosthetic valves.¹⁰ Mechanical valves are durable, with one group reporting 6.9%
51 reintervention rate at 15 years versus 12.1% in those who underwent surgery with a
52
53
54
55
56
57
58
59
60

1
2
3 bioprosthesis.²⁹ For this reason, it has been the most commonly considered prosthesis in
4 those under the age of 60, as in our study where 60.2% of participants <60 years had a
5 mechanical valve. Mechanical valves have the disadvantage of requiring anticoagulation,
6 although, newer generations require a lower level of anticoagulation.³⁰ Whilst mechanical
7 valves are more durable, this has to be balanced against the greater risk of bleeding.²⁹
8 At 15 years follow up, Chiang and colleagues also demonstrated no significant difference
9 in survival and stroke between patients who underwent SAVR with mechanical vs
10 bioprosthetic valve.²⁹ Another group demonstrated in the 50-70 year old cohort that
11 survival at 5 years was higher in patients who had undergone SAVR with mechanical
12 valve vs bioprosthesis and also demonstrated similar freedom from major bleeding
13 events.³¹
14
15
16
17
18
19
20
21
22
23

24 **Bicuspid aortic valve and aneurysm of the aorta**

25 A significant number of patients requiring SAVR have bicuspid aortic valve, which has an
26 incidence of 1-2% in the general population and may present with aortic valve stenosis,
27 regurgitation and ascending aortic aneurysm. The type of native aortic valve is not
28 recorded in the database of our study. BAV may be present in up to 30% of patients
29 undergoing SAVR.³² Bicuspid aortic valve anatomy, larger annular size, bulky and
30 asymmetric leaflet calcification and dilated ascending aorta all pose technical challenges
31 to TAVI which are not prohibitive risk factors for surgery. In fact, associated pathology of
32 aneurysms of the aortic root and ascending aorta can be treated at the time of SAVR with
33 little additional risk.³³
34
35
36
37
38
39
40
41
42

43 European guidelines recommend discussing people with aortic valve disease in a multi-
44 disciplinary setting referred to as Heart Team, comprising of a surgeon, a non-
45 interventional and an interventional cardiologist.³⁴ This will allow the best treatment option
46 to be put forward to the person.
47
48
49
50
51
52

53 **CONCLUSIONS**

54
55
56
57
58
59
60

SAVR with and without CABG has low mortality risk and a low level of complications in the UK in people of all ages and risk factors. Our study provides real world experience of surgical results to improve understanding of the risks of surgery and decision making in a multi-disciplinary team (MDT) setting with Heart Team. The results of this study can be utilised by people with aortic valve disease, referring general practitioners, physicians, surgeons and policy makers. Future studies need to address long term follow-up including factors like quality of life which are currently not collected by the specialist centres.

Acknowledgement. We would like to thank all the units (listed below) and the consultant surgeons who submitted their data for analysis. We are indebted to all the database managers and audit officers who have collected this data.

We would like to express our gratitude to Edwards Lifesciences for their support for a part time research fellow and administrator for this study.

Contributorship Statement: The first five authors and the senior author have designed this project, compile the data set, collected, analysed the data and reviewed the various versions of the manuscript. Other authors have collated, validated and submitted their data on behalf of their unit. They have assisted in the design and analysis of the manuscript. In addition, each author has contributed to the various versions of the manuscript with constructive comments. Every author has contributed to the interpretation of data. More specifically:

1. Marjan Jahangiri - Thought of the concept, designed the project, plan data collection, identified units, approached each unit, collected and analysed the data. Wrote the first draft and author for subsequent versions.
2. Rajdeep Bilkhu - thought of the concept, designed the project, planned data collection, collected the data and cleaned it, contributed significantly to writing major sections of the paper
3. Andrew Embleton-Thirsk – Involved in the design of the study at the outset, of the two main statistician who carried out the statistical work. Attended several meetings to discuss the project, involved in writing all the versions.

- 1
- 2
- 3
- 4 4. Hakim-Moulay Dehbi - Involved in the design of the study at the outset, of the two main
- 5 statistician who carried out the statistical work. Attended several meetings to discuss the
- 6 project, involed in writing all the versions.
- 7
- 8 5. Krishna Mani - thought of the concept, designed the project, planned data collection,
- 9 collected the data and cleaned it, contributed significantly to writing major sections of the
- 10 paper, checked the literature contents and references.
- 11
- 12 6. Jon Anderson – Planned the project with the first two authors, acquired the data and
- 13 contributed to several verisons during the wiriing up phase
- 14
- 15 7. Vassilios Avlonitis - Planned the project with the first two authors, acquired the data
- 16 and contributed to several verisons during the wirting up phase
- 17
- 18 8. Max Baghai - Planned the project with the first two authors, acquired the data and
- 19 contributed to several verisons during the writing up phase
- 20
- 21 9. Inderpaul Birdi – Planned the project with the first two authors, acquired the data and
- 22 contributed to several verisons during the writing up phase
- 23
- 24 10. Karen Booth - Planned the project with the first two authors, acquired the data and
- 25 contributed to several verisons during the writing up phase
- 26
- 27 11. Amal Bose - Collected, submitted, reviewed and analysed the data.
- 28
- 29 12. Norman Briffa - Planned the project with the first two authors, acquired the data and
- 30 contributed to several verisons during the writing up phase
- 31
- 32 13. Keith Buchan - Planned the project with the first two authors, acquired the data and
- 33 contributed to several verisons during the writing up phase
- 34
- 35 14. Sunil Bhudia - Planned the project with the first two authors, acquired the data and
- 36 contributed to several verisons during the wiriing up phase
- 37
- 38 15. Alex Cale - Planned the project with the first two authors, acquired the data and
- 39 contributed to several verisons during the writing up phase
- 40
- 41 16. Indu Deglurkar - Planned the project with the first two authors, acquired the data and
- 42 contributed to several verisons during the writing up phase
- 43
- 44 17. Shakil Farid - Planned the project with the first two authors, acquired the data and
- 45 contributed to several verisons during the writing up phase
- 46
- 47 18. Leonidas Hadjinikolaou - Planned the project with the first two authors, acquired the
- 48 data and contributed to several verisons during the writing up phase
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

19. Martin Jarvis - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wiriing up phase
20. Seyed Hossein Javadpour - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
21. Reubendra Jeganathan - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
22. Manoj Kuduvali - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
23. Kulvinder Lall - Planned the project with the first two authors, acquired the data
24. Jorge Mascaro - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
25. Dheeraj Mehta - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
26. Sunil Ohri - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
27. Prakash Punjabi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
28. Venkateswaran Rajamiyer - Planned the project with the first two authors, acquired the data and contributed to several verisons during the wirting up phase
29. Paul Ridley - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
30. Christopher Satur - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
31. Serban Stoica - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
32. Uday Trivedi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
33. Afzal Zaidi - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase
34. Patrick Yiu - Planned the project with the first two authors, acquired the data and contributed to several verisons during the writing up phase

1
2
3 35. Narain Moorjani - Planned the project with the first two authors, acquired the data and
4 contributed to several verisons during the writing up phase. Facilitated the acquisition of
5 thedata through the Society for Cardiothoracic Surgery of GB & Ireland.
6
7

8 36. Simon Kendall - Planned the project with the first two authors, acquired the data and
9 contributed to several verisons during the writing up phase. Facilitated the acquisition of
10 thedata through the Society for Cardiothoracic Surgery of GB & Ireland.
11
12

13 37. Nick Freemantle – Senior statistician who designed the project, defiend the original
14 plan for the study, assisted the other two statistician to analyse the data, took part in
15 several meetings interpreting the data with further analysis,
16 assisted in writing the paper and final analysis
17
18
19
20
21

22 **Competing interests:** All authors declare no competing interests.
23
24

25 **Ethical approval:** Anonymised data were submitted to the Society for Cardiothoracic
26 Surgery of Great Britain & Ireland (SCTS) for 27 of the 30 units and then stored in a
27 secure database. This data is ordinarily submitted to National Institute of Cardiovascular
28 Outcome Research (NICOR) for which local and national Caldicott guardian approvals
29 have been obtained. A further approval from the Caldicott Guardian was obtained in
30 2020.
31
32
33
34
35

36 **Funding:** We would like to express our gratitude to Edwards Lifesciences for their support for a
37 part time research person and administrator for this study
38
39
40

41 **Data sharing:** Requests on data sharing can be made by contacting the corresponding
42 author. Data will be shared after review and approval by the authors and terms of
43 collaboration will be reached together with a signed data access agreement.
44
45
46
47

48 The corresponding author (MJ) affirms that the manuscript is an honest, accurate, and
49 transparent account of the study being reported; that no important aspects of the study
50 have been omitted; and that any discrepancies from the study as planned (and, if relevant,
51 registered) have been explained. The manuscript is read and approved by all authors.
52
53
54
55
56
57
58
59
60

Ethics statement

This data is ordinarily submitted to National Institute of Cardiovascular Outcome Research (NICOR) for which local and national Caldicott guardian approvals have been obtained. The data are validated by the surgical teams and their database managers/audit officers. For the current study a further approval from the Caldicott Guardian was obtained.

REFERENCES

- 1 Zakkar M, Bryan AJ, Angelini GD. Aortic stenosis: diagnosis and management. *BMJ* 2016;355:1–9.
- 2 Otto CM, Burwash IG, Legget ME, *et al.* Prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. *Circulation* 1997;95:2262–70.
- 3 Cribier A, Eltchaninoff H, Tron C, *et al.* Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. *J Am Coll Cardiol* 2004;43:698–703.
- 4 Leon MB, Smith CR, Mack M, *et al.* Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med* 2010;363:1597–607.
- 5 Adams DH, Popma JJ, Reardon MJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;370:1790–8.
- 6 Mack MJ, Leon MB, Thourani VH, *et al.* Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med* 2019;380:1695–705.
- 7 Popma JJ, Michael Deeb G, Yakubov SJ, *et al.* Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *N Engl J Med* 2019;380:1706–15.
- 8 De Backer O, Luk NHV, Olsen NT, *et al.* Choice of Treatment for Aortic Valve Stenosis in the Era of Transcatheter Aortic Valve Replacement in Eastern Denmark

- (2005 to 2015). *JACC Cardiovasc Interv* 2016;9:1152–8.
- 9 Martin E, Dagenais F, Voisine P, *et al.* Surgical aortic valve replacement outcomes in the transcatheter era. *J Thorac Cardiovasc Surg* 2015;150:1582–8.
- 10 Silaschi M, Conradi L, Treede H, *et al.* Trends in Surgical Aortic Valve Replacement in More Than 3,000 Consecutive Cases in the Era of Transcatheter Aortic Valve Implantations. *Thorac Cardiovasc Surg* 2016;64:382–9.
- 11 Tam DY, Rocha R V., Wijeyesundera HC, *et al.* Surgical valve selection in the era of transcatheter aortic valve replacement in the Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg* 2020;159:416–27.
- 12 Simonato M, Dvir D. Transcatheter aortic valve replacement in failed surgical valves. *Heart* 2019;105:S38–43.
- 13 Landes U, Webb JG, De Backer O, *et al.* Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. *J Am Coll Cardiol* 2020;75:1882–93.
- 14 Huygens SA, Mokhles MM, Hanif M, *et al.* Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2016;50:605–16.
- 15 Thourani VH, Suri RM, Gunter RL, *et al.* Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. *Ann Thorac Surg* 2015;99:55–61.
- 16 Tokuda Y, Yamamoto H, Miyata H, *et al.* Contemporary outcomes of surgical aortic valve replacement in Japan. *Circ J* 2020;84:277–82.
- 17 Barili F, Freemantle N, Pillozzi Casado A, *et al.* Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. *Eur J Cardiothorac Surg* 2020;58:221–9.
- 18 Thyregod HGH, Steinbrüchel DA, Ihlemann N, *et al.* Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. *J Am Coll Cardiol* 2015;65:2184–94.
- 19 Makkar RR, Thourani VH, Mack MJ, *et al.* Five-Year Outcomes of Transcatheter or

- 1
2
3 Surgical Aortic-Valve Replacement. *N Engl J Med* 2020;382:799–809.
- 4
5 20 Barbanti M, Tamburino C, D'Errigo P, *et al*. Five-Year Outcomes of Transfemoral
6 Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in
7 a Real World Population: Final Results from the OBSERVANT Study. *Circ*
8 *Cardiovasc Interv* 2019;12:1–9.
- 9
10
11 21 Sabbagh A El, Nishimura RA. Clinical conundrum of coronary artery disease and
12 aortic valve stenosis. *J Am Heart Assoc* 2017;6:1–3.
- 13
14
15 22 Leon MB, Smith CR, Mack MJ, *et al*. Transcatheter or Surgical Aortic-Valve
16 Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016;374:1609–20.
- 17
18 23 Sankaramangalam K, Banerjee K, Kandregula K, *et al*. Impact of coronary artery
19 disease on 30-day and 1-year mortality in patients undergoing transcatheter Aortic
20 valve replacement: A meta-analysis. *J Am Heart Assoc* 2017;6:1–11.
- 21
22
23 24 Goldsweig AM, Tak HJ, Chen LW, *et al*. Relative Costs of Surgical and
24 Transcatheter Aortic Valve Replacement and Medical Therapy. *Circ Cardiovasc*
25 *Interv* 2020;13:1–9.
- 26
27
28 25 Tripathi A, Flaherty MP, Abbott JD, *et al*. Comparison of Causes and Associated
29 Costs of 30-Day Readmission of Transcatheter Implantation Versus Surgical Aortic
30 Valve Replacement in the United States (A National Readmission Database Study).
31 *Am J Cardiol* 2018;122:431–9.
- 32
33
34 26 O'Neill A. Life expectancy (from birth) in the United Kingdom from 1765 to 2020.
35 Statista. 2020. <https://www.statista.com/statistics/1040159/life-expectancy-united-kingdom-all-time/> (accessed 7 Aug 2020).
- 36
37
38 27 Foroutan F, Guyatt GH, O'Brien K, *et al*. Prognosis after surgical replacement with
39 a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis:
40 Systematic review of observational studies. *BMJ* 2016;354:1–9.
- 41
42
43 28 McClure RS, Narayanasamy N, Wiegerinck E, *et al*. Late Outcomes for Aortic Valve
44 Replacement With the Carpentier-Edwards Pericardial Bioprosthesis: Up to 17-
45 Year Follow-Up in 1,000 Patients. *Ann Thorac Surg* 2010;89:1410–6.
- 46
47
48 29 Chiang YP, Chikwe J, Moskowitz AJ, *et al*. Survival and long-term outcomes
49 following bioprosthetic vs mechanical aortic valve replacement in patients aged 50
50 to 69 years. *JAMA - J Am Med Assoc* 2014;312:1323–9.
- 51
52
53
54
55
56
57
58
59
60

- 1
2
3 30 Puskas JD, Gerdisch M, Nichols D, *et al.* Anticoagulation and Antiplatelet Strategies
4 After On-X Mechanical Aortic Valve Replacement. *J Am Coll Cardiol*
5 2018;71:2717–26.
6
7
8 31 Huckaby L V., Sultan I, Gleason TG, *et al.* Outcomes of tissue versus mechanical
9 aortic Valve Replacement Reduces Long-Term Survival. *Ann Thorac*
10
11 32 Cozijnsen L, van der Zaag-Loonen HJ, Cozijnsen MA, *et al.* Differences at surgery
12 between patients with bicuspid and tricuspid aortic valves. *Netherlands Hear J*
13 2019;27:93–9.
14
15 33 Wallen T, Habertheuer A, Bavaria JE, *et al.* Elective Aortic Root Replacement in
16 North America: Analysis of STS Adult Cardiac Surgery Database. *Ann Thorac Surg*
17 2019;107:1307–12.
18
19 34 Baumgartner H, Falk V, Bax J et al. 2017 ESC / EACTS Guidelines for the
20 management of valvular heart disease The Task Force for the Management of
21 Valvular Heart Disease of the European Society of Cardiology (ESC) and the
22 European. *Eur Heart J* 2017;38:2739–86.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Multivariable modelling of post-operative outcomes using pre-operative and operative factors

Predictor	missing	Category	Hospital mortality		Return to theatre for bleeding		New stroke	
			Odds ratio	P-value	Odds ratio	P-value	Odds ratio	P-value
Age (years)	7.9%	<i>per unit increase</i>	1.03 (1.02-1.04)	<0.001	1.01 (1.00-1.01)	0.006	1.02 (1.01-1.03)	0.001
Gender	10.3%	Female Male	- 0.63 (0.51-0.77)	<0.001	- 1.18 (1.02-1.36)	- 0.026	- 1.02 (0.80-1.29)	- 0.89
LVEF	3.1%	Good (>50%) Moderate (30-50%) Poor (<30%)	- 1.48 (1.18-1.85) 1.90 (1.36-2.69)	- 0.001 <0.001	- 1.08 (0.91-1.27) 1.10 (0.82-1.48)	- 0.38 0.53	- 1.13 (0.86-1.48) 0.78 (0.44-1.38)	- 0.38 0.40
EuroSCORE Logistic	12.1%	<i>per unit increase</i>	1.02 (1.02-1.03)	<0.001	1.01 (1.00-1.01)	0.16	1.00 (0.99-1.02)	0.30
Operative Urgency	0.02%	1. Elective 2. Urgent 3. Emergency 4. Salvage	- 1.63 (1.30-2.00) 6.87 (4.70-10.16) 11.79 (5.73-24.27)	- <0.001 <0.001 <0.001	- 1.26 (1.08-2.00) 2.22 (1.51-3.26) 1.51 (0.56-4.02)	- 0.002 <0.001 0.41	- 1.08 (0.83-1.41) 7.65 (5.00-11.70) 4.38 (1.47-13.1)	- 0.55 <0.001 0.008
Cumulative Bypass Time (mins)	2.4%	<i>per unit increase</i>	1.02 (1.01-1.02)	<0.001	1.00 (1.00-1.01)	<0.001	1.00 (1.00-1.01)	<0.001
Cumulative Cross Clamp Time (mins)	2.5%	<i>per unit increase</i>	0.99 (0.99-0.99)	<0.001	1.00 (1.00-1.00)	0.23	1.00 (0.99-1.00)	0.58
CABG	0%	No Yes	- 1.15 (0.93-1.42)	- 0.20	- 1.07 (0.93-1.24)	- 0.33	- 1.12 (0.88-1.42)	- 0.37

LVEF; left ventricular ejection fraction, CABG; coronary artery bypass graft surgery

Table 2. Mortality (%) for different categories of age and EuroSCORE

Euroscore	N (%)	SAVR+CABG (Mortality %)	SAVR (Mortality %)
<3%	15619 (50.0)	2.0	1.3
3-6%	5020 (16.1)	0.9	1.0
>6%	6846 (21.9)	4.4	3.9
Age (years)		SAVR+CABG	SAVR
<60		2.2	2.0
60-75		1.8	1.5
>75		3.1	2.2

For peer review only

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. Baseline characteristics in the current study (UK SAVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ⁴	NOTIO	PIVOTAL ⁵		NOTIO
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVR N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N=357	TAVI N=390	SAVR N=135
Age (mean±SD)	70.1±11.5	67.6 ± 13.4	NR	81.7±6.7	81.5±6.7	73.6±6.1	73.3±5.8	73.6±5.9	77.1±5.8	83.2±6.4	83.1±7.1	79 ± 4.7
% Male	59	58	51.1	54.8	54.2	71.1	67.5	66.2	64	52.4	53.1	53.8
BMI (kg/m ²)	28.9±5.5	29.3 ± 6.6	NR	28.3±6.2	28.6±6.2	30.3±5.1	30.7±5.5	NR	NR	NR	NR	NR
NYHA class III/IV (%)	44.4	38.4	15.9	76.3	77.3	23.8	31.2	28.4	25.1	86.9	85.7	45.5
Logistic EuroSCORE (%)	4.3±7.3	NR	NR	NR	NR	1.5±0.9*	1.5±1.2*	NR	NR	18.6±13.0	17.7±13.1	8.9 ± 5.5
Diabetes Mellitus (%)	22.2	25.5	NR	34.2	37.7	30.2	31.2	30.5	31.4	45.4	34.9	20.7
Chronic Kidney Disease (%)	3.1	NR	NR	5.2	5.0	0.2	0.2	0.1	0.4	12.8	12.2	0.7
Hypertension (%)	64.9	NR	NR	NR	NR	NR	NR	82.6	84.8	96.1	95.1	76.3
Peripheral vascular disease (%)	8.7	9.2	NR	32.9	27.9	7.3	6.9	7.5	8.3	41.7	41.1	6.7
Previous stroke (%)	8.2	12.6	0.13	31	32.1	5.1	3.4	10.2	11.8	14.0	12.6	16.3
COPD (%)	13.4	NR	13.6	30.0	31.8	6.2	5.1	15.0	18.0	9.0	13.3	11.9
LV ejection fraction (%)	53.2	54.9 ± 12.9	NR	55.3±11.9	56.2±10.8	66.2±8.6	65.7±9.0	61.9 ± 7.7	61.7 ± 7.9	NR	NR	NR
Coronary artery disease (%)	37.1	NR	NR	66.5	69.2	28.0	27.7	NR	NR	75.9	75.4	NR
Atrial fibrillation	10.3	NR	5.6	35.2	31.0	18.8	15.7	14.5	15.4	45.9	40.9	25.6
Permanent pacemaker	1.9			12.0	11.7	2.9	2.4	3.8	3.2	21.3	23.3	4.4

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, BMI; body mass index, NYHA; New York Heart Association classification,

COPD; chronic obstructive pulmonary disease, NR; not reported

*EuroSCORE II reported only

Table 4. Operative characteristics in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Characteristic	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUT ¹⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=25	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 145
Operative urgency													
Elective (%)	74.3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Urgent (%)	24	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Emergency/Salvage (%)	1.7	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Concomitant CABG (%)	37.1	NR	NR	NR	-	12.8	-	13.6	6	4.8	-	1	-
Staged PCI	-	NR	NR	-	NR	-	6.5	-	6	-	0.3%	-	0
Cross clamp time (minutes)	79.0	77.0 ± 28.5	NR	NR	-	74.3 ± 27.78	-	68.7 ± 29.0	55	74.0 ± 31.4	-	NR	NR
Cardiopulmonary bypass time (minutes)	104	104.9 ± 39.1	NR	NR	-	97.7 ± 33.75	-	93.4 ± 40.2	55	104.0± 45.8	-	NR	NR
Procedure time (minutes)	NR	NR	NR	NR	NR	208.3 ± 62.1	58.6 ± 36.5	276.6 ± 79.5	148	221 ± 84.8	60.4 ± 35.3	177.2 ± 39.8	90.3 ± 38.6

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery

NR; not reported

136/bmjopen-2020-01491 on 28 October 2021. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

136/bmjopen-2020-046491 on 29 October 2021. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Table 5. Outcomes following SAVR in the current study (UK AVR) and those in other national registries and recent trials comparing SAVR with TAVI

Outcome	UK SAVR	Thourani ¹⁵	Tokuda ¹⁶	PARTNER 2A ²²		PARTNER 3 ⁶		EVOLUS ⁷		PIVOTAL ⁵		NOTION ¹⁸	
	SAVR N=31,277	SAVR N=141 905	SAVR N=20 514	SAVR N=1021	TAVI N=1011	SAVR N=454	TAVI N=496	SAVR N=678	TAVI N=725	SAVR N= 357	TAVI N= 390	SAVR N= 135	TAVI N= 140
In-hospital death/30-day mortality (%)	1.9	2.5	NR	8.0	6.1	1.1	0.4	1.3	0.5	4.5	3.3	3.7	2.1
Stroke (%)	1.1	NR	1.6	6.1	5.5	2.4	0.6	3.4	3.4	6.2	4.9	3.0	1.4
Reoperation for bleeding* (%)	3.6	3.9	3	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Post procedure bleeding* (%)	-	NR		43.4	10.4	11.9	1.2	7.5	2.4	69.5	41.7	11.3	20.9
Deep sternal wound infection (%)	0.14	0.3	1.1	NR	-	NR	-	NR	-	NR	-	NR	-
Length of hospital stay (days)	7	7.9 ± 7.2	NR	NR	-	7.0	3.0	NR	NR	NR	NR	8.9 ± 6.2	12.9 ± 11.6
New pacemaker implantation (%)	1.6	NR	NR	6.9	8.	4.0	6.5	6.1	7.4	7.1	19.8	1.6	34.1

SAVR; surgical aortic valve replacement, TAVI; transcatheter aortic valve implantation, CABG; coronary artery bypass graft surgery, NR; not reported

*Reoperation for bleeding and post-operative bleeding were major and required intervention

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	4-6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	4-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6
		(e) Describe any sensitivity analyses	6

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8
		(b) Report category boundaries when continuous variables were categorized	7-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9

Discussion

Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	9

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA
---------	----	---	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.